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Abstract 
Osteoarthritis (OA) is the most common form of musculoskeletal disorder and is a 
leading cause of disability in the elderly. Some key pathophysiological features of 
OA joints include articular cartilage degradation and abnormal subchondral bone 
metabolism; however, the aetiology is largely unknown. Angiogenesis, controlled by 
a balance between endogenous angiogenic and anti-angiogenic factors, has been 
found to contribute to the pathogenesis and progression of OA. It is well known that 
articular cartilage is an avascular tissue by nature, in which the resident chondrocytes 
maintain a stable phenotype that avoids hypertrophy and angiogenesis throughout 
life. It is of great importance to better understand the physiology of healthy cartilage 
in order to develop therapies capable of arrest or reverse OA progression. Healthy 
cartilage is known to contain considerable amount of anti-angiogenic factors. Among 
them, chondromodulin-1 (ChM-1) is the most specific and abundant in cartilage and 
the regulatory effect of ChM-1 in chondrocyte maturation and bone remodelling has 
been verified in genetically modified mice. However, the contribution of anti-
angiogenic factors in the maintenance of chondrocyte phenotype is largely unknown. 
Motivated by these findings, the aim of this project is to address the balance between 
angiogenesis and anti-angiogenesis in OA cartilage with the focus on the function of 
anti-angiogenic factor ChM-1.  
For this purpose, cartilage tissues from the knees of OA patients were collected to 
establish the profile of angiogenic and anti-angiogenic cytokines using angiogenesis 
qRT-PCR array, human cytokine antibody membrane array, qRT-PCR, and Western 
blot. The results revealed that the majority of angiogenic factors increased in severe 
OA cartilage, while anti-angiogenic factors decreased, including ChM-1, tissue 
inhibitor of metalloproteinase (TIMP)-1, TIMP-2, thrombospondin (TSP)-1 and 
TSP-2, which implies loss of the balance between pro-angiogenic and anti-
angiogenic properties may be one of the most important characteristic of the cartilage 
during OA progression. The down-regulation of ChM-1 and up-regulation of 
vascular endothelial growth factor A (VEGFA) were also confirmed in both gene and 
protein levels.  
Subsequently, the involvement of ChM-1 in chondrogenesis and OA progression in 
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vivo and in vitro was systematically studied. Genetic manipulation of ChM-1 
expression was performed using either lentiviral constructs carrying ChM-1 cDNA 
(LV-ChM-1) or ChM-1siRNA. The results showed that ChM-1 expression was 
correlated with chondrogenesis in cells derived from both cartilage and bone 
marrow. Chondrocytes infected with LV-ChM-1 effectively resisted tumour necrosis 
factor alpha (TNF-α) induced hypertrophy, with decreased gene and protein levels of 
hypertrophic markers matrix metalloproteinase (MMP)-13, type X collagen α1 
(COL10A1) and VEGFA; whereas chondrocytes infected with ChM-1 siRNA were 
more sensitive to TNF-α induced hypertrophy. Next, the functional relevance of 
ChM-1 supplementation to OA progression was tested in vivo using an experimental 
rat OA model. It was demonstrated that intra-articular injection of lentivirus ChM-1 
significantly ameliorated OA progression, as evidenced by reduced expression of 
hypertrophic markers and matrix degradation. 
Subsequent studies were performed to explore the molecular mechanism by which 
ChM-1 exerts its anti-hypertrophic function. The hypoxia-inducible factor (HIF)-2α 
pathway has recently been shown to be a central catabolic regulator of osteoarthritic 
cartilage destruction with directly targeting multiple hypertrophic genes. Given that 
cartilage is an avascular tissue, positive expression of HIF-2α in normal articular 
cartilage has been detected in my study, and has been reported by other researchers 
too. However, the presence of HIF-2α in normal cartilage is not enough in itself to 
initiate the angiogenic and catabolic cascades. I hypothesized that ChM-1, as an 
intrinsic and abundant protein in cartilage, may play a regulatory role in HIF-2α 
function. Indeed, the results showed that ChM-1 overexpression delayed 
translocation of HIF-2α to the nucleus at early time-point and inhibited its DNA 
binding activity to the promoter of COL10A1, MMP-13 and VEGFA. This suggests 
that the protective effect of ChM-1 on TNF-α-induced hypertrophy might be 
achieved, at least in part, through the inhibition of HIF-2α activity. 
In conclusion, this thesis extends our knowledge on the importance of anti-
angiogenic factor in cartilage to maintain the physiological function of chondrocytes 
and prevent hypertrophy. My results indicate that ChM-1 is important to maintain the 
chondrocyte phenotype and prevent hypertrophy by inhibiting catabolic factors of 
COL10A1, MMP-13 and VEGFA via the HIF-2α signalling pathway. Moreover, this 
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study provides a potential therapeutic strategy for OA through supplementation of 
anti-angiogenic factor of ChM-1. 
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Chapter 1: Introduction 
1.1 BACKGROUND 
Osteoarthritis (OA) is the most common form of musculoskeletal disorder and is a 
leading cause of disability in older members of society. The key pathophysiological 
features of OA joints include articular cartilage degradation and abnormal 
subchondral bone metabolism; however the aetiology is largely unknown. Loss of 
proteoglycans (mainly aggrecan) and degradation of collagen matrix are the most 
prominent characteristics of OA cartilage. Furthermore, hypertrophy markers 
including type Х collagen α1 (COL10A1), matrix metallopeptidase-13 (MMP-13) 
and runt-related transcription factor-2 (RUNX2) are up-regulated in OA cartilage, 
leading to disruption of homeostasis and cartilage degradation. The molecular 
mechanisms regulating phenotypic changes of OA cartilage are largely unknown. 
Angiogenesis has recently been found to contribute to pathogenesis of OA. It is well 
documented that articular cartilage is an avascular tissue by nature, in which the 
resident chondrocytes maintain stable phenotype that suppresses hypertrophy and 
angiogenesis throughout life. Therefore, articular cartilage may possess its own 
intrinsic factors to maintain the phenotype. It is of great importance to understand the 
physiology of healthy cartilage in order to develop therapies capable of arresting or 
reversing OA progression. Several growth factors, such as the transforming growth 
factor beta (TGF-β) family, have been proposed to be essential for chondrogenesis 
and cartilage development (Goldring et al., 2006; Lafont et al., 2008). But TGF-β is 
not exclusively expressed in cartilage tissue and furthermore, intra-articular 
supplement of TGF-β results in osteoarthritis-like changes and osteophyte formation 
(Bakker et al., 2001; Van Beuningen et al., 2000; Van Beuningen et al., 1994), 
which may deny its importance in mature cartilage maintenance. It has been 
observed that cartilage contains appreciable amounts of anti-angiogenic factors, such 
as chondromodulin-1 (ChM-1) and thrombospondin (TSPs), which are expressed in 
the chondrocyte cytoplasm and cartilage matrix (Bonnet & Walsh, 2005; Hiraki et 
al., 1997a; Hiraki et al., 1997b; Patra & Sandell, 2012). ChM-1, one of the most 
specific and abundant anti-angiogenic factors in cartilage, is a 121-amino acid 
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residue glycoprotein derived from a transmembrane precursor and distributed mainly 
in interstitial space of cartilage matrix (Hiraki, et al., 1997a; Shukunami & Hiraki, 
1998). The inhibition of angiogenesis by ChM-1 in cartilage, cardiac valves and 
several tumours has been well documented (Hayami et al., 1999; Miura et al., 2010; 
Yoshioka et al., 2006). The regulatory effect of ChM-1 in cartilage development was 
verified by genetically modified mice. In vivo, ChM-1 null mice have retarded 
chondrocyte maturation in the periosteal callus, aberrant cartilage formation during 
fracture repair (Yukata et al., 2008), and marked reduction in bone remodelling 
(Nakamichi et al., 2003). A recent study demonstrated that application of adeno-
associated virus (AAV) carrying ChM-1 in micro-fractured porcine cartilage lesions 
stimulate chondrogenic differentiation of ingrowing progenitor cells, and inhibited 
endochondral ossification by an unknown mechanism (Klinger et al., 2011). 
However, the contribution of anti-angiogenic factors in the maintenance of 
chondrocyte phenotype is largely unknown. 
Another observation is that hypoxia stabilizes the hypoxia-inducible factor-α (mainly 
HIF-1α and HIF-2α) and initiates an angiogenic signalling cascade. In cartilage, 
however, the avascular nature of the tissue and the resulting hypoxia normally would 
not support angiogenesis. HIF-1α and HIF-2α have both been found in normal 
articular cartilage (Bohensky et al., 2009; Coimbra et al., 2004). Although HIF-1α is 
reported to be essential for chondrocyte survival, energy generation and matrix 
synthesis, it has also been shown that HIF-1α can induce vascular endothelial growth 
factor A (VEGFA) expression in chondrocytes (Lin et al., 2004; Pfander et al., 2003; 
Schipani et al., 2001; Thoms et al., 2013). HIF-2α has been recently demonstrated as 
a central catabolic regulator of osteoarthritic cartilage destruction by directly 
targeting the hypertrophic genes VEGFA, COL10A1, MMP-13 and RUNX2 (Saito 
et al., 2010; Yang et al., 2010). So, given that HIFs do not typically initiate the 
angiogenic and catabolic cascades in normal cartilage, there must exist a mechanism 
that prevents this effect. The question as to whether the abundant expression of 
ChM-1 in cartilage interferes with the activity of HIFs has until now remained 
unknown.  
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1.2 CONTEXT AND RESEARCH QUESTIONS 
The pathology of OA involves both of loss of cartilage avascularity and chondrocyte 
hypertrophy. However, it is not clear whether the angiogenic and anti-angiogenic 
equilibrium would be shifted and whether this imbalance could exacerbate cartilage 
degradation and disease process. As discussed above, ChM-1 is the most abundant 
endogenous anti-angiogenic protein expressed in cartilage, and its expression is 
confined to normal avascular cartilage. However, there remains a large knowledge 
gap in our understanding of the contribution of ChM-1 to maintain the chondrocyte 
phenotype. In addition, although hypoxia is the physiologic environment for articular 
cartilage, in vascular tissues it is a stress condition. HIF-2α has recently been shown 
to be a catabolic regulator in growth plate and osteoarthritis. How chondrocytes 
survive in hypoxic conditions and why HIFs initiate angiogenic and hypertrophic 
pathways in OA cartilage – but not in normal cartilage – is a fundamental question in 
cartilage biology. Whether ChM-1’s role is primarily to protect chondrocytes by 
regulating the HIF-2α pathway remained to be investigated.  
 
1.3 HYPOTHESES AND AIMS  
The hypothesis of my PhD study was that the anti-angiogenic factor is essential in 
maintaining the physiological functions of chondrocytes and preventing hypertrophy 
in OA development.  
The specific aims of this study are summarized as follows: 
Aim 1: To characterize the profiles of angiogenic and anti-angiogenic cytokines in 
human OA cartilage. (Chapter 4) 
Aim 2: To investigate the involvement of ChM-1 in chondrogenesis and chondrocyte 
hypertrophy in vitro. (Chapter 5) 
Aim 3: To investigate the therapeutic potential of ChM-1 supplementation in OA 
progression using an experimental rat OA model. (Chapter 5) 
Aim 4: To explore the molecular mechanism underlying anti-hypertrophic function 
of ChM-1 with a focus on the HIF-2α pathway. (Chapter 6) 
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1.4 SIGNIFICANCE 
The identification of the specific biological factors responsible for maintaining 
cartilage homeostasis is of great importance to develop novel therapeutic strategies 
of OA. The present study has focused on the cartilage-derived anti-angiogenic factor 
ChM-1, and highlighted its function in phenotype transition of OA cartilage. More 
knowledge about anti-angiogenesis and the maintenance of cartilage homeostasis has 
been revealed as the result of this project. This project is the first to systematically 
investigate the role of ChM-1 during chondrogenic differentiation and chondrocyte 
hypertrophy, as well as in OA progression in vivo. It also pioneers the exploration of 
anti-hypertrophic mechanisms of ChM-1 in relation to the HIF-2α pathway. These 
findings will provide a new perspective on the molecular mechanisms of cartilage 
maintenance and OA progression, and also suggest potential new treatment options 
of OA. 
 
1.5 THESIS OUTLINE 
This thesis comprises seven chapters:  
(1) Introduction of my PhD topics, hypothesis and aims;  
(2) Literature review on the topic investigated;  
(3) Methodology and material used in this study;  
(4) Results from aim 1, showing the profile of angiogenic and anti-angiogenic factors 
in severe OA cartilage;  
(5) Results from aims 2 and 3, showing the role of ChM-1 during chondrocyte 
hypertrophy and its therapeutic efficacy in OA development in vitro and in vivo; 
(6) Results from aim 4, showing that ChM-1 regulates the HIF-2α pathway by 
delaying HIF-2α nuclear translocation thus inhibiting its transcriptional activity; 
(7) General discussion and conclusion of this study.   
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2.1  STRUCTURE AND PHYSIOLOGY OF ARTICULAR CARTILAGE 
Cartilage is a specialized connective tissue composed of chondrocytes and a large 
amount of extracellular matrix including collagen fibres, ground substance rich in 
proteoglycan and elastin fibres (Pacifici et al., 2000). According to the amounts of 
these three components, cartilage is classified into three types: elastic cartilage, 
hyaline cartilage and fibrocartilage. Articular cartilage – also referred to as hyaline 
cartilage – is the main component of joint surface with biophysical properties and the 
ability of withstanding high compressive forces (Las Heras et al., 2012). 
2.1.1 Articular cartilage development 
Formation of articular cartilage 
The process of articular joint formation is classically divided into two phases 
(Goldring, 2012). The first phase is the formation of mesenchymal prechondrogenic 
condensations and their differentiation into cartilaginous skeletal anlagen. The 
second phase includes the formation of joint structures including synovium, 
ligaments and capsule, and space (cavitation) (Las Heras, et al., 2012). In 
vertebrates, the axial and appendicular skeleton development begins with 
endochondral bone formation (Karsenty et al., 2009). At first, mesenchymal 
progenitors condense and differentiate into chondrocytes in the shape of the future 
long bone. Then an avascular cartilaginous template forms, which is surrounded by a 
perichondrium (Goldring, 2012; Karsenty, et al., 2009). Osteoblasts, also derived 
from mesenchymal precursors in the perichondrium, develop a bone collar, which 
will be the future cortical bone (Karsenty, et al., 2009; Maes et al., 2010). As skeletal 
development proceeds, the majority of chondrocytes will eventually undergo 
secondary ossification, a process known as endochondral ossification (Goldring, 
2012; Goldring, et al., 2006; Las Heras, et al., 2012).  
Endochondral ossification is the normal mechanism of long bone formation and 
growth, referring to the formation of calcified bone within a cartilaginous scaffold 
(Figure 2-1) (DeLise et al., 2000; Las Heras, et al., 2012; Maes, et al., 2010; 
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Solomon et al., 2008). Differentiated chondrocytes undergo a series of late 
differentiation steps, resulting in mature hypertrophic chondrocytes that express 
osteogenic markers (such as alkaline phosphatase (ALP)), angiogenic factor (such as 
VEGF) and secrete matrix proteins (such as COL10A1). Angiogenesis is required for 
endochondral ossification in this process (Goldring, 2012; Karsenty, et al., 2009). 
Blood vessels invade into the hypertrophic cartilage from the bone collar, and bring 
in osteoblast progenitors from the perichondrium (Karsenty, et al., 2009; Maes, et 
al., 2010). The cartilage matrix is gradually degraded and the bone matrix secreted 
and deposited by osteoblasts to form the ossification centre. At this stage, the growth 
plate consists of hypertrophic chondrocytes and layers of spongy/trabecular bone 
(Karsenty, et al., 2009; Maes, et al., 2010; Solomon, et al., 2008). Afterwards, linear 
bone growth continues via the endochondral ossification process in growth plate, 
while osteoblasts in the perichondrium generate cortical bone on the outside 
circumference (Karsenty, et al., 2009; Maes, et al., 2010). Eventually, the majority of 
cartilaginous tissue is replaced by bone; however, chondrocytes at the end of the long 
bone persist and form the permanent mature articular cartilage of the joints 
(Goldring, 2012; Karsenty, et al., 2009).  
 
Figure 2-1. Procession of endochondral ossification.  Enchondral ossification takes place in the 
growth plates at the distal ends of the long bones between the later epiphysis and diaphysis. Resting 
chondrocytes start to proliferate, differentiate into hypertrophic chondrocytes, and finally undergo 
apoptosis. Blood vessel invasion then takes place. The cartilage matrix is degraded and replaced with 
the typical trabecular bone matrix produced by osteoblasts. (Adapted from Pearson Education, Inc. 
Publishing as Benjamin Cummings).    
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Fate of hypertrophic chondrocytes in endochondral ossification 
According to traditional view, it is thought that after endochondral bone formation 
terminally differentiated hypertrophic chondrocytes undergo apoptosis, leaving a 
cartilaginous matrix that is mineralized prior to the formation of new bone (Goldring, 
2012; Las Heras, et al., 2012; Yang et al., 2014). However, a recent study conducted 
by Yang et al. showed that hypertrophic chondrocytes can survive during the 
cartilage-to-bone transition and finally become osteogenic cells (osteoblasts and 
osteocytes) in fetal and postnatal endochondral bones and persist into adulthood. 
This view completely changes the accepted wisdom regarding the process of 
endochondral bone formation (Yang, et al., 2014). 
2.1.2 Structure of mature articular cartilage 
Articular cartilage consists of cartilage cells (chondrocytes) and large amounts of 
extracellular matrix (ECM). Cell density in cartilage is relatively low compared to 
other tissues, at approximately 1% to 10% of the cartilage tissue volume (Archer & 
Francis-West, 2003; Buckwalter & Mankin, 1998). The ECM is composed of 
complex organized macromolecules, including collagen fibres (predominantly 
COL2A1), soluble negatively charged proteoglycans (such as aggrecan, small 
leucine-rich proteoglycans and perlecan) and noncollagenous proteins, as well as 
ions (mainly Na+ and Cl- ions). The tissue fluid accounts for 65% to 80% of the wet 
weight of articular cartilage. The fluid is what enables nutrients and oxygen to 
diffuse through the cartilage matrix to chondrocytes in the absence of a vasculature 
(Kuettner et al., 1991). 
Adult articular cartilage is divided into four distinct zones (Figure 2-2): (a) the 
superficial zone, composed of thin collagen fibrils arranged parallel to the surface, 
high concentration of decorin and low concentration of aggrecan; (b) the middle 
(transitional) zone, composed of thick collagen fibrils arranged as gothic arches; (c) 
the deep (radial) zone, consist of thick collagen bundles arranged in a radial fashion; 
and (d) the calcified cartilage zone, located between the tidemark and the 
subchondral bone. Tidemark is referred to the interface between the noncalcified 
cartilage and the calcified cartilage. The calcified cartilage is composed of unique 
matrix composition, such as COL10A1, and hypertrophic chondrocytes. 
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Vascularization and innervation originating from the subchondral bone could 
probably invade into calcified cartilage in association with advancing age (Goldring, 
2012).  
 
Figure 2-2. Structure of mature articular cartilage. Four distinct zones are observed: the superficial 
zone (tangential layer); the middle (transitional) zone; the deep (radial) zone; and the calcified 
cartilage zone, which located between the tidemark (the interface between the noncalcified cartilage 
and the calcified cartilage) and the subchondral bone (Hill, 2014). 
2.1.3 Chondrocyte phenotype in cartilage 
Chondrocyte phenotype is dependent upon the developmental and maturational stage 
of the tissue (Pacifici, et al., 2000). Chondrogenesis occurs as a result of 
condensation of mesenchymal cells, which express type I, III and V collagens. 
Chondroprogenitor cell differentiation is characterized by expression of cartilage-
specific type II, IX, and XI collagens. In terms of transcription factors, SOX9 (sex 
determining region Y (SRY)-box 9) determines chondrogenic lineage differentiation 
from mesenchymal cells by directly activating cartilage matrix gene of COL2A1 
(Akiyama et al., 2002; Akiyama et al., 2005; de Crombrugghe et al., 2000; Lefebvre 
et al., 1997). The proliferating chondrocytes express type VI collagen. In the process 
of endochondral ossification, the hypertrophic zone is characterized by expression of 
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COL10A1 and matrix calcification. In addition, MMP-9, -13, and -14, and 
vascularization marker VEGFA are also highly expressed by hypertrophic 
chondrocytes during endochondral ossification (Kuettner, et al., 1991; Las Heras, et 
al., 2012).  
Mature chondrocytes exhibit a stable phenotype characterized by a round shape and 
low proliferation rate. However, chondrocytes are metabolically active cells, 
responsible for synthesis and turnover collagens (mainly COL2A1), proteoglycans 
(mainly aggrecan), glycoproteins and hyaluronan (Goldring & Marcu, 2009; Jackson 
& Gu, 2009; Las Heras, et al., 2012). Expression of MMPs is very low in articular 
chondrocytes under normal condition. COL2A1, aggrecan and transcriptional factor 
SOX9 have frequently been used as marker for chondrogenic lineage differentiation 
and cartilage regeneration, as they are the most prominent feature of chondrogenesis 
and mature cartilage. 
Sex determining region Y (SRY)-box 9 (SOX9) 
Transcriptional factor SOX9 is regarded as the master regulator for cartilage 
development (de Crombrugghe, et al., 2000). As early as the condensation process of 
mesenchymal cells, SOX9 expression becomes evident, which precedes production 
of COL2A1 (Lefebvre, et al., 1997). Lefebvre et al. demonstrated that COL2A1 
expression is closely correlated with high levels of SOX9 RNA and protein in 
chondrocytes, furthermore, SOX9 binds to a consensus sequence in the COL2A1 
enhancer region and activates gene transcription (Lefebvre, et al., 1997). It has been 
shown that lineage determination towards chondrocytes is controlled by the 
expression of SOX9 (Akiyama, et al., 2002; Akiyama, et al., 2005; de Crombrugghe, 
et al., 2000). In mouse embryonic development, SOX9 inactivation in limb buds 
before mesenchymal condensations leads to absence of both cartilage and bone, 
while SOX9 deletion after mesenchymal condensations shows a severe generalized 
chondrodysplasia and inhibition of chondrocyte proliferation (Akiyama, et al., 2002). 
In vitro studies have shown that chondrogenic differentiation of embryonic stem cells 
in SOX9-/- mouse is completely absent (Hargus et al., 2008). In addition, in humans 
haploinsufficiency of SOX9 exhibits the campomelic dysplasia syndrome, featured 
by bowing of the long bones and other skeletal disorders (Archer & Francis-West, 
2003; de Crombrugghe, et al., 2000). Therefore, SOX9 is a major transcriptional 
factor in the lineage commitment and development of chondrogenic cells.  
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Type II collagen α1 (COL2A1) 
Cartilage matrix contains multiple different collagen molecules, specifically types II, 
III, VI, IX, X, XI, XII and XIV, and COL2A1 is the principal ECM component and 
accounts for 90 to 95% of the collagens in articular cartilage (Buckwalter & Mankin, 
1998; Eyre, 1995). COL2A1 is the primary component for the cross-banded fibrils, 
and electron microscopy has revealed the COL2A1 cross-bands with type IX and XI 
collagens to form a tight meshwork, providing the tensile stiffness and strength of 
cartilage tissue, as well as the cohesiveness of ECM (Buckwalter & Mankin, 1998; 
Eyre, 1995). The functions of type IX and type XI collagens have not been well 
understood. Type IX collagen molecules may bind together the collagen-fibril 
meshwork and connect with proteoglycans. In contrast, COL10A1 is only expressed 
near the cells of the calcified cartilage zone of the articular cartilage and the 
hypertrophic zone of the growth plate (Buckwalter & Mankin, 1998; Roughley & 
Lee, 1994).  
Aggrecan 
Articular cartilage contains two major categories of proteoglycans: large aggregating 
proteoglycan monomers (mainly aggrecan, gene names ACAN), and small 
proteoglycans such as decorin, biglycan, and fibromodulin (Buckwalter & Mankin, 
1998; Roughley & Lee, 1994). Aggrecans occupy the interfibrillar space of the 
cartilage matrix, contributing to approximately 90% of the total proteoglycan mass 
(Buckwalter & Mankin, 1998). In general, proteoglycans consist of a protein core 
with linked glycosaminoglycan chains, which are long unbranched polysaccharide 
chains consisting of disaccharides repeat that contain an amino sugar. Aggrecans 
have a protein core filament linked with large numbers of chondroitin-sulfate and 
keratan-sulfate chains (Buckwalter & Mankin, 1998; Knudson & Knudson, 2001). 
Large quantities of aggrecans are the most prominent feature of articular (hyaline) 
cartilage, providing the osmotic environment to withstand compressive loads 
(Knudson & Knudson, 2001; Roughley & Lee, 1994). 
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2.2  OSTEOARTHRITIS (OA) 
OA is the most common form of musculoskeletal disorder and a leading cause of 
disability in the elderly. It has been estimated that worldwide 9.6% of men and 18% 
of women > 60 years have symptomatic OA (Woolf & Pfleger, 2003). In Australia, 
OA affects more than 1.3 million people and more than 41,000 total hip and knee 
replacements were performed for OA each year (Department of Health and Ageing, 
Australia (http://www.aihw.gov.au/)). Clinically, OA is degenerative joint disease 
characterized by pain, tenderness, limitation of movement and reduction of life 
quality. According to World Health Organization Guidelines, OA is defined as a 
result of both mechanical and biological events that uncouple the normal balance 
between degradation and synthesis by articular cartilage chondrocytes and ECM, and 
subchondral bone (Mollenhauer & Erdmann, 2002). Ultimately, OA is manifested by 
morphologic, biochemical and biomechanical changes (Mollenhauer & Erdmann, 
2002).  
2.2.1 Aetiology 
The aetiology of OA is multifactorial and is as yet not fully understood (Felson et al., 
2000; Loeser, 2009). Age is the most prominent factor for OA, since the incidence of 
OA increases dramatically over the age of 50 (Felson, et al., 2000; Sowers, 2001). 
Gender distribution indicates females have a greater risk to suffer from OA than 
male. Family inheritance (genetic component) also appears to be a risk factor as 
shown by twin studies and family clustering (Felson, et al., 2000; Sowers, 2001). 
Other potentially modifiable factors for OA include joint overload (occupational 
repetitive heavy load), obesity, mechanical injury from trauma, and joint instability 
or malalignment (Coggon et al., 2000; Felson, et al., 2000). These risk factors may 
stimulate biomechanical and/or biochemical molecular signalling pathways, which 
result in cartilage degradation and joint destruction (Kapoor et al., 2011).  
2.2.2 Clinical significance of OA  
OA occurs mainly in weight bearing joints such as knees, hip and spine; it can also 
affect the joints of hands and feet, although the incidence are rare (Cushnaghan & 
Dieppe, 1991). The main symptoms of OA include pain, stiffness, limited function 
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and joint movement, instability of joint, crepitus, deformity due to bony enlargement 
and joint effusion/swelling (Hunter et al., 2008).  
There is currently no cure for OA. Joint (knee/hip) replacement surgery is the most 
common option for the late stage of OA patients, since there is no clinical 
presentation in the early stage with joint destruction being irreversible once OA is 
diagnosed (Michael et al., 2010). Generally, the treatment of OA is divided into non-
pharmacological, pharmacological, and surgical treatments (Altman, 2010; Michael, 
et al., 2010; Woolf & Pfleger, 2003). Non-pharmacological treatment includes 
physiotherapy, acupuncture, exercise, and weight loss. Pharmacological management 
of OA, focusing on the control of pain and inflammation, improvement joint function 
and quality of life, includes analgesics (paracetamol/acetaminophen), non-selective 
non-steroidal anti-inflammatory drugs (NSAIDs), cyclooxygenase (COX)-2 
inhibitors, topical NSAIDs, intra-articular corticosteroids and hyaluronic acid 
(Altman, 2010; Michael, et al., 2010). Symptomatic slow acting drugs for OA 
include glucosamine, chondroitin sulfate and collagen hydrolysate. Current research 
of pharmaceutical interventions for OA includes tumor necrosis factor alpha (TNF-α) 
antibodies, anti-inflammatory cytokines such as interleukin (IL)-10, and inhibitors 
for MMPs (Michael, et al., 2010).  
2.2.3 Pathophysiology of OA  
The key pathophysiological features of OA joints include articular cartilage 
dagradation and abnormal subchondral bone metabolism. In osteoarthritic joints, 
cartilage damage is manifested by loss of smooth appearance, softening, fissuring 
and reduced thickness. Cartilage pathology in OA is associated with changes of 
cellular phenotype of articular chondrocytes to a state of terminal differentiation 
(Pfander et al., 2001; Pullig et al., 2000). In mature adult articular cartilage, 
chondrocytes have a stable phenotype with an anabolic metabolic activity; 
osteoarthritic chondrocytes, on the other hand, manifest catabolic metabolic 
phenotypes, in which matrix breakdown outweighs new matrix synthesis (Rousseau 
& Delmas, 2007).  
Inflammation has now been implicated as an important mediator in OA progression, 
although OA has been seen as a non-inflammatory arthropathy for a long time 
(Bonnet & Walsh, 2005). Pro-inflammatory factors, such as IL-1, IL-6 and TNF-α, 
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are mediators that initiate and enhance the catabolism in OA cartilage (Kapoor, et al., 
2011). These cytokines, which are produced by chondrocytes, mononuclear cells, 
osteoblasts and synovial tissues, stimulate chondrocytes to release proteolytic 
enzymes and suppress the synthesis of proteoglycan and collagen, thereby 
accelerating cartilage degradation (Kapoor, et al., 2011). 
2.2.4 Chondrocyte hypertrophy in OA cartilage 
Expression of the matrix proteins COL2A1 and aggrecan are significantly reduced in 
OA chondrocytes (Knudson & Knudson, 2001). OA chondrocytes secrete 
osteogenic-related proteins such as type I collagen (COL1), ALP, bone sialoprotein 
(BSP) and COL10A1 that are normally absent in healthy cartilage (Kapoor, et al., 
2011). Extracellular MMPs, such as collagenase (MMP-1, 8 and 13), stromelysin 
(MMP-3) and gelatinase (MMP-2 and 9), are responsible for degradation of collagen 
and proteoglycans (Cawston & Wilson, 2006; Murphy & Lee, 2005). A-disintegrin 
and metalloproteinase with thrombospondin-like repeats (ADAMTS)-4 and 
ADAMTS-5 are the dominant aggrecanase enzymes (Murphy & Lee, 2005). The 
abundance and activity of MMPs and ADAMTS are markedly enhanced by OA 
chondrocytes and play a crucial role in degrading the normal cartilage ECM 
components in OA (Cawston & Wilson, 2006; Kapoor, et al., 2011; Murphy & Lee, 
2005; Tetlow et al., 2001). Activity of MMPs and ADAMTS are inhibited by 
specific endogenous tissue inhibitors of metalloproteinases (TIMPs) (Murphy et al., 
2003). For instance, TIMP-1, the most abundant protease inhibitor in healthy 
cartilage, inhibits activity of MMP-1 (Davidson et al., 2006); TIMP-3 effectively 
inhibits ADAMTS-4 and -5 (Kashiwagi et al., 2001; Murphy, et al., 2003). However, 
in OA cartilage the expressions of TIMPs are decreased and lead to an imbalance in 
the regulation of MMPs which contributes to cartilage degradation (Davidson, et al., 
2006; Franses et al., 2010).  
In the current view of osteoarthritis, expression of COL10A1, MMP-13 and ALP has 
been regarded as hypertrophic markers of cartilage. Gene expression of these 
hypertrophic markers are controlled by transcriptional factor RUNX2, transducing 
the extracellular signals into regulated gene expression (Hirata et al., 2012; 
Kamekura et al., 2006; Li et al., 2011). Several signalling pathways have been 
demonstrated to be involved in this process, such as mitogen-activated protein kinase 
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(MAPK), TGF-β and wingless-type MMTV integration site family member (Wnt), 
which all target the transcriptional factor RUNX2 with the result of up-regulation of 
hypertrophic markers (Zheng et al., 2003).   
Runt-related transcription factor 2 (RUNX2) 
RUNX2 is essential for specifying the osteoblast lineage differentiation, as well as 
guiding chondrocyte hypertrophy by directly targeting the osteogenic marker osterix 
in osteoblasts and the hypertrophic genes of COL10A1 and MMP-13 in chondrocytes 
(Hirata, et al., 2012; Li, et al., 2011). RUNX2 is induced in the articular cartilage of 
wild-type mice at the early stage of OA, almost simultaneously with COL10A1 but 
earlier than MMP-13 (Kamekura, et al., 2006). RUNX2+/- mice show resistance to 
osteoarthritis development following induced knee joint instability, and cartilage 
exhibits decreased cartilage destruction and osteophyte formation accompanied by 
reduced abundance of COL10A1 and MMP-13 (Kamekura, et al., 2006).   
Type X collagen α1 (COL10A1)  
COL10A1 is the most specific marker of hypertrophic chondrocytes (Girkontaite et 
al., 1996; Schmid et al., 1994; von der Mark et al., 1992). COL10A1 is a non-
fibrillar, network-forming short collagen with a triple helical core with half the 
length of the fibril-forming collagen types I, II and III (Schmid, et al., 1994). The 
globular domain at the carboxyl end helps assemble the molecules into a hexagonal 
meshwork (Schmid, et al., 1994). COL10A1 is expressed in pre-hypertrophic and 
hypertrophic chondrocytes in the growth plate and involved in matrix mineralization 
and endochondral ossification, since a transgenic mouse with Col10α1 gene mutation 
showed severe reduction in the hypertrophic zone (Jacenko et al., 1993). In human 
adult articular cartilage, COL10A1 is restricted to the calcified cartilage zone below 
the tide mark, whereas the osteoarthritic chondrocytes synthesize large amounts of 
COL10A1; In OA cartilage, COL10A1 is found predominantly in chondrocyte 
clusters in the deep zones, as well as in middle and upper zones in severe OA 
cartilage, as shown by biochemical, immunohistological and in situ hybridization 
methods (Girkontaite, et al., 1996; Schmid, et al., 1994; von der Mark, et al., 1992). 
Matrix metalloproteinases (MMP)-13 
MMPs are a family of zinc-dependent endopeptidases that degrade extracellular 
matrix components (Murphy & Lee, 2005; Neuhold et al., 2001; Wang et al., 2013). 
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In cartilage, MMPs could be synthesized by synovial cells and chondrocytes. 
Compared to other MMPs, MMP-13 expression tends to be restricted to connective 
tissues (Vincenti & Brinckerhoff, 2002). MMP-13, also known as collagenase-3, is 
the major enzyme that targets cartilage for degradation (Wang, et al., 2013). In OA, 
MMP-13 play an important role in degrading COL2A1, as well as proteoglycan, 
types IV and type IX collagen, osteonectin and perlecan (Shiomi et al., 2010). It has 
been shown that transgenic mice overexpressing MMP-13 develop a spontaneous 
OA-like cartilage phenotype (Neuhold, et al., 2001). Clinical evidence has also 
revealed that patients with articular cartilage destruction have increased expression 
of MMP-13, suggesting that its increases closely associated with cartilage 
degradation (Roach et al., 2005). 
 
2.3 HYPOXIA  
Articular cartilage is a typically avascular tissue by nature. Synoviocytes, which lies 
in the outer layer in the synovium, secrete synovial fluid into the joint space. This 
fluid plays an important role in lubricating the joint surface and provides nutrient and 
gas exchange to cartilage chondrocytes and buffers the force between the two joints 
(Lafont, 2010; Lorenz & Richter, 2006). It has been reported that oxygen supply to 
articular chondrocytes depends on the oxygen capacity in synovial fluids and its flow 
during the movement of the respective joint. Therefore, oxygen supply in cartilage is 
very limited (Lee et al., 2007; Lund-Olesen, 1970; Pfander & Gelse, 2007).   
2.3.1 Oxygen tension in cartilage 
It was known for a long time that oxygen partial pressure (pO2) of mature cartilage is 
particularly low compared to other tissues. In human synovial fluid, the oxygen 
tension is around 1-9% (Falchuk et al., 1969; Lund-Olesen, 1970; Treuhaft & 
MCCarty, 1971). Falchuk et al. reported that pO2 values ranged from 53 to 9 mmHg 
in synovial fluids (Falchuk, et al., 1969). Lund-Olesen et al. reported that mean pO2 
values is 63 mmHg in traumatic exudates and 43 mmHg in osteoarthritic synovial 
fluids, while the lowest value occurs in rheumatoid arthritis patients, which is around 
27 mmHg (Lund-Olesen, 1970). Paradoxically, in spite of increased blood vessel 
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penetration into the calcified cartilage layer in rheumatoid arthritis and osteoarthritis, 
oxygen tension seems to decrease even further in these pathological conditions. 
In articular cartilage tissue, it has been shown that oxygen gradients are steep 
compared with fibrous connective tissues, and the absolute value at the centre of 
0.5mm cartilage blocks is 5–8 mmHg, as compared to 15–20 mmHg in the inter-
capillary soft tissues (Silver, 1975). Based on this particular study, it has been 
estimated that oxygen tension in the upper zones of mature normal cartilage is 
around 6–10%, while oxygen content drops to 1% in the deep layers next to the 
calcified cartilage (Pfander & Gelse, 2007; Silver, 1975). In compressed cartilage, it 
has been calculated that oxygen tension is close to zero at a depth of 0.096 cm from 
the cartilage surface (Pfander & Gelse, 2007). 
Chondrocytes appear to be the only cell type that can adapt to the hypoxic 
environment of cartilage, It has been shown that oxygen consumption by cartilage is 
only 2–5% of that of liver or kidney, even when cultured in air-saturated medium 
instead of synovial fluid, which typically has 6 ± 10% O2 concentration (Lee & 
Urban, 1997; Silver, 1975).  Furthermore, it has been demonstrated that oxygen 
consumption by chondrocytes is independent on the ambient oxygen pressure, and 
that chondrocytes will always have a minimal oxygen consumption whether oxygen 
level is less than 1% (anoxia) or as high as 21% (Schneider et al., 2007). 
2.3.2 Overview of hypoxia inducible factor (HIF) signalling pathway 
The cellular response to hypoxia is mediated by HIF family members (mainly HIF-
1α, -2α, -3α). Among these family members, the functions of HIF-1α and HIF-2α 
have been widely studied. It is well documented that hypoxia initiates an angiogenic 
signals via stabilizing HIF-1α and/or HIF-2α. The functional unit of HIF signalling is 
composed of two subunits: the α-subunit confers oxygen responsiveness of HIF; 
while the β-subunit is constitutively expressed, which is also named aryl 
hydrocarbon receptor nuclear translocator (ARNT) (Huang et al., 1996; Jiang et al., 
1997). The abundance and stability of the HIF-α subunit determines the function of 
HIFs signalling pathway (Huang, et al., 1996; Jiang, et al., 1997; Salceda & Caro, 
1997).  
Both of HIF-1α and HIF-2α belong to the PER-ARNT-SIM (PAS) subfamily of the 
basic helix-loop-helix (bHLH) family of transcription factors (Wang et al., 1995). 
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The protein structure of HIF-1α and HIF-2α are closely related, including a bHLH 
domain on N-terminal for DNA binding; an intermediate PAS domain for the 
specificity and dimerization of target gene; and a transactivation domain (TAD), 
including N-terminal TAD (NTAD) and one C-terminal TAD (CTAD) (Sowter et al., 
2003; Wang, et al., 1995; Yan et al., 2007). Overall, HIF-2α and HIF-1α share 48% 
amino acid identity and, more specifically, an 83% sequence identify in the bHLH 
region and approximately 70% sequence homology across the PAS domain (Ema et 
al., 1997; Flamme et al., 1997; Hogenesch et al., 1997). HIF-3α has no TAD 
domain; it is, therefore, thought to be a dominant negative of HIF-1α and HIF-2α 
(Maynard et al., 2005). 
The HIF transcription factors were originally identified by the fact that their 
expression and function mainly depend on oxygen level surrounding the cells 
(Bruick & McKnight, 2001; Epstein et al., 2001). Under normal oxygen condition, 
HIF-α have a very short half-life (about 5 min), degrading rapidly (Salceda & Caro, 
1997). In brief, prolyl residues of HIF-α in C-terminal (Pro402 and Pro564 in TAD 
region) are hydroxylated by prolyl hydroxylase (PHD-1 to -3) (Ivan et al., 2001; 
Jaakkola et al., 2001; Yu et al., 2001). PHDs serve as oxygen sensors, since their  
activity requires oxygen as co-factor and directly sense O2 level within the cell 
(Bruick & McKnight, 2001; Epstein, et al., 2001). Hydroxylated HIF-α is 
ubiquitinated through binding to von Hippel-Lindau protein (VHL), a target of E3 
ubiquition-ligase complex, and finally rapidly degraded by 26S proteasome (Ohh et 
al., 2000; Salceda & Caro, 1997; Tanimoto et al., 2000). On the other hand, under 
hypoxic condition (1-5% oxygen), PHDs activity is inhibited and prolyl 
hydroxylation of HIF-α is, therefore, hampered (Huang et al., 1998; Salceda & Caro, 
1997). The HIF-α is stabilized and accumulates in the cytoplasm after which it 
translocates into the nucleus and heterodimerizes with the constitutively expressed 
HIF-β (ARNT) (Jiang et al., 1996; Semenza et al., 1994; Wang & Semenza, 1993). 
Then the HIF-α/β heterodimer trans-activates hypoxia-responsive genes via binding 
to hypoxia-response elements (HRE, 5’-RCGTG-3’; R is A or G) (Semenza et al., 
1996; Semenza, et al., 1994; Wang & Semenza, 1993). In addition, the recruitment 
of co-activator p300/CBP is also an essential component for transcriptional activity 
of HIFs (Lando et al., 2002). One of the well-known gene targets of HIFs is 
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angiogenic genes, such as VEGF and erythropoietin (EPO) (Firth et al., 1994; 
Forsythe et al., 1996).  
2.3.3 Role of HIFs pathway in cartilage development and homeostasis 
The importance of HIF-1α and HIF-2α during cartilage development, mainly in 
endochondral ossification and growth plate development, has been demonstrated in 
several studies. Schipani et al. established the mouse model of tissue-specific 
deletion of HIF-1α in cartilaginous growth plate of developing bone, and found that 
the interior developmental growth plate in mammals was hypoxic; cell death 
increased in the interior of the growth plate that lacked HIF-1α, indicating HIF-1α is 
essential for chondrocytes growth arrest and survival (Schipani, et al., 2001). Provot 
et al., using conditional knockout of HIF-1α in limb bud mesenchyme, showed 
alterations to the formation of the cartilaginous primordia, and late hypertrophic 
differentiation was also affected due to the delay in early chondrogenesis (Provot et 
al., 2007). Stewart et al. showed that HIF-2α expression was elevated during 
terminally differentiating growth plate chondrocyte accompanied by an increase in 
VEGF expression, suggesting that HIF-2α is involved in the initiation of blood vessel 
formation and a metabolic shift in the growth plate and crucial for endochondral 
ossification (Stewart et al., 2006). Moreover, deletion of pVHL in chondrocytes, 
which leads to HIF-1α and -2α overexpression, increases matrix deposition during 
growth plate development (Pfander et al., 2004).  
Being avascular, hypoxia is the physiological environment for adult cartilage, and 
was, therefore, long considered the most favourable condition for chondrocyte 
survival, differentiation and cartilage regeneration; it is, nevertheless, a stress 
condition in vascular tissues. In cartilage, as in other tissues, hypoxia enhances the 
expression of HIFs. Both of HIF-1α and HIF-2α are detectable in normal articular 
cartilage (Bohensky, et al., 2009; Coimbra, et al., 2004). HIF-1α has been reported to 
be essential for chondrocyte survival, energy generation and matrix synthesis 
(Pfander, et al., 2003; Yudoh et al., 2005). Pfander et al. showed that HIF-1α is 
necessary for anaerobic energy generation and proteoglycan synthesis in articular 
chondrocytes (Pfander, et al., 2003). In vitro studies showed that hypoxia increases 
the accumulation of COL2A1 and enhances the transcriptional factor SOX9, a master 
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regulator of cartilage-specific matrix proteins (Duval et al., 2009; Robins et al., 
2005).   
2.3.4 Role of HIFs pathway in osteoarthritis 
Recent studies have demonstrated the catabolic effect of HIF signalling in 
osteoarthritic cartilage, in particularly HIF-2α. It has been proposed that the shift 
from HIF-1α to HIF-2α initiates and promotes chondrocyte hypertrophy and cartilage 
degradation in OA (Husa et al., 2010). In spite of having approximately 50% 
sequence homology, HIF-1α and HIF-2α have remarkably different expression 
patterns and functions in cartilage metabolism (Husa, et al., 2010). HIF-1α, which 
has been extensively studied as a beneficial factor for matrix production and cartilage 
metabolism, seems to play an important role in cartilage developmental stages 
including endochondral ossification and growth plate development, as well as in 
maintaining mature cartilage homeostasis; whereas, until recently, HIF-2α has been 
shown to be a catabolic regulator in cartilage metabolism during pathological 
process, such as chondrocyte hypertrophy in osteoarthritis (Husa, et al., 2010; Saito, 
et al., 2010; Yang, et al., 2010).  
Expression of HIF-2α in OA cartilage  
The scientific literature concerning the expression of HIF-2α in OA cartilage is 
contradictory – both increased and decreased levels have been reported (Bohensky, 
et al., 2009; Coimbra, et al., 2004). For example, studies conducted by  Yang et al. 
and Saito et al. showed an increase in HIF-2α levels in human OA cartilage as well 
as  in experimentally-induced mouse OA cartilage (Saito, et al., 2010; Yang, et al., 
2010). Bohensky, however, reported that HIF-2α is reduced in human OA cartilage 
(Bohensky, et al., 2009). In vitro studies showed that HIF-2α is not solely dependent 
on oxygen level, but also quite sensitive to non-hypoxic stimulus including 
inflammatory cytokines, growth factors and catabolic stress. Both of Yang’s and 
Saito’s studies showed that IL-1β and TNF-α stimulation resulted in an upregulation 
of HIF-2α in chondrocytes and, furthermore, suggested that NF-κB and p38 may be 
the upstream mechanism that regulates HIF-2α (Saito, et al., 2010; Yang, et al., 
2010). TGF-β1 can also induce HIF-2α gene and protein expression under non-
hypoxic condition, and further activates VEGF transcription in a Smad3-dependent 
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manner (Chae et al., 2011). However, there is as yet only one study that shows that 
IL-1α decreases HIF-2α level in human chondrocytes (Thoms, et al., 2013).  
Catabolic effect of HIF-2α in OA cartilage 
HIF-2α has recently been demonstrated as a central catabolic regulator of cartilage 
destruction in osteoarthritis by directly targeting key hypertrophic genes involved in 
the pathogenic transition of an osteoarthritic chondrocyte (such as COL10A1, MMP-
13 and VEGFA), and also regulating chondrocyte apoptosis and autophagy 
(Bohensky, et al., 2009; Ryu et al., 2012; Saito, et al., 2010; Yang, et al., 2010).  
Coincidently, two independent studies have recently reported that HIF-2α directly 
targets the promoters of hypertrophic genes in OA cartilage (Saito, et al., 2010; 
Yang, et al., 2010). Endochondral bone formation is seen as an outcome typical of 
OA cartilage, which results in osteophyte formation (Kawaguchi, 2008; Kronenberg, 
2003; Saito, et al., 2010). The process of endochondral bone formation is 
characterized by sequential steps, including chondrocyte hypertrophic differentiation 
(represented by COL10A1 secretion), cartilage degradation (represented by 
expression of proteinases MMP-13) and vascular invasion (angiogenic stimuli, such 
as VEGF) (Kawaguchi, 2008; Kronenberg, 2003; Saito, et al., 2010). Saito et al. 
demonstrated that HIF-2α is strongly implicated in catabolic mechanisms leading to 
cartilage breakdown and endochondral bone formation (Saito, et al., 2010). HIF-2α 
enhances the transcriptional activities of COL10A1, MMP-13 and VEGFA by 
binding to the respective hypoxia-responsive elements on their promoters (Saito, et 
al., 2010). Epas1-heterozygous (gene name of HIF-2α) deficient mice showed 
resistance to osteoarthritis development (Saito, et al., 2010; Yang, et al., 2010). 
Yang’s study further confirmed the catabolic role of HIF-2α in osteoarthritis (Yang, 
et al., 2010). Consistent with Saito’s result, they showed that Epas1 transgenic mice 
induced spontaneous cartilage destruction, while heterozygous deletion of Epas1 
gene suppressed cartilage destruction in mice OA model (Yang, et al., 2010). It has, 
furthermore, been shown that catabolic factors including MMP-1, MMP-3, MMP-9, 
MMP-12, MMP-13, ADAMTS4, nitric oxide synthase-2 (NOS2) and prostaglandin 
endoperoxide synthase-2 (PTGS2), are direct targets of HIF-2α (Yang, et al., 2010).  
Besides catabolic factors, HIF-2α could also induce osteogenic factors, such as 
RUNX2 and Indian hedgehog (IHH) (Saito, et al., 2010; Tamiya et al., 2008). IHH 
signal promotes chondrocyte hypertrophy during endochondral ossification and 
 Chapter 2: Literature Review 21 
osteoarthritis progression through the Patched-1 (PTCH1) receptors and 
transcriptional factors of glioma-associated oncogene homolog (GLI) family member 
(Lin et al., 2009). RUNX2 is another key transcriptional factor of chondrocyte 
hypertrophy, which directly targets COL10A1 and MMP-13 (Kamekura, et al., 2006; 
Sato et al., 2008; Zheng, et al., 2003). HIF-2α enhances RUNX2 promoter activity; 
however, RUNX2 does not seem essential for HIF-2α to initiate chondrocyte 
hypertrophy (Husa, et al., 2010; Saito, et al., 2010).  
Another study showed that HIF-2α regulates Fas-mediated chondrocyte apoptosis in 
osteoarthritis destruction, which also indicates the catabolic role of HIF-2α in OA 
(Ryu, et al., 2012). Overexpression of HIF-2α in mouse cartilage tissues by 
adenovirus injection or chondrocyte-specific Epas1 transgenic mice increased 
chondrocyte apoptosis and cartilage destruction, while chondrocyte-specific 
knockout of Epas1 in mice suppressed these catabolic processes in OA mice model 
(Ryu, et al., 2012).  
Autophagy is a normal physiological process that degrades and recycles damaged 
and dysfunctional intracellular organelles and molecules in order to maintain 
homeostasis or normal function (Bohensky, et al., 2009). Bohensky et al. showed 
that HIF-1α promotes the onset of autophagy in chondrocytes and that HIF-2α acts as 
a brake on the autophagy accelerator ability of HIF-1α (Bohensky, et al., 2009).  
Catabolic effects of HIF-1α in OA cartilage 
HIF-1α has been considered a key factor for chondrocyte survival and cartilage 
homeostasis; however, there are now a number of studies that demonstrate that HIF-
1α is a catabolic effector in cartilage pathogenesis. Rather than a strictly hypoxia-
inducible factor, HIF-1α has been seen as a stress-inducible factor, since evidence 
shows that pro-inflammatory cytokines of IL-1β and TNF-α, insulin-like growth 
factor 1 (IGF-1) oxidative stress elevates HIF-1α stability in chondrocytes in vitro 
through p38 kinase and phosphoinositide (PI)-3 kinase pathways (Thoms, et al., 
2013; Yudoh, et al., 2005). HIF-1α could indeed induce VEGFA expression in 
chondrocytes. Lin et al. found that hypoxia-induced VEGF expression is HIF-1α-
dependent in chondrocyte, indicating that the hypoxic-angiogenesis (HIF-1α-VEGF) 
response pathway remains intact in cartilage (Lin, et al., 2004). Prostaglandin (PG), 
especially PGE2, is involved in IL-1β induced pathophysiology of OA cartilage by 
inducing expression of matrix-degrading enzymes. Grimmer et al. showed that HIF-
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1α up-regulates PG metabolism in OA cartilage through enhancing microsomal PGE 
synthase 1 (mPGES-1), which opens the possibility that HIF-1α participates in 
catabolic metabolism of OA cartilage (Grimmer et al., 2007).  
 
2.4 CHONDROMODULIN-1 (CHM-1) IN CARTILAGE DEVELOPMENT, 
HOMEOSTASIS AND DISEASES 
The balance of angiogenic and anti-angiogenic factors is critical for normal 
development and homeostasis. In the developmental stage of endochondral bone 
formation, cartilage switches its phenotype from anti-angiogenic to pro-angiogenic at 
the primary ossification centre where the hypertrophic and calcified cartilage zone 
forms. Angiogenic factors, such as VEGF, fibroblast growth factor (FGF), platelet-
derived growth factor (PDGF), angiopoietins, chemokines and MMPs, play an 
important role during endochondral ossification. However, mature articular cartilage 
normally resists vascular invasion due to the dominant role of anti-angiogenic 
factors. Cartilage contains considerable amount of anti-angiogenic factors, such as 
ChM-1, TSP-1, TIMPs and troponin-1, which are responsible for maintaining its 
avascular nature and resist angiogenesis (Bonnet & Walsh, 2005; Patra & Sandell, 
2012). However, the functional role of anti-angiogenic factors in the maintenance of 
chondrocyte phenotype is largely unknown. 
ChM-1 is a 121-amino acid residue glycoprotein derived from a transmembrane 
precursor and distributed mainly in the interstitial space of cartilage matrix. It is an 
anti-angiogenic factor that is highly and specifically expressed in cartilage (Hiraki, et 
al., 1997a; Shukunami & Hiraki, 1998). The inhibition of angiogenesis by ChM-1 in 
cartilage, endothelial cells, cardiac valves and several tumors is well documented 
(Hayami, et al., 1999; Miura, et al., 2010; Yoshioka, et al., 2006). Recent studies 
have revealed the regulatory effect of ChM-1 in cartilage development and tissue 
repair, indicative of the importance of ChM-1 in governing chondrocyte phenotype 
changes (Klinger, et al., 2011; Nakamichi, et al., 2003; Yukata, et al., 2008).  
2.4.1 Structure of ChM-1 
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ChM-1, also known as the leukocyte cell-derived chemotaxin 1, is encoded by the 
LECT1 gene in humans. It is a 25 kDa glycoprotein, first identified in fetal bovine 
epiphyseal cartilage extracts, with the ability to stimulate DNA synthesis in cultured 
rabbit growth plate chondrocytes in the presence of FGF (Hiraki, et al., 1997a; Inoue 
et al., 1997). The human ChM-1 precursor gene, mapped to chromosome 13 
(13q14.3), comprises seven exons. Figure 2-3A shows the primary amino acid 
sequences of human and mouse ChM-1 (both of 120 residues) predicted from the 
nucleotide sequences of ChM-1 precursor cDNA (Hayami, et al., 1999; Shukunami 
et al., 1999a; Shukunami et al., 1999b). Mature ChM-1 was found to be the C-
terminal portion of a larger 334 amino acids type II transmembrane precursor, from 
which the mature protein is cleaved by a furin-like endopeptidase and secreted from 
the cell. The amino acid sequence of the human ChM-1 precursor was found to be 
conserved across species including fish (Figure 2-3B). The membrane-bound 
precursor has only a short half-life, while the cleaved, mature ChM-1 is abundant in 
the extracellular matrix (Hayami, et al., 1999; Shukunami, et al., 1999a; Shukunami, 
et al., 1999b). 
 
Figure 2-3. Molecular structure of ChM-1.  A. The amino acid sequence of human mature ChM-1. 
The 17 amino acid residues that are not conserved in the mouse counterpart are indicated in green. A 
conserved N-glycosylation site is found in domain 1. Domain 2 contains four disulfide bonds that are 
indicated by orange bars. B. The phylogenetic tree of the chondromodulin-1 precursor and a ChM-1 
related protein, TeM (Hiraki et al., 2009). 
 24 Chapter 2: Literature Review 
2.4.2 Role of ChM-1 in cartilage development and regeneration 
Expression of ChM-1 during cartilage development 
Cartilage is the most prominent site of ChM-1 expression in mammals (Patra & 
Sandell, 2012). During fetal developmental stages, the expression of ChM-1 is 
closely related to chondrocyte phenotype. Endochondral ossification takes place in 
the growth plates at the distal ends of the long bones between the late epiphysis and 
diaphysis. Resting chondrocytes first undergo proliferation, then differentiate into 
hypertrophic chondrocytes, and finally transit into osteoblast or undergo apoptosis. 
ChM-1 is highly expressed in the avascular cartilage regions of the growth plate. The 
immunoreactivity for mature ChM-1 has been shown to specifically localize in 
cartilaginous bone primordia, where it is maintained at a high level in the avascular 
zone of cartilage, including the resting, proliferating, and early hypertrophic zones 
(Hiraki, et al., 1997a; Shukunami, et al., 1999a; Shukunami et al., 2008). However, 
in embryonic epiphyseal cartilage, ChM-1 expression is abolished in the area of late 
hypertrophic chondrocytes, where blood vessel invasion takes place (Hiraki, et al., 
1997a; Shukunami, et al., 1999a; Shukunami, et al., 2008). Concomitant with the 
disappearance of ChM-1, calcified cartilage begins to express VEGFA and MMP-13, 
which initiates the remodelling of calcified cartilage matrix (Hiraki, et al., 1997a; 
Shukunami, et al., 1999a; Shukunami, et al., 2008) (Figure 2-4). Concurrent 
expression of angiogenic-related factors (such as MMP-9) facilitates vascular 
invasion at the centre of bony collars surrounding the late hypertrophic and calcified 
zone of cartilage. The cartilage matrix is then degraded and replaced with the typical 
trabecular bone matrix produced by osteoblasts (Las Heras, et al., 2012). In addition, 
it is also found that expression of ChM-1 is down-regulated in rescued RUNX2 
knockout mice, in contrast to that of VEGF, which is up-regulated in the same 
animals, suggesting that ChM-1 and VEGF have opposite roles (Kamekura, et al., 
2006). Thus, the expression pattern of ChM-1 suggests it may possess important 
function in skeletal development. 
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Figure 2-4. Immunolocalization of ChM-1 in the avascular mesenchyme of the developing mouse 
forelimb.  A frozen section of mouse forelimb was double-stained with platelet endothelial cell 
adhesion molecule (PECAM)-1 antibody (red) and ChM-1 antibody (green). Positive staining for 
ChM-1 is observed in the avascular cartilage ECM zones of the phalanges, carpal bones and ulna and 
radius in the PECAM-1 negative domains. Orange arrowheads indicate the sites of vascular invasion 
into hypertrophic/calcified cartilage of cartilaginous bone primordial (Hiraki, et al., 2009). 
Function of ChM-1 in cartilage development and regeneration 
The regulatory effect of ChM-1 in cartilage development has been verified by 
genetically modified mice. ChM-1 null mice display no abnormalities in vascular 
invasion or cartilage development (Brandau et al., 2002), however, adult ChM-1 null 
mice exhibit aberrant cartilage formation during fracture repair (Yukata, et al., 2008). 
The majority of the chondrocytes in the periosteal callus in ChM-1 null mice fail to 
differentiate into mature chondrocytes, resulting in a marked reduction of the 
external cartilaginous callus (Yukata, et al., 2008). In addition, ChM-1 null adult 
mice display a marked reduction in bone remodelling, manifested by a significant 
increase in the bone mineral density due to an imbalance between osteoclastic bone 
resorption and osteoblastic bone formation (Nakamichi, et al., 2003). Hence, these 
studies indicate that ChM-1 participates in regulation of chondrocyte phenotype and 
bone remodelling. 
In vitro studies have demonstrated that ChM-1 increases the proliferation and 
differentiation of chondrocytes. Hiraki et al. showed that ChM-1 purified from fetal 
bovine cartilage stimulates DNA synthesis of cultured growth-plate chondrocytes in 
the presence of basic FGF (bFGF) (Hiraki et al., 1991). Inoue et al. observed that 
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ChM-1 stimulates the colony formation of rabbit growth plate chondrocytes in 
agarose culture, in a dose-dependent manner and synergistically in the presence of 
FGF-2, indicating that ChM-1 might participate in an autocrine signalling of 
anchorage-independent growth of chondrocytes in vitro (Inoue, et al., 1997). 
The inhibitory effect of ChM-1 on angiogenesis is well-documented. Recombinant 
ChM-1 inhibits proliferation and tube morphogenesis of endothelial cells in cell 
culture experiments (Hiraki, et al., 1997a; Hiraki, et al., 1997b; Yoshioka, et al., 
2006). ChM-1 inhibited the migration human umbilical cord vascular endothelial 
cells (HUVECs) by the disruption of actin reorganisation and suppression of 
Rac1/Cdc42 GTPase activity (Miura, et al., 2010).  
ChM-1 also plays a role in cartilage regeneration. Inferior microfracture-induced 
fibrocartilage is characterized by a lack of ChM-1, which may contribute to the 
observed matrix calcification, vascular ingrowth, and excessive ossification within 
the cartilage lesions (Blanke et al., 2009). Direct application of adeno-associated 
virus (AAV)-ChM-1 vectors into microfractured porcine cartilage lesions stimulated 
chondrogenic differentiation of ingrowing progenitor cells, but significantly inhibited 
terminal chondrocyte hypertrophy, the invasion of vessel structures, and excessive 
endochondral ossification, which were otherwise observed in untreated lesions 
(Klinger, et al., 2011). During chondrogenic differentiation of BMSCs, anti-
hypertrophic factors such as parathyroid hormone-related protein (PTH-rP) and anti-
angiogenic proteins including ChM-1 or TSP-1 can inhibit endochondral ossification 
(Gelse et al., 2012).  
2.4.3 Role of ChM-1 in other tissues and diseases 
Besides cartilage, ChM-1 has been detected in the eye, cardiac valves and thymus 
(Brandau, et al., 2002; Funaki et al., 2001), and furthermore, ChM-1 is also a 
candidate for anti-cancer proteins due to its anti-angiogenesis and anti-tumorigenic 
effects (Hayami, et al., 1999; Mera et al., 2009; Oshima et al., 2004), which will be 
summarized below.  
ChM-1 expression has been detected in the eye and cerebellum in rats (Funaki, et al., 
2001). ChM-1 mRNA expression is evident in the iris-ciliary body, retina, and scleral 
compartments and vitreous body, specifically in the ganglion cells, inner nuclear 
layer cells, and pigment epithelium in the retina and in the non-pigment epithelium 
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of the ciliary body. In addition, recombinant human ChM-1 inhibits tube 
morphogenesis of human retinal endothelial cells in vitro, suggesting its role in the 
regulation of retinal vascularization during development and the maintenance of an 
intact retina and vitreous body (Funaki, et al., 2001).    
Cardiac valves have the same level of avascularity as cartilage under normal 
conditions, but under pathological conditions, such as aortic stenosis, these valves 
express angiogenic factors that causes neovascularization (Akiyama et al., 2004; 
Kalluri & Zeisberg, 2006). ChM-1 has been detected throughout the valvular 
interstitial cells of all four cardiac valves and their extracellular matrix, but not in the 
outer endothelial cell layer (Yoshioka, et al., 2006). The non-overlapping 
localizations of ChM-1 and VEGFA are apparent at all development stages of the 
heart under normal conditions, and ChM-1 maintains cardiac valvular function by 
preventing angiogenesis (Yoshioka, et al., 2006).  
In chondrosarcoma, transcripts for ChM-1 are substantially reduced, compared to 
normal articular cartilage and other benign cartilage tumours (Hayami, et al., 1999). 
The susceptibility of chondrosarcoma to tumour angiogenesis may therefore be 
accounted for by a loss of ChM-1 expression. Local administration of recombinant 
human ChM-1 completely blocked vascular invasion and tumour growth of 
chondrosarcoma, and also inhibited the growth of HT-29 colon adenocarcinoma in 
vivo, implying its therapeutic potential for solid tumours (Hayami, et al., 1999). 
Furthermore, the adenoviral transduction of human ChM-1 in mouse melanoma cells 
results in the suppression of tumour growth in association with decreased tumour 
angiogenesis (Oshima, et al., 2004). It is reported that ChM-1 can act directly on 
tumour cells and not just endothelial cells. Mera et al. showed that ChM-1 reduced 
growth and DNA synthesis of human tumour cells, such as HepG2, PC-3 and NOS-1 
(Mera, et al., 2009). ChM-1 also down-regulates cell cycle proteins and up-regulate 
the cell cycle inhibitor (Mera, et al., 2009; Patra & Sandell, 2012). These data 
suggest that ChM-1 mediates its cytotoxic effect on human tumour cells primarily by 
cell cycle arrest.  
In rheumatoid arthritis, recombinant human ChM-1 suppresses the proliferation of 
synovial cells (Setoguchi et al., 2004). ChM-1 has also been found to suppress the 
proliferative response of T cells that had been stimulated with anti-CD3/CD28 
antibodies. The suppression of T cell responses and synovial cell proliferation 
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indicates a unique therapeutic potential for ChM-1 in rheumatoid arthritis (Setoguchi, 
et al., 2004). 
2.4.4 Molecular mechanisms involving the expression and function of ChM-1  
The regulation systems associated with ChM-1 production are poorly understood. 
ChM-1 has been reported as a hypoxia-inducible and SOX9-regulated gene in human 
articular chondrocytes (Lafont, et al., 2008). SOX9 is a potent transactivator of 
chondrocyte-specific genes. The adenoviral co-expression of SOX9, SOX5 and 
SOX6 induces chondrogenic differentiation as well as ChM-1 mRNA in mouse 
embryonic stem cells (Ikeda et al., 2004). In chondrocyte differentiation, ChM-1 
mRNA is down-regulated when treated with FGF-2, TGF-β2 and PTH-rP 
(Shukunami & Hiraki, 1998). However, there is no evidence showing whether 
transcriptional factor SOX9 directly targets ChM-1 gene transcription.   
In the study of cartilage regeneration, overexpression of ChM-1 in cultured 
osteochondral progenitor cells showed a tendency to reduce the expression of 
hypertrophic maker COL10A1 by mechanisms unknown (Klinger, et al., 2011). In 
addition, in the studies involving the anti-angiogenesis and anti-tumour effect of 
ChM-1, it is reported that ChM-1 reduces growth of tumour cells presumably by 
suppressing the signal transducer and activators of transcription (STAT) signalling 
pathway (Mera, et al., 2009). ChM-1 also down-regulates cell cycle proteins such as 
cyclin D1, cyclin D3 and cdk6 and up-regulate the cell cycle inhibitor protein 
p21cip1, suggesting that ChM-1 possess the ability of arresting cell cycle (Mera, et 
al., 2009; Patra & Sandell, 2012). Nevertheless, whether ChM-1 binds to specific 
receptors, activates signalling pathways or directly targets gene transcription remains 
unknown and needs to be elucidated to gain further insight into the mechanisms of 
maintaining chondrocyte phenotype. 
2.4.5 The research progress of angiogenesis and anti-angiogenesis in OA 
Normal articular cartilage remains avascular throughout life. In an osteoarthritic 
environment, however, it seems that cartilage loses its ability to stay avascular 
(Murata et al., 2008; Walsh et al., 2010). Blood vessels and channels can be seen to 
invade from the subchondral bone into the calcified and noncalcified cartilage in OA, 
and sympathetic and sensory nerves are present within vascular channels in both 
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mild and severe OA cartilage (Suri et al., 2007; Suri & Walsh, 2012; Walsh, et al., 
2010). Moreover, OA chondrocytes produce VEGF and express VEGF receptor 
(VEGFR) (Enomoto et al., 2003). By contrast, normal adult chondrocytes are 
negative for both ligand and receptor (Enomoto, et al., 2003; Walsh, et al., 2010). In 
vitro studies have demonstrated that VEGF expression in chondrocytes can be 
induced by inflammatory cytokines, hypoxia and mechanical stress, which are 
factors all symptomatic in OA (Giatromanolaki et al., 2003; Loeser, 2006; Pufe et 
al., 2004b). HIF-α, Jun N-terminal kinase (JNK) or p38 MAPK pathway are known 
to be involved in this process (Giatromanolaki, et al., 2003; Murata et al., 2006; 
Pufe, et al., 2004b).  
Immunohistochemical staining shows decreased ChM-1 expression in osteoarthritic 
cartilage and that the loss of ChM-1 coincides with blood vessels invading the 
cartilage (Hayami et al., 2003). The function of angiogenic stimulators has been 
extensively studied in the past two decades. VEGFA has the ability to shift the 
balance between MMPs and TIMPs and this may contribute to matrix degradation in 
OA cartilage (Pufe et al., 2004a; Pufe, et al., 2004b). However, in recent years, it has 
been recognized that the role of endogenous angiogenesis inhibitors are increasingly 
important to elucidate the balance between angiogenesis and tissue homeostasis. 
Anti-angiogenic factor ChM-1 and angiogenic factor VEGFA are expressed in a 
mutually exclusive pattern, as shown in the growth plate during cartilage 
development, as well as in heart valves and in rescued RUNX2 null mice (Kamekura, 
et al., 2006; Takeda et al., 2001). But it remains unclear if anti-angiogenic factor 
ChM-1 participates in maintaining the chondrocyte phenotype and the mechanisms 
underlying this role.  
 
2.5 SUMMARY AND IMPLICATIONS 
This literature review has sought to summarize the natural anatomical structure and 
physiological property of cartilage and pathological change of chondrocytes in 
osteoarthritis in terms of angiogenic and anti-angiogenic factors. During chondrocyte 
development, angiogenesis has to be turned on and off at various stages. 
Angiogenesis is necessary for endochondral ossification in the normal growth plate, 
whereas anti-angiogenesis is necessary in mature healthy cartilage. In OA pathology, 
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chondrocytes undergo hypertrophy, similar to growth plate development. However, it 
is not clear whether the angiogenic and anti-angiogenic equilibrium would be shifted 
once more, and whether this imbalance could exacerbate cartilage degradation and 
disease processes. ChM-1 is the most abundant endogenous anti-angiogenic protein 
in cartilage. This review has highlighted the expression pattern of ChM-1 and its 
related biological functions. Indeed, it has been shown that expression of ChM-1 is 
confined in normal avascular cartilage, whereas its expression is abolished in 
hypertrophic chondrocytes both in the growth plate and in osteoarthritis. There 
remains a great knowledge gap in understanding the contribution of ChM-1 in 
chondrocyte phenotype. This review also summarizes HIF signalling pathways in 
general and specifically in cartilage. Although hypoxia has been regarded as a 
favourable condition to induce the chondrocyte phenotype, HIF-2α has been shown 
to be a catabolic regulator in the growth plate and osteoarthritis. Interestingly, 
hypoxia initiates angiogenic signals in vascular tissues by stabilizing HIF-α, but the 
existence of HIFs in normal cartilage could not initiate the angiogenic and 
hypertrophic cascades. It remains to be demonstrated whether the abundant 
expression of ChM-1 in cartilage directly interferes with the activity of HIFs. 
Motivated by previous studies, the aim of this project is to address the balance 
between angiogenesis and anti-angiogenesis in OA cartilage with the focus on the 
function of anti-angiogenic factor ChM-1. I hypothesise that the anti-angiogenic 
factor is essential in maintaining the physiological functions of chondrocytes and 
preventing hypertrophy in OA progression. Therefore, profiling of angiogenic-
related cytokines in human OA cartilage was performed in this study. The 
involvement of ChM-1 in chondrogenesis and inflammatory cytokine-induced 
hypertrophy were studied in vitro by transfection of ChM-1 lentivirus or siRNA in 
chondrocytes; the in vivo role of ChM-1 in OA progression was investigated in an 
OA rat model. Furthermore, the possible molecular mechanisms involved in this 
process were also explored by investigating regulation of the HIF-2α pathways in 
chondrocytes. The results from this project will contribute to a better understanding 
of the aetiology of OA by providing fresh insights into the molecular mechanisms of 
OA progression; thereby highlighting potential new treatment options of OA.  
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Chapter 3: Materials and Methods 
3.1 INTRODUCTION 
All materials and methods referred to in the results chapters are described in this 
chapter. Any modifications of the protocols, sample size and statistical analysis are 
detailed in the results chapters in which they were performed. 
 
3.2 REAGENTS AND ANTIBODIES 
Transforming growth factor beta 3 (TGF-β3) was purchased from Bioscientific Pty 
Ltd, Kirrawee, NSW, Australia. COL2 antibody (Abcam, ab53047), COL10 (Abcam, 
ab58632 and ab49945), MMP-13 (Abcam, ab75606) and VEGFR3 (Abcam, 
ab27278) were from Sapphire Bioscience Pty Ltd, Waterloo NSW, Australia. 
VEGFR2 (Cell Signaling Technology, #2479) were purchased from Genesearch Pty 
Ltd, QLD, Australia. VEGF antibody (#RB-222-P), COL2 (MS-235-P0), MMP-13 
(RB-1681-P0) were purchased from Thermo Scientific, VIC, Australia. ChM-1 
antibody (sc-33563, sc-20310), RUNX2 (sc-10758), GAPDH (sc-47724) and GFP 
(sc-9996) were purchased from Santa Cruz, Biotechnology, CA, USA. Aggrecan 
(AB1031) was purchased from Merck Millipore, MA, USA. V5 antibody 
(Invitrogen, R96025) were purchased from Life Technologies, VIC, Australia. HIF-
1α (NB100-105) and HIF-2α (NB100-122) were obtained from Novus Biologicals, 
CO, USA. TRIzol® Reagent (Ambion®), SYBR green qPCR master mix and 96-well 
plates for qRT-PCR analysis were all obtained from Life Technologies. DyNAmo 
cDNA Synthesis Kit (F-470L) was purchased from Thermo Scientific. All other 
reagents were all obtained from Sigma-Aldrich (NSW, Australia) unless otherwise 
stated.  
 
3.3 SAMPLE COLLECTION 
Ethics approval for this project was obtained from the Queensland University of 
Technology and Prince Charles Hospital Ethics Committees and a consent form was 
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signed by all patients involved. Detailed information of weight and age of the 
patients was recorded, and the radiographs of knee were taken before operation. The 
average age of OA patients participating in the study was 68.17 ± 5.74 years old. The 
patients selected for this project had all ceased anti-inflammatory treatment more 
than one-month prior to surgery. Severe OA cartilage was sourced from the main 
defective area of the medial compartment tibia cartilage showing degenerative 
changes. The relative healthy counterpart (mild OA cartilage) was sourced from the 
anterior compartment of the distal femur cartilage showing smooth surface. A portion 
of each individual cartilage sample was snap frozen in liquid nitrogen and stored at - 
80°C for RNA extraction. 
 
3.4 HISTOLOGY AND IMMUNOHISTOCHEMICAL STAINING 
The isolated cartilage tissues were processed for histological and 
immunohistochemical staining. Tissue samples were fixed in 4% paraformaldehyde 
(PFA) for 24 h, and then dehydrated through gradient alcohol, embedded in paraffin 
and sectioned to 5 µm thickness. For immunohistochemical staining, the slices were 
de-waxed in xylene and rehydrated in ethanol. The sections were incubated with 
proteinases K (DAKO Multilink, CA, USA) for 10 min for antigen retrieval and 
endogenous peroxidases were inhibited by incubation in 3% hydrogen peroxide 
(H2O2) in phosphate buffered saline (PBS) for 15 min. Next, non-specific binding 
were blocked by incubation with 10% swine serum for 1 h. The slices were then 
incubated with the polyclonal rabbit VEGF antibody (1:400), ChM-1 antibody 
(1:200, sc-33563) overnight at 4ºC, followed by incubation at room temperature with 
secondary antibody for 45 min, and then with horseradish perioxidase-conjugated 
avidin-biotin complex (Universal LSAB™+ Kit/HRP, DAKO, Denmark) for another 
15 min. The antibody complexes were visualized by diaminobenzidine (DAB) 
substrate. Mayer’s haematoxylin was used for counter staining. The stained 
specimens were viewed and photographed under microscope (Zeiss Axio Imager M2, 
Zeiss, Germany).  
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3.5 PROTEIN EXTRACTION AND IMMUNOBLOTTING 
3.5.1 Protein extraction from cartilage tissues 
Total protein from human OA cartilage samples were extracted by first snap freezing 
in liquid nitrogen then homogenizing to very fine powder by manual crushing with 
pestle. The frozen tissue powder was collected in a cryovial containing radio-
immunoprecipitation assay (RIPA) lysis buffer (150 mM NaCl, 1% IGEPAL CA-
630, 0.5% sodium deoxycholate, 0.1% SDS and 50 mM Tris-HCl, pH8.0. Sigma-
Aldrich, R0278) and steel beads. Protease inhibitor cocktail (Roche, Swiss) and 
phosphatase inhibitor (Roche) were added fresh to the RIPA buffer. The samples 
were then milled using bead-beater (Mini-Beadbeater-16, BioSpec, USA), and 
further homogenized with a sonicator. After centrifuging at 12000 g for 10 min, the 
supernatants were collected and stored at - 80°C for subsequent bicinchoninic acid 
(BCA) assay and Western blot.  
3.5.2 Protein extraction from chondrocytes 
Primary articular cartilage chondrocytes (ACCs), human chondrocyte cell line 
C28/I2, and HEK293T cell line were used in this project. Whole cell protein or 
nucleus/cytoplasmic protein were extracted from these cells following indicated 
treatment.  
Whole cell lysates were extracted using RIPA lysis buffer with freshly added 
protease inhibitor cocktail and phosphatase inhibitor. Typically, 100-200 μL lysis 
buffer with inhibitors were added into 1 well of 6-well plate. After shaking at 4ºC 
until lysed, whole cell lysates were collected with scrapper and transferred into 1.5 
mL tube. The samples were vortexed for 15 s, centrifuge at 4ºC for 15 min at 12000 
g, the supernant transferred to a clean tube and stored at -80ºC.  
Nuclear and cytoplasmic protein fractions were prepared using NE-PER Nuclear and 
Cytoplasmic extraction kit (Thermo Scientific, USA). Protease inhibitor cocktail and 
phosphatase inhibitor were added prior to cell lysis. Typically, for one well of 6-well 
plate (approximately 2 × 106 cells for C28/I2 or HEK293T cell line), 150-200 μL 
Cytoplasmic Extraction Reagent I (CER I), 8.75-11 μL Cytoplasmic Extraction 
Reagent II (CER II), and 75-100 μL Nuclear Extraction Reagent (NER) were the 
volumes used to separate out the nuclear and cytoplasmic lysates.  
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3.5.3 Western blot 
The protein concentration from cartilage tissues, whole cell lysates or nuclear and 
cytoplasmic protein fractions was determined with Pierce BCA Protein Assay kit 
(Thermo Scientific, Australia). Following the determination of protein concentration, 
10 μg protein was separated by SDS polyacrylamide gel electrophoresis (PAGE) on 
10% acrylamide gels. The protein was transferred to nitrocellulose membrane (Pall 
Corporation, East Hills, NY, USA) which was blocked with Odyssey® blocking 
buffer (Millennium Science, Australia) for 1 h at room temperature. The membranes 
were incubated with each primary antibody, including VEGF (1:1000), ChM-1 
(1:1000), V5 (1:2000), GFP (1:5000), RUNX2 (1:2000), COL2 (1:1000, Abcam, 
ab53047), MMP-13 (1:1000, Abcam, ab75606), COL10 (1:1000, Abcam, ab49945), 
aggrecan (1:1000), VEGFR2 (1:1000), VEGFR3 (1:1000) and GAPDH (1:2000) 
overnight at 4°C. Membranes were then washed twice and incubated with 
corresponding fluorescent secondary antibodies (1:4000, Cell Signaling Technology, 
Inc., USA) for 1 h at room temperature. The protein bands were visualized using the 
Odyssey® infrared imaging system. The relative intensity of protein bands was 
quantified using Image J software.   
 
3.6 TOTAL RNA EXTRACTION FROM CARTILAGE TISSUE 
A portion of each cartilage sample was stored at −80°C, from which total RNA was 
extracted. The samples were flash frozen in liquid nitrogen and then homogenized to 
fine powder by manual crushing with pestle. The frozen tissue powder was collected 
in a cryovial containing TRIzol Reagent and steel beads. The samples were then 
milled using bead-beater. After centrifugation at 12000 g for 10 min, the aqeous 
phase was collected and the RNA extracted with the chloroform and isopropanol 
method.   
 
3.7 REVERSE TRANSCRIPTION AND QRT-PCR 
The complementary DNA was synthesized from 1 μg of total RNA using 
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DyNAmo™ cDNA Synthesis Kit, as per the manufacturer’s protocol. qRT-PCR was 
performed using SYBR reagent on an ABI 7500 Thermal Cycler (Applied 
Biosystems, Australia). The sequences of primers are showed in Table 3-1. The 
following cycling conditions were used: 95°C for 10 min for activation, followed by 
40 cycles of denaturation step of 95°C for 15 s and primer extension at 60°C for 1 
min. All reactions were performed in triplicate from each of three independent 
experiments. The mean cycle threshold (Ct) value of each target gene was 
normalized against Ct value of house-keeping gene 18S ribosomal RNA (18S 
rRNA), GAPDH and β-actin. The relative expression calculated using the following 
formula: 2-(normalized average Cts) ×104. 
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Table 3-1. Primers used in qRT-PCR  (Continued to next page) 
Gene: Homo sapiens (H) 
& Rattus norvegicus (R) 
Primers: Forward (F) & Reverse (R) 
IL-1β (H) F: 5'- AGCCATGGCAGAAGTACCTGAGC -3' 
R: 5'- GAAGCCCTTGCTGT GTGGTGG-3' 
IL-6 (H) F: 5'-AGGAGACTTGCCTGGTGAAA-3' 
R: 5'-CAGGGGTGGTTATTGCATCT-3' 
TNF-α (H) F: 5'-CCTGGTATGAGCCCATCTATC-3' 
R: 5'-GGTTGGATGTTCGTCCTCCTC-3' 
ChM-1 (H) F: 5’- CGCAAGTGAAGGCTCGTA -3’ 
R: 5’-TGGAGGAGATGCTCTGTTTGG-3’ 
VEGFA (H) F: 5’-GCTGTCTTGGGTGCATTGG-3’ 
R: 5’-GCAGCCTGGGACCACTTG -3’ 
VEGFR2 (H) F: 5’-CAAACGCTGACATGTACGGTCTA -3’ 
R: 5’-CCAACTGCCAATACCAGTGGAT -3’ 
COL2A1 (H) F: 5’- GGATGGCTGCACGAAACATACCGG -3’ 
R: 5’- CAAGAAGCAGACCGGCCCTATG -3’ 
ACAN (H) F: 5’-AGTCACACCTGAGCAGCATC -3’ 
R: 5’- AGTTCTCAAATTGCATGGGGTGTC -3’ 
SOX9 (H) F: 5’- AGCACTCGGGGCAATCCCAG -3’ 
R: 5’- TTGGAGATGACGTCGCTGC -3’ 
Endostatin (H) F: 5’- AGTGGCCCGGTACCACTTC -3’ 
R: 5’- CGGATGTGGAACAGCAGTGA -3’ 
RUNX2 (H) F: 5’- AAGAAGAGCCAGGCAGGTGC -3’ 
R: 5’-CATACCGAGGGACATGCCTGAG -3’ 
COL10A1 (H) F: 5’- AGCACGCAGAATCCATCTGAG -3’ 
R: 5’- AGGGAATGAAGAACTGTGTCTTGGTG -3’ 
MMP-13 (H) F: 5’-ACTTCACGATGGCATTGCTG -3’ 
R: 5’-CATAATTTGGCCCAGGAGGA -3’ 
MMP-2 (H) F: 5'-CCGTCGCCCATCATCAA-3' 
R: 5'-AGATATTGCACTGCCAACTCT-3' 
MMP-9 (H) F: 5'-TCGTGGTTCCAACTCGGTTT-3' 
R: 5'-GCGGCCCTCGAAGATGA-3' 
HIF-2α (H) F: 5’- CGCACAGAGTTCTTGGGAGC -3’ 
R: 5’-TGCAGACCTTGTCTTGAAGGTG -3’ 
PECAM1 (H) F: 5’-TGGAGCACAGTGGCAACTACAC -3’ 
R: 5’-CCACGATGCTGCTGACCTT-3’ 
ANGPT2 (H) F: 5’- GAAGAGATCAAGGCCTACTGTG -3’ 
R: 5’-CTCCTGAAGGGTTACCAAATCCCAC -3’ 
TGF-β1 (H) F: 5’-CGAGCCTGAGGCCGACTAC -3’ 
R: 5’-AGATTTCGTTGTGGGTTTCCA -3’ 
GAPDH (H &R) F: 5’- TCAGCAATGCCTCCTGCAC -3’ 
R: 5’- TCTGGGTGGCAGTGATGGC -3’ 
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Table 3-1. Primers used in qRT-PCR 
Gene: Homo sapiens (H) & 
Rattus norvegicus (R) 
Primers: Forward (F) & Reverse (R) 
18S (H) F: 5'-TTCGGAACTGAGGCCATGAT-3' 
R: 5'-CGAAC CTCCGACTTCGTTC-3' 
ChM-1 (R&H) F: 5’- CGTTTTGCTGGAGGAGAG -3’ 
R: 5’- GACTGGCATGATCTTGCC -3’ 
VEGFA (R) F: 5’- CTCCACCATGCCAAGTGGTC -3’ 
R: 5’- AGATGTCCACCAGGGTCTCA  -3’ 
COL10A1 (R) F: 5’- GCAGCCTGGAGAGAGCATATC  -3’ 
R: 5’- AATGGATTCTGGTGCTCAGAGG -3’ 
MMP-13 (R) F: 5’- GGAACCACGTGTGGAGTTATG  -3’ 
R: 5’- TCTTCTTCTATGAGGCGGGGA -3’ 
β-actin (R) F: 5'- CATACCCAAGAAGGAAGGCTGG -3' 
R: 5'- GCTATGTTGCTCTAGACTTCGAGC -3' 
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3.8 ANGIOGENESIS QRT-PCR ARRAY 
Total RNA was extracted from severe and mild OA cartilage by using TRIzol 
Reagent and was reverse transcripted by cDNA Synthesis Kit (Finnzymes). Human 
Angiogenesis RT2 Profiler PCR Array was purchased from SuperArray Bioscience 
Corporation (PAHS-024Z, Qiagen, VIC, Australia). Quantitative real-time PCR was 
performed in an ABI Prism 7300 Sequence Detector (Applied Biosystems). The 
qRT-PCR cycling conditions are the same as described in Section 3.7. The ΔΔCt 
formula was used for data analysis. Fold-changes were calculated as difference in 
gene expression between severe and mild OA cartilage. As demonstrated in the 
result, the positive value indicates gene up-regulation and the negative value 
indicates gene down-regulation.  
 
3.9 HUMAN CYTOKINE ANTIBODY MEMBRANE ARRAY ANALYSIS  
The expression level of 54 cytokines were analyzed in individual samples of 
cartilage derived from three different donors using human cytokine antibody 
membrane arrays (AAH-CYT-8, RayBiotech, Inc., GA, USA) according to the 
manufacturer’s recommendations. Severe OA cartilage was sourced from the main 
defective area of the medial compartment tibia cartilage showing degenerative 
changes. The relative healthy counterpart (mild OA cartilage) was sourced from the 
anterior compartment of the distal femur cartilage showing smooth surface. The 
configuration of the cytokine antibody membrane array is given in Figure 4-4. The 
protein concentrations from the cartilage samples were normalized using BCA 
protein assay. For each membrane, 40 μg of protein in 1 mL lysis buffer was applied. 
After blocking, membranes were incubated overnight at 4°C. Detection of cytokines 
was performed by biotin-conjugated secondary antibodies raised against the 
particular chemokines and horseradish peroxidase-conjugated streptavidin. For 
detection by chemiluminescence, the membranes were briefly exposed to X-ray films 
(Kodak) for 1 min. Images were scanned and spot intensity was determined by 
densitometric measurements. In brief, a color was defined representing the 
background color of the array in a given area (negative control). For each spot, the 
number of stained and unstained pixels was determined within a given area. For 
normalization of arrays, signal values of cytokines were divided by the mean value 
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of the positive control and multiplied with 100. A value of 100 represents a spot 
intensity as shown in the positive control, while a value of zero represents the spot 
intensity as seen in the negative control.  
 
3.10 CELL CULTURE 
3.10.1 Cell isolation and expansion 
Articular cartilage chondrocytes (ACCs) were cultured from the healthy parts of the 
articular cartilage and only passage 1 cells were used for subsequent experiments. 
Briefly, cartilage was dissected into small pieces and chondrocytes were released by 
digesting the tissues in 0.15% collagenase type ΙΙ. The cells suspension was filtered 
(70 µm mesh) and resuspended in Dulbecco's Modified Eagle Medium: Nutrient 
Mixture F-12 (DMEM/F12; Gibco®, Life Technologies Pty Ltd., Australia) 
containing 10% (v/v) fetal bovine serum (FBS; In Vitro Technologies, Australia) and 
1% (v/v) penicillin/streptomycin (P/S; Gibco®, Life Technologies) and plated at a 
density of 3000 cells/cm2.  
The human bone marrow stromal cells (hBMSCs) were isolated and cultured 
according to the previously published procedures (Wu et al., 2013). 
3.10.2 Chondrogenic differentiation  
For chondrogenic differentiation, 2 × 105 cells of ACCs, BMSCs and mixture of 
ACCs and BMSCs (1:1) were resuspended and centrifuged at 600 g for 20 min to 
form a pellet. The pellets were grown in 2 mL of chondrogenic differentiation 
medium for 3-weeks. The chondrogenic medium was composed of high glucose 
DMEM (Life Technologies) supplemented with 10 ng/mL of TGF-β3, 1% insulin–
transferrin–selenium (ITS) supplement (1 mg/mL insulin from bovine pancreas, 0.55 
mg/mL human transferrin, 0.5 μg/mL sodium selenite, 50 mg/mL bovine serum 
albumin, 470 μg/mL linoleic acid), 0.1 mM ascorbic acid, 0.4 mM proline, 10-7 M 
dexamethasone and 10 mg/mL of sodium pyruvate. The medium was replaced every 
3 days. At day 7, 14 and 21, the pellets were collected and processed for RNA 
extraction and histological evaluation.  
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3.11 LENTIVIRUS MEDIATED GENE MANIPULATING  
3.11.1 Lentivirus ChM-1 construct 
Human chondromodulin-1 cDNA was isolated from human chondrocytes and 
amplified by PCR with the SpeΙ and XhoΙ restriction enzyme cutting site inducted 
(Finnzymes, Thermo Fisher Scientific, USA). The primers for PCR were designed 
based on Homo sapiens ChM-1 mRNA sequences from National Center for 
Biotechnology Information (NCBI)’s site. The forward primer: 
TAGAGGATCCACTAGTCCACCATGACAGAGAACTCCGACAAAGTTC, was 
designed to include a SpeΙ restriction enzyme site (italic underlined). The reverse 
primer: GCCCTCTAGACTCGAGCCCACCATGCCCAAGATACGG, included a 
XhoΙ restriction enzyme site (italic underlined). The length of amplified segment 
was 1041 bp. The amplified segment was subcloned into the plasmid pLenti6/V5 
with the control of Human CMV promoter using In-Fusion HD Cloning Kit 
(Clontech Laboratories, Inc. A Takara Bio Company, USA). The insert sequence was 
confirmed by restriction-enzyme digestions and DNA sequencing. The third-
generation pLenti6/V5-ChM-1 was used for lentivirus production. The lentiviral 
packaging plasmids pRSVRev, pMDLgpRRE and pMD.G have been described by 
Gu, et al. (Gu et al., 2011). The pLenti6/V5-ChM-1 and the packing plasmids were 
transformed and amplified in Escherichia coli (SURE 2 and DH5α respectively), and 
isolated using NucleoBond® Xtra Maxi-Prep Kits (Macherey-Nagel, Dueren, 
Germany).  
3.11.2 Lentivirus production and titration  
HEK293T cell line was used to package the lentivirus. Briefly, 6.6 μg pLenti6/V5-
ChM-1 and 3.3 μg of each packaging plasmid with 133 μL 1.25 M CaCl2, 0.5 mL 
H2O and 0.66 mL 2 × HEPES buffered saline (140 mM NaCl, 1.5 mM Na2HPO4, 50 
mM HEPES with pH 7.05) were added to transfect HEK293T cell line in a T75 flask. 
The virus containing supernatant was harvested after 48-72 h and concentrated using 
Amicon Ultra-15 Centrifugal Filter Unit (100MW, Merck Millipore, Kilsyth, 
Australia). The concentrated lentivirus was stored at -80°C for cell infection.  
For virus titration, HEK293T cells were seeded in 6-well plates at density of 4 × 105 
cells/well and incubated for 12-24 h. Before infecting the cells the lentivirus solution 
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was serial diluted in DMEM medium containing 8 μg/mL polybrene to contain 10 
μL, 1 μL, 0.1 μL, 0.01 μL, 0.001 μL and 0 μL of concentrated lentivirus solution 
(dilution factors: 0.1, 1, 10, 100 and 1000, respectively). After incubated with 
lentivirus overnight, the media were replaced and the cells cultured for another 48 h. 
Then cells were trypsinised and fixed with 1% PFA for 30 min.  
In this experiment, the LV-ChM-1 contained no GFP fluorescence, but instead 
contained a V5-tag. This allowed flow cytometry to determine the percentage of V5-
tag positive cells by first fixing the cells then incubating with anti-V5-tag primary 
antibody for 1 h, followed by incubation with DyLight® 488-conjugated goat anti-
mouse IgG H&L (ab96879, abcam) secondary antibody for 30 min. 
For LV-GFP titration, the fixed cells were subjected to flow cytometry analysis to 
determine the percentage of GFP-positive cells. The lentiviral particle concentrations 
(particles/μL) were calculated using the following formulation: percentage positive 
cells × 4 × 105 × dilution factor.  
3.11.3 LV-ChM-1 infection of chondrocytes 
Primary ACCs or C28/I2 cells were infected with lentivirus in polybrene-containing 
(8 μg/mL) medium when cells were 50-60% confluence. Cells were transfected with 
lentivirus containing ChM-1 cDNA (LV-ChM-1) or GFP (LV-GFP, serves as empty 
vector control), respectively. After 24 h, the culture medium was changed and 48 h 
later, transfected cells were subjected to TNF-α stimulation for specific time-points, 
after which the cells were harvested for qRT-PCR and Western blot analysis.   
 
3.12 CHM-1 KNOCKDOWN BY SIRNA TRANSFECTION IN PRIMARY 
CHONDROCYTES 
Primary human chondrocytes were transfected with ChM-1siRNA (ON-TARGET 
plus Human LECT1 (11061) siRNA-SMART pool, Millennium Science, Australia) 
and scrambled siRNA at 100 nM using Lipofectamine 2000 following to the 
manufacturer’s instruction (Life Technologies). 24 h after transfection, cells were 
subjected to TNF-α stimulation for 48 h, after which the cells were harvested for 
qRT-PCR and Western blot analysis.   
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3.13 ANIMAL STUDY 
3.13.1 Rat OA model 
All animal experiment and protocols were approved by Animal Ethic Committee of 
Queensland University of Technology (no.1200000248 and no. 1400000274). 
Experimental osteoarthritis was induced in 8-week-old female Wistar rat by 
surgically removal of meniscus (menisectomy, MSX) of the right knee. Sham 
operated rats were used as controls. Rats were randomly divided into the following 
four groups: group 1, Sham + PBS; group 2, MSX + PBS; group 3, MSX + LV-
ChM-1; group 4, MSX + LV-GFP. Starting one week after the surgery, rats were 
anesthetized with isoflourane inhalation and given intra-articular injections of 50 μL 
lentivirus or PBS at 8, 12, 16 and 20 days post OA surgery. For the lentivirus groups, 
a total amount of 1 × 109 pfu lentivirus was injected into each knee joint. Five-weeks 
and nine-weeks after OA surgery, rats were sacrificed and knee joints were harvested 
for histology and immunohistochemical analysis, and RNA extraction. 
3.13.2 Histological and immunohistochemical staining 
The harvested rat knees were processed for histological and immunohistochemical 
staining. Tissue samples were fixed in 4% PFA for 24 h and decalcified in neutral 
10% EDTA for 2 months at 4°C on a rocking platform. Following that, the samples 
were dehydrated through gradient alcohol, embedded in paraffin and sectioned to 5 
µm thickness.  
To evaluate OA severity, four representative sections from various depths of the joint 
were stained with Safranin-O to visualize the presence of proteoglycans in cartilage 
matrix (Rosenberg, 1971). Mankin’s histologic grading system (Mankin score, 0 to 
14) was used to evaluate OA severity in tibial plateau (Mankin et al., 1971; Pearson 
et al., 2011; Van der Sluijs et al., 1992). Briefly, sections were de-waxed in xylene 
and rehydrated in ethanol. The sections were incubated with Weigert’s iron 
hematoxylin for 2 min and washed with running water for 10 min. Then 0.01% w/v 
Fast Green was applied to the sections for 5 min, followed by quickly rinsing in 1% 
v/v acetic acid for 10-15 s. Subsequently, the sections were treated with 0.1% w/v 
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Safranin-O for 10 min. Finally, sections were dehydrate and cleared by 70%, 90% 
and 100% ethanol and xylene, and mounted with Depex mounting medium (Sigma). 
The stained specimens were viewed under microscope (Zeiss Axio Imager M2, Zeiss, 
Germany) and scanned by Leica SCN400 scanning system (Leica Microsystems, 
Wetzlar, Germany). 
To visualize GFP fluorescence in lentivirus transfected knee cartilage, frozen sections 
(8 µm) were prepared using cryo microtome and viewed under confocal microscopy 
(Leica TCS SP5, Germany).  
Protocol of immunohistochemical staining has been described in section 3.4. The 
slices were incubated with the primary antibodies of VEGF (1:400), ChM-1 (1:200), 
aggrecan (1:200), COL2 (1:200, MS-235-P0), MMP-13 (1:200, RB-1681-P0), 
COL10 (1:200, ab58632), V5 (1:200), HIF-1α (1:50) and HIF-2α (1:100). The 
stained specimens were viewed under microscope (Zeiss Axio Imager M2, Zeiss) and 
scanned by Leica SCN400 scanning system (Leica Microsystems). 
3.13.3 Detection of gene expression in rat OA cartilage 
The rat knees were harvested immediately after rats sacrificed and the knee samples 
were kept in dry ice to preserve RNA. Rat knee cartilage was scratched using blades 
and dissected into thin and small pieces (0.5 mm × 0.5 mm) and deposited into 
cryovials containing TRIzol Reagent and steel beads. The samples were then milled 
using bead-beater. After centrifugation at 12000 g for 10 min, the supernatants were 
collected and used for subsequent RNA extraction with chloroform and isopropanol. 
The protocols for cDNA synthesis and qRT-PCR were described in section 3.7. 
 
3.14 IMMUNOCYTOCHEMICAL STAINING 
The human chondrocyte cell line C28/I2 was cultured on the coverslips with 
DMEM/F12 medium containing 10% FBS and 1% P/S. At 60% confluence, C28/I2 
was then transfected with LV-ChM-1 or LV-GFP. Transfected C28/I2 were exposed 
to TNF-α for indicated time-point and subsequently fixed by 4% PFA for 15 min. 
The fixed cells were then permeabilized with 0.2% Triton X-100 in PBS for 10 min 
and non-specific binding were blocked by incubation with 1% bovine serum albumin 
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(BSA) for 10 min. After blocking, fixed cells were incubated with primary antibody 
of HIF-2α (1:50) overnight at 4°C with rocking. On the second day, fixed cells were 
then washed three times with PBS and then incubated with anti-rabbit secondary 
antibodies conjugated with Alexa Fluor 488 fluorescent dyes (1:1000, Cell Signaling 
Technology, #4412) for 1 h at room temperature. Finally, cell nuclei were visualized 
by DAPI (1:1000). The stained coverslips were sealed on slides with ProLong® Gold 
Antifade Mountant with DAPI (Life technologies) and viewed under confocal 
microscopy (Leica TCS SP5).  
 
3.15 CHROMATIN IMMUNOPRECIPITATION (CHIP) ASSAY 
ChIP assay was performed using Pierce Agarose ChIP kit (Thermo Scientific, USA). 
Firstly, LV-ChM-1 or LV-GFP infected C28/I2 cells were passaged and cultured for 
48 h. After stimulation with TNF-α for 6 h, the cells were fixed with 1% 
formaldehyde for 10 min at room temperature to preserve protein-DNA complexes. 
Chromatin was digested by micrococcal nuclease to yield fragments ranging from 
200 to 1000 base pairs. For immunoprecipitation, primary HIF-2α antibody and 
normal rabbit IgG were used to incubate with the protein-DNA complexes at 4°C 
overnight. A/G agarose resin was used to precipitate the fragments. The purified 
DNA from ChIP samples and input DNA was subjected to qRT-PCR analysis. Based 
on the published literature, primers were designed to span the identified hypoxia-
responsive element (HRE) in the promoter or intron of target genes (Liu et al., 1995; 
Saito, et al., 2010), as follows: COL10A1 (HRE: +84 to +95bp; primer set -59 to 
+121bp) forward primer 5’-GGGTAACCTCATGTAGTAAGGG-3’; reverse primer 
5’- GCAAGTTAA CATGGAAGTCC-3’. MMP-13 (HRE: -106 to -101bp; primer 
set –214 to –28 bp) forward primer 5’-GCCAGATGGGTTTTGAGAC-3’; reverse 
primer 5’-ATAGGCCTGCAATGG TGAG -3’.VEGFA (HRE: -982 to -977 bp; 
primer set –1,000 to–795 bp) forward primer 5’- GCCAGACTCCACAGTGCA-3’; 
reverse primer5’- GCCTGCAGACATCAAAGTGAGC-3’. Control primer sets were 
designed that are not spanned the HRE region of target genes, as follows: 
COL10A1,−2,131to −1,900bp; MMP-13 , –4,797 to –4,551 bp; VEGFA, –4,685 to –
4,507 bp, respectively.  
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3.16 STATISTICAL ANALYSIS 
The results were generated from experiments with tissues or cells from multiple 
donors, which detailed in the relevant chapters. Each condition was tested in 
triplicate in each experiment, unless otherwise stated in the respective result chapters. 
Data from qRT-PCR, Western blot and Mankin score were presented as means ± 
standard error of mean (SEM). Analysis of variance was conducted by using a 
general linear model and the donor was regarded as the random factor. p < 0.05 was 
considered a statistically significant difference. If significant differences were 
revealed among conditions, Student–Newman–Keuls (SNK) post hoc tests were used 
for pairwise comparisons. Statistical analyses were performed by using Statistical 
Package for Social Science (SPSS) version 21.0 software (SPSS Inc., Chicago, 
USA). 
 
 
 
 
 
 
 
 
 
 
  

 Chapter 4: Profile of angiogenic and anti-angiogenic cytokines in OA cartilage 47 
Chapter 4: Profile of angiogenic and anti-
angiogenic cytokines in OA 
cartilage  
4.1 INTRODUCTION 
Angiogenesis is an essential physiological process during embryonic and postnatal 
development and its regulation is finely balanced between endogenous pro-
angiogenic and anti-angiogenic factors (Bonnet & Walsh, 2005). Normal articular 
cartilage remains avascular throughout life. During chondrocyte development, 
angiogenesis is switched on and off at different stages. Angiogenesis is necessary for 
endochondral ossification in the normal growth plate, during which hypertrophic 
chondrocytes produce angiogenic factors, including VEGF, and induce vascular 
invasion, a prerequisite for new bone formation (Bonnet & Walsh, 2005; Goldring, 
2012; Las Heras, et al., 2012). However, anti-angiogenesis becomes dominant in 
healthy mature cartilage, which contains a large amount of anti-angiogenic factors, 
such as ChM-1, TSP-1, TIMPs and troponin-1 (Bonnet & Walsh, 2005; Patra & 
Sandell, 2012).  
Research has shown that in an osteoarthritic environment cartilage loses its ability to 
remain avascular. Blood vessels and channels can be seen to invade from the 
subchondral bone into the calcified and noncalcified cartilage in OA (Suri, et al., 
2007; Suri & Walsh, 2012). Earlier studies into angiogenic regulators have tended to 
focus on the osteoarthritic synovium and synovial fluid (Bonnet & Walsh, 2005). It 
has been observed that angiogenesis in the synovium of osteoarthritic joints – 
manifested by increased endothelial cell proliferation, vascular density, macrophage 
infiltration and increased VEGF abundance within synovium and synovial fluid – 
closely associated with chronic synovitis in OA. However, there is a lack of studies 
concerning ectopic angiogenesis in cartilage. In OA cartilage tissue, chondrocytes 
are known to undergo hypertrophy, which is similar to growth plate development, 
but it is not clear whether the angiogenic and anti-angiogenic equilibrium is 
perturbed, and whether this imbalance could exacerbate cartilage degradation and 
disease process. 
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The hypothesis of this study is that cartilage shifts from a highly anti-angiogenic 
phenotype towards angiogenic phenotype in osteoarthritis. To demonstrate this 
hypothesis, firstly, the expression patterns of VEGFA and ChM-1 in severe OA and 
mild OA cartilage were investigated, since VEGFA is the most potent angiogenic 
factor and ChM-1 is the most abundant anti-angiogenic factor in cartilage. Then the 
expression profiles of a panel of angiogenic and anti-angiogenic cytokines in OA 
cartilage were studied using various cytokines arrays.   
 
4.2 MATERIALS AND METHODS 
Detailed descriptions of materials and methods used in this chapter are found in 
Chapter 3. The following is a brief outline of the materials and methods used to 
generate the data in this chapter.  
4.2.1 Sample collection  
Human articular cartilage samples were obtained from osteoarthritic patients 
undergoing knee replacement surgery, as described in section 3.3.  
4.2.2 Immunohistochemical staining 
The isolated cartilage samples were fixed and sectioned to 5 µm thickness. 
Immunohistochemical staining of ChM-1 and VEGFA in severe and mild OA 
cartilage tissues were performed as described in section 3.4. Primary antibodies used 
were: VEGFA (1:400) and ChM-1 (1:200). Immunohistochemical staining was 
performed by using cartilage samples from three different OA donors. 
4.2.3 Total RNA extraction and Angiogenesis qRT-PCR array 
Total RNA from severe and mild OA cartilage tissues were extracted as described in 
section 3.6. The RNAs were subjected to Angiogenesis qRT-PCR array analysis 
(Qiagen), as described in section 3.8. Assays were performed in duplicate from two 
different OA patients. 
qRT-PCR was used to validate the array data by measuring expression levels of 
selected genes of interest. For full details of reverse transcription of RNA and qRT-
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PCR analysis refer to section 3.7. Assays were performed in triplicate, with each 
sample tested individually three times from three different OA patients. 
4.2.4 Protein extraction and cytokine array 
Protein from severe and mild OA cartilage tissues were extracted as described in 
section 3.5.1. Western blot was performed to detect protein levels of angiogenic-
related cytokines of ChM-1, TIMP-1, TIMP-2, VEGFA and its receptor VEGFR2, 
VEGFR3, hypertrophic marker RUNX2 and endogenous control GAPDH (refer to 
section 3.5.2).  
Protein level of angiogenic and inflammatory cytokines in severe and mild OA 
cartilage were detected by Cytokine antibody membrane array (RayBiotech) as 
described in section 3.9. Western blot and cytokine arrays were performed in 
triplicate, with each sample tested individually twice from three different OA 
patients. 
4.2.5 Statistical analysis 
The qRT-PCR assays were performed in triplicate with each treatment tested 
individually three times from three different patients. The expression of the target 
gene was first normalized to 18S. All data were converted to fold change relative to 
the control (mild OA cartilage) and tested by one-way analysis of variance (ANOVA) 
for statistical significance. A p-value of < 0.05 was regarded as significant.  
For analysis of cytokine antibody membrane array, the spot values of each cytokine 
were normalized to the positive control, i.e., the signal values of cytokines were 
divided by the mean value of the positive control and multiplied with 100 (Positive 
control can be used to normalize the results from different membranes being 
compared). A value of 100 represents a spot intensity as shown in the positive 
control, while a value of zero represents the spot intensity of the negative control. 
The data were then analyzed by randomized block design ANOVA in which p < 0.05 
was considered as statistically significant difference. 
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4.3 RESULTS  
4.3.1 Loss of ChM-1 in severe OA cartilage  
Both VEGFA and ChM-1 were shown to be expressed in mild and severe OA 
cartilage. Immunohistochemical staining showed that ChM-1 was expressed strongly 
in mild OA cartilage and was distributed in the cytoplasm as well as in the 
surrounding extracellular matrix. VEGFA expression was detectable in chondrocytes 
in mild OA (Figure 4-1A). However, in severe OA cartilage, the intensity of ChM-1 
staining was lower than that in mild OA cartilage, whereas VEGFA expression was 
stronger than that in mild OA and distributed in both chondrocytes and the 
surrounding matrix. Western blot analyses showed detectable levels of the mature 
secretory form of ChM-1 (~25 kDa) in both mild and severe OA cartilages; however, 
its expression was significantly lower in severe OA cartilage compared with mild OA 
samples (Figure 4-1B and C). The expression of the anti-angiogenic factors TIMP-1 
and TIMP-2 were down in the severe OA samples, whereas expression of the 
angiogenic factors VEGFA, VEGFR2 and VEGFR3 were up in these samples. These 
results suggested that loss of anti-angiogenic factor (ChM-1) and overabundance of 
angiogenic factor (VEGFA) in severe OA cartilage.  
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Figure 4-1. Expression of angiogenic and anti-angiogenic cytokines in OA cartilage. (A) 
Immunohisto-chemical staining of ChM-1 and VEGFA in human OA cartilage. Scale bars, 100 µm. 
(B) Protein levels of anti-angiogenic factors (ChM-1, TIMP-1 and TIMP-2), angiogenic factors 
(VEGFA, VEGFR2 and VEGFR3) and hypertrophic marker (RUNX2) in human OA cartilage tissues 
were determined by Western blot. (C) Relative density of proteins in (B). Expression of target protein 
was measured by quantifying the intensity of the bands and further normalized to the expression of 
GAPDH.  Error bars indicate mean  ±  SEM (𝑛 = 3). ∗p < 0.05 versus mild OA cartilage.  
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4.3.2 Angiogenesis qRT-PCR array 
Human Angiogenesis qRT-PCR array experiments were carried out to gain an overall 
profile of angiogenic and anti-angiogenic factors in OA cartilage. Results (depicted 
as fold differential expression) are shown in Figure 4-2. Of the eighty-four 
angiogenic-related cytokines assayed, a total of forty-five pro-angiogenic cytokines 
were up-regulated, whereas the expressions of twelve anti-angiogenic cytokines were 
decreased in severe OA cartilage comparing with mild ones. Figure 4-2 showed the 
representative cytokines. OA related pro-inflammatory cytokines (IL-1β, IL-6 and 
TNF-α) were up-regulated in qRT-PCR array, which is consistent with previous 
studies. Several anti-angiogenic cytokines, which are abundantly expressed in normal 
cartilage, were significantly decreased in severe OA samples, such as ChM-1, TIMP-
1, TIMP-2, TSP-1 and TSP-2. On the other hand, the majority of angiogenic growth 
factors and receptors were all increased, including VEGFA, VEGFR2, angiopoietin 
(ANGPT) 1, ANGPT2 and TIE2. These genes are expressed during vascularisation 
and promote organization, survival or migration of endothelial cells. Pro-angiogenic 
adhesion molecules and chemokines were also upregulated in severe OA cartilage, 
such as vascular endothelial (VE)-Cadherin, chemokine (C-X-C motif) ligand 
(CXCL) 5, CXCL6, CXCL9 and CXCL10. In addition, expression of proteases and 
some matrix proteins, including MMP-2, MMP-9, PECAM-1 were increased in 
severe OA cartilage.  
To validate the qRT-PCR array data, the expression of twelve genes with key roles in 
angiogenesis or anti-angiogenesis in cartilage was assessed using qRT-PCR analysis. 
As shown in Figure 4-3, the expression of seven up-regulated angiogenic genes was 
confirmed by qRT-PCR, including IL-1β, TNF-α, VEGFA, VEGFR2, MMP-2, 
MMP-9 and VE-Cadherin. The decreased level of anti-angiogenic factor, such as 
ChM-1, TIMP-1 and TIMP-2, was also confirmed. In addition, the down-regulation 
of chondrogenic genes (COL2A1 and SOX9) and up-regulation of hypertrophic 
marker (RUNX2 and MMP-13) in severe OA cartilage samples were also validated. 
In summary, these results demonstrated increased angiogenic activity and reduced 
anti-angiogenic ability in severe OA cartilage. 
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Figure 4-2. Human Angiogenesis qRT-PCR array on OA cartilage tissue. Columns represent fold 
changes of individual gene expression between severe and mild OA cartilage. Upper columns (> 1.00) 
represent up-regulated genes, lower columns (< 1.00) genes means down-regulated genes. Result is 
one representative data from two independent experiments, which showed similar results. 
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Figure 4-3. qRT-PCR validation of differential expressed genes in severe OA cartilage identified by 
angiogenesis qRT-PCR array analysis. (A) Expression of angiogenic and anti-angiogenic genes in 
mild and severe OA cartilage. (B) Expression of chondrogenic (COL2A1 and SOX9) and 
hypertrophic markers (RUNX2 and MMP-13) in mild and severe OA cartilage. The results were 
generated from experiments with tissues from three OA donors. Assays were performed in triplicate, 
with each sample tested individually three times. The expression of the target gene was first 
normalized to 18S and then further converted to the fold change of the control (mild OA cartilage). 
Error bars indicate mean ± SEM (𝑛 = 3). ∗p < 0.05 versus mild OA cartilage.  
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4.3.3 Cytokine profile of human OA cartilage  
The protein level of angiogenic cytokines were further confirmed using human 
cytokine antibody arrays. Cytokine analysis was conducted in three sets of samples, 
comprising three severe and mild OA samples pairs. The array configuration is 
shown in Figure 4-4; all cytokines were assayed in duplicates. The complete 
cytokine profile of cartilage tissues is shown in Table 4-1. Of all the fifty-four 
cytokines, forty-nine had elevated expression levels in severe OA cartilage. 
Densitometric analysis revealed that twenty-one reached statistical significance (p < 
0.05). However, none of the down-regulated cytokines showed statistically 
significant differences.  
Functional analysis of these cytokines showed that up-regulated cytokines in severe 
OA cartilage are mostly related to angiogenic growth factors, cell migration related 
cytokines, adhesion molecules and pro-inflammatory interleukins (Table 4-1). As 
shown in Figure 4-5, several potent angiogenic growth factors and receptors were 
significantly increased, including VEGFR2, VEGFR3, TIE1 and TIE2, which are 
consistent with the qRT-PCR array result. Functionally, within the list of increased 
cytokines given in Figure 4-5, there were pro-angiogenic secreted molecules (PDGF 
AA, PDGF-AB, TGF-β2), cell surface receptors (PDGF-R alpha), pro-angiogenic 
adhesion molecules (VE-Cadherin), chemokines (IP-10/CXCL10, SDF-1β), and 
enzymatic extracellular matrix molecules and matrix proteins (MMP-9, PECAM-1). 
In summary, these data support the angiogenic qRT-PCR array results that the 
majority of angiogenic factors are up-regulated in severe OA environment, indicating 
the importance of regulatory cytokines of angiogenesis in OA pathogenesis. 
In addition, signalling pathway analysis was performed to clarify the relation of the 
differentially expressed cytokines to the well-documented biological pathways. 
Result was summarized in Table 4-2. Several related signalling pathways were 
identified in severe OA cartilage tissue, including MAPK, nuclear factor-kappa B 
(NF-κB), TGF-β and Janus kinase/signal transducers and activators of transcription 
(JAK/STAT) signalling pathways. These results provide further insights into the 
identification of signalling pathways responsible for cartilage degradation in severe 
OA. 
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Figure 4-4. Cytokine profiles in severe and mild OA cartilage. Representative cytokine antibody array 
membranes showing the cytokine profile of cartilage derived from severe OA (A) and mild OA (B) 
cartilage. The respective cytokines of each dot are showed in C. Positive controls are used as loading 
control, which serves to normalize the results from different membranes being compared. Cytokine 
antibody array were performed in triplicate, with each sample tested individually twice from three 
different OA patients. Result is one representative data from three independent experiments, which 
showed similar trends.   
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Figure 4-5. Relative expression of angiogenic cytokines in severe and mild OA cartilage.  Human 
cartilage samples were collected from three osteoarthritic patients undergoing knee replacement 
surgery. Cytokine antibody array were performed in triplicate, with each sample tested individually 
twice from three different OA patients. For analysis, the spot values of each cytokines were divided by 
the mean value of the positive control and multiplied with 100. A value of 100 represents a spot 
intensity as shown in the positive control, while a value of zero represents the spot intensity as seen in 
the negative control. And then the data are analyzed by randomized block design ANOVA. *p < 0.05, 
significant difference between severe and mild OA cartilage.   
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Table 4-1. Profile of cytokines in OA cartilage (Classified by function) 
Cytokines Severe/Mild 
Ratio 
p-value  Cytokines Severe/Mild 
Ratio 
p-value 
Angiogenic growth factor and receptors  Adhesin molecules  
VEGFR2* 1.4535 0.0297  ALCAM 0.9909 0.9563 
VEGFR3* 1.2416 0.0144  L-Selectin* 1.4551 0.0107 
PDGF AA* 1.4325 0.0198  PECAM-1* 1.8224 0.0284 
PDGF-AB* 1.6895 0.0010  E-Selectin 1.0032 0.9846 
PDGF R alpha* 2.5098 0.0082  ICAM-2 1.0428 0.8027 
PDGF R beta 1.2514 0.1810  VE-Cadherin* 1.8010 0.0010 
Tie-1* 1.7604 0.0162     
Tie-2* 1.3940 0.0191  Interleukins   
TGF-alpha* 1.4044 0.0037  IL-1R2 1.2747 0.1477 
IGF-2 1.1845 0.2387  IL-2R beta 1.2011 0.1148 
Endoglin 1.1193 0.1460  IL-2R gamma* 1.3905 0.0079 
    IL-5R alpha 0.9103 0.4086 
MMPs    IL-9 1.1239 0.4263 
MMP-1 1.1553 0.1086  IL-10Rbeta 1.3540 0.1980 
MMP-3 1.0104 0.9139  IL-13 R alpha 2 1.1649 0.1773 
MMP-9* 1.5024 0.0299  IL-18 BP alpha 1.2974 0.0817 
MMP-13* 1.3219 0.0135  IL-18Rbeta 1.1102 0.2797 
TIMP-4* 1.4137 0.0196  IL-21R* 1.3901 0.0205 
    Cardiotrophin-1 1.2335 0.1896 
Osteogenic related cytokines   LIF 1.1865 0.2367 
Activin A 1.0736 0.4987     
BMP-5 1.1205 0.2474  Others   
BMP-7 1.0793 0.4281  B7-1(CD80) 0.9916 0.9531 
TGF beta 2* 1.4099 0.0010  CD14 1.2173 0.1782 
LAP 1.0547 0.6837  DR6(TNFRSF21) 1.0968 0.5360 
    ErbB3 0.9943 0.9685 
Cell migration related cytokines   Fas Lignad 0.9181 0.6488 
IP-10* 1.1921 0.0279  Leptin R 1.0922 0.6177 
SDF-1beta* 1.5849 0.0123  M-CSF R 1.4635 0.0620 
CXCL16 1.1403 0.0737  NGF R* 1.4551 0.0092 
MPIF-1 1.1863 0.2566  Prolactin 1.3435 0.1815 
SCF R* 1.4218 0.0029  Siglec-5* 1.6277 0.0000 
 
Data showed fold change of severe OA cartilage compared to the mild OA cartilage after 
densitometric analysis and normalization. *p < 0.05, significant difference between severe and mild 
OA cartilage. 
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Table 4-2. Profile of cytokines in OA cartilage (Classified by signalling pathway) 
Cytokines Severe/Mild 
Ratio 
P-value  Cytokines Severe/Mild 
Ratio 
P-value 
MAPK    JAK/STAT3   
DR6(TNFRSF21) 1.0968 0.5360  IL-1R2 1.2747 0.1477 
IL-1R2 1.2747 0.1477  IL-2R beta 1.2011 0.1148 
IL-2R beta 1.2011 0.1148  IL-2R gamma* 1.3905 0.0079 
IL-2R gamma* 1.3905 0.0079  IL-10Rbeta 1.3540 0.1980 
IL-18 BP alpha 1.2974 0.0817  IL-13 R alpha 2 1.1649 0.1773 
IL-18Rbeta 1.1102 0.2797  IL-18 BP alpha 1.2974 0.0817 
MMP-1 1.1553 0.1086  IL-18Rbeta 1.1102 0.2797 
MMP-3 1.0104 0.9139  IL-21R* 1.3901 0.0205 
MMP-9* 1.5024 0.0299  MMP-1 1.1553 0.1086 
MMP-13* 1.3219 0.0135  MMP-3 1.0104 0.9139 
LIF 1.1865 0.2367  MMP-9* 1.5024 0.0299 
    MMP-13* 1.3219 0.0135 
NF-κB    VEGFR2* 1.4535 0.0297 
Fas Lignad 0.9181 0.6488  VEGFR3* 1.2416 0.0144 
IL-1R2 1.2747 0.1477  PDGF R alpha* 2.5098 0.0082 
IL-10Rbeta 1.3540 0.1980  PDGF R beta 1.2514 0.1810 
MMP-1 1.1553 0.1086  TGF beta 2* 1.4099 0.0010 
MMP-3 1.0104 0.9139  B7-1(CD80) 0.9916 0.9531 
MMP-9* 1.5024 0.0299  Cardiotrophin-1 1.2335 0.1896 
MMP-13* 1.3219 0.0135  IP-10* 1.1921 0.0279 
Cardiotrophin-1 1.2335 0.1896  Leptin R 1.0922 0.6177 
DR6(TNFRSF21) 1.0968 0.5360  LIF 1.1865 0.2367 
SDF-1beta* 1.5849 0.0123     
TGF-alpha* 1.4044 0.0037     
       
TGF-β     
Activin A 1.0736 0.4987     
BMP-5 1.1205 0.2474     
BMP-7 1.0793 0.4281     
Endoglin 1.1193 0.5395     
TGF beta 2* 1.4099 0.0010     
 
Data showed fold change of severe OA cartilage compared to the mild OA cartilage after 
densitometric analysis and normalization. *p < 0.05, significant difference between severe and mild 
OA cartilage. 
 
 
 60 Chapter 4: Profile of angiogenic and anti-angiogenic cytokines in OA cartilage 
4.4 DISCUSSION 
The balance between angiogenic and anti-angiogenic factors is critical for cartilage 
homeostasis (Bonnet & Walsh, 2005; Shukunami, et al., 1999a; Shukunami, et al., 
2008). In normal articular cartilage, anti-angiogenic factors play a dominant role in 
maintaining homeostasis, as in physiological condition cartilage is essentially devoid 
of vascular structure. However, this property seemed to be lost in OA cartilage.  
ChM-1 is reported to play an important role in the resistance of cartilage to 
angiogenesis. During the developmental phase, the gene transcript of ChM-1 is 
maintained at a high level in the avascular zones of bone rudiments, including the 
resting, proliferating and early hypertrophic zones (Shukunami, et al., 2008). In 
contrast, its expression is abolished in the lower hypertrophic and calcified zones of 
cartilage, allowing vascular invasion and initiation of endochondral bone formation 
(Shukunami & Hiraki, 1998; Shukunami, et al., 1999a). Although ChM-1 null mice 
show no obvious phenotype in terms of cartilage and vasculogenesis (Brandau, et al., 
2002), adult ChM-1 null mice exhibit delayed chondrocyte maturation in the 
periosteal callus, aberrant cartilage formation during fracture repair (Yukata, et al., 
2008), and marked reduction in bone remodelling (Nakamichi, et al., 2003), 
indicating that ChM-1 may participate in the maintenance of the chondrocyte 
phenotype. An earlier study showed decreased ChM-1 expression in early stages of 
experimental rat OA, even prior to the loss of COL2 (Hayami, et al., 2003), 
indicating loss of ChM-1 might be an early event in cartilage degradation. My results 
also showed that ChM-1 protein and mRNA was highly expressed in relatively 
healthy human cartilage, which is consistent with the physiological function of ChM-
1, but it was markedly down-regulated in late stage of OA, which may contribute to 
osteochondral angiogenesis. The involvement of ChM-1 in chondrogenesis and 
chondrocyte hypertrophy is investigated in the following chapter.  
To be noticed, human ChM-1 precursor is a 334 amino acids transmembrane protein, 
and mature ChM-1 is the C-terminal portion of its precursor, which is secreted from 
the chondrocytes and distributed in the cartilage matrix. In this study, ChM-1 
antibodies (C-20, sc-20310; H-300, sc-33563) were used to verify the protein 
expression. The former antibody epitope mapping corresponds to near the C-
terminus of ChM-1, and the later one corresponds to 1-300 mapping at the N-
terminal of ChM-1 of human origin, which means these two antibodies can detect 
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both of the precursor and mature ChM-1 protein in cells and tissues.  
The imbalanced gene profile of angiogenic and anti-angiogenic factors in severe OA 
cartilage were demonstrated in this study. Angiogenesis qRT-PCR array analysis (by 
using cartilage from two donors) showed a  trend that down-regulation of various 
anti-angiogenic factors (ChM-1, TIMP-1, TIMP-2, TSP-1, TSP-2) in severe OA 
cartilage and up-regulation of angiogenic molecules, providing further evidence that 
the phenotype of cartilage shifts from highly anti-angiogenic property to angiogenic 
potential in osteoarthritis. Quantitative RT-PCR was used to validate the array data 
by measuring expression levels of selected genes of interest, and the data confirmed 
the significantly up-regulated angiogenic genes, including IL-1β, TNF-α, VEGF, 
VEGFR2, MMP-2, MMP-9 and VE-Cadherin and the significantly decreased level of 
anti-angiogenic factor, such as ChM-1, TIMP-1 and TIMP-2. Although a few 
angiogenic inhibitors were increased in OA, e.g. TIMP-3 and PF4, such increases 
appear insufficient to prevent vascular invasion. Expression of VEGFR2, PECAM-1, 
VE-Cadherin, ANGPT2, TIE2, AKT, CXCL5, CXCL6, PF4 and ANGPTL4, whose 
relationship with osteoarthritis has never been reported, was altered in late OA 
cartilage. The altered angiogenic profile in OA cartilage not only explains the 
observed invasion of blood vessels, but may also indicate loss of anti-angiogenic 
phenotype may be one of the most important characteristics of OA cartilage and its 
role in cartilage destruction has been underestimated. These angiogenic factors may 
be associated with the OA pathogenesis. For instance, VEGF is chemotactic for 
osteoblasts and also a mediator for osteophyte formation and subchondral 
mineralization (Gerber et al., 1999). VEGF stimulation of chondrocytes induced 
VEGFR2 phosphorylation, activation of the MAPK-ERK 1/2, and long-lasting 
activation of the transcription factor activator protein-1 (AP-1) (Pufe, et al., 2004a; 
Pufe, et al., 2004b). VEGF also increased secreted MMP-1, MMP-3 and MMP-13 
from chondrocytes, but diminished the expression of TIMP-1 and TIMP-2 (Pufe, et 
al., 2004a).  
Furthermore, I have identified up-regulation of other important pro-angiogenic 
factors such as angiopoietin-Tie system. Apart from the VEGF system, the Tie 
receptors and their angiopoietin ligands have been identified as the second vascular 
tissue-specific receptor Tyrosine kinase system (Augustin et al., 2009). This system 
enhances remodelling of blood vessels or survival of endothelial cells via 
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phosphatidylinositol (PI) 3-kinase/Akt or ERK/MAPK signalling pathway (Augustin, 
et al., 2009). A study in rheumatoid arthritis showed that angiopoietin-1 could 
directly potentiate synovium overgrowth and degradation of the cartilaginous matrix 
via ERK/MAPK and PI 3-kinase/Akt pathways (Hashiramoto et al., 2007). In OA 
progression, both the ERK/MAPK pathway and the PI 3-kinase/Akt pathway are 
activated. Therefore, the up-regulated angiopoietin-1, angiopoietin-2 and their 
receptor Tie in OA may have direct effect on chondrocytes and mediate cartilage 
destruction through these signalling pathways. In addition to angiogenic growth 
factors, neovascularisation also depends on ECM proteolysis by MMPs, which are 
negatively regulated by TIMPs (Kapoor, et al., 2011; Pufe, et al., 2004a). In this 
experiment, the increased expression of MMP-2 and MMP-9 and decreased level of 
TIMP-1, TIMP-2 in OA joints support the potential role of these MMPs in promoting 
vascular invasion as an important step in OA pathogenesis. 
Chemokines, a large family of chemotactic cytokines, exert their function as 
chemoattractants for leukocytes, recruiting monocytes, neutrophils and other effector 
cells to sites of tissue damage (Endres et al., 2010). Most chemokines are 
inflammatory and are released in response to pro-inflammatory cytokines such as IL-
1β. This study demonstrated that chemokines PF4, CCL11, CXCL1, CXCL10 (IP-
10), CXCL3, CXCL5, CXCL6, CXCL9 and SDF-1β were significantly up-regulated 
in OA cartilage. The protein level of CXCL16 was surprisingly high both in OA and 
normal cartilage, suggesting that this chemokine may have an impact in cartilage 
homeostasis, except for its immunological function. The well-known chemokine 
CXCL12/SDF-1 could significantly induce proliferation and COL1 expression in 
osteoblasts from osteoarthritis patients (Lisignoli et al., 2006). Endres’s study 
demonstrated that CCL25, CXCL10 and CXCL1 effectively stimulated migration of 
human subchondral progenitor cells, which presumably would enter the cartilage 
defect and form cartilaginous repair (Endres, et al., 2010). However, the potential 
role and mechanisms of chemokines in the destruction of cartilage in osteoarthritis 
still requires further investigations.  
In conclusion, the decrease in ChM-1 and increase in VEGFA expression, as well as 
the changed profile of other angiogenesis-related cytokines, occurred in the late stage 
of OA, suggesting that OA progression might be correlated with the imbalanced 
angiogenesis in OA cartilage. However, whether the anti-angiogenic factors 
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contribute to the maintenance of the chondrocyte phenotype is largely unknown. 
Therefore, the function and regulatory mechanisms of ChM-1 during cartilage 
degradation in OA are investigated in the next chapter of the study.  
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Chapter 5: Role of ChM-1 during 
chondrocyte hypertrophy and its 
therapeutic efficacy in OA 
progression in vitro and in vivo 
5.1 INTRODUCTION 
Articular cartilage is an avascular tissue by nature, in which the resident 
chondrocytes maintain stable phenotype that avoids hypertrophy and angiogenesis 
throughout life. Several growth factors, such as TGF-β family, have been proposed to 
be essential for chondrocyte differentiation and cartilage development (Goldring, et 
al., 2006; Lafont, et al., 2008). But TGF-β is not exclusively expressed in cartilage 
tissue and furthermore, intra-articular supplement of TGF-β results in osteoarthritis-
like changes and osteophyte formation (Bakker, et al., 2001; Van Beuningen, et al., 
2000; Van Beuningen, et al., 1994), which may deny its importance in maintaining 
mature cartilage. Articular cartilage may, therefore, possess its own intrinsic factors 
to maintain its phenotype. Cartilage is known to contain considerable amounts of 
anti-angiogenic factors, such as ChM-1, TSPs, TIMPs and troponin-1, which are 
extensively expressed in chondrocyte cytoplasm and cartilage matrix (Bonnet & 
Walsh, 2005; Patra & Sandell, 2012). In pathological conditions such as OA, 
cartilage loses the anti-angiogenic potential with decreased abundance of ChM-1. In 
OA cartilage, hypertrophy markers including COL10A1, MMP-13 and RUNX2 are 
up-regulated, leading to matrix degradation and disruption of homeostasis (Hirata, et 
al., 2012; Kapoor, et al., 2011; Li, et al., 2011; Murphy & Lee, 2005). However, the 
contribution of anti-angiogenic factors in the maintenance of chondrocyte phenotype 
is largely unknown. 
ChM-1 is a 121-amino acid glycoprotein derived from a transmembrane precursor 
and distributed mainly in interstitial space of cartilage matrix (Hiraki, et al., 1997a; 
Shukunami & Hiraki, 1998). The inhibition of angiogenesis by ChM-1 in cartilage, 
endothelial cells, cardiac valves and several tumors has been well documented 
(Hayami, et al., 1999; Miura, et al., 2010; Yoshioka, et al., 2006). The regulatory 
effect of ChM-1 in cartilage development was verified by genetically modified mice. 
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In vivo, ChM-1 null mice exhibit delayed chondrocyte maturation in the periosteal 
callus, aberrant cartilage formation during fracture repair (Yukata, et al., 2008), and 
marked reduction in bone remodelling (Nakamichi, et al., 2003).  
Due to the short half-life of recombinant ChM-1 protein, genetic manipulation 
method was always utilized to provide a more efficient delivery of ChM-1 to cells or 
tissues (Klinger, et al., 2011; Yoshioka, et al., 2006). Among contemporary vector 
systems, adeno-associated virus (AAV) and lentivirus (LV) hold a particular promise 
for therapeutic potential (Fleming et al., 2001). These vectors possess the capacity to 
transduce both of dividing cells and non-dividing cells and to obtain the efficient 
gene transfer (Fleming, et al., 2001; Kaplitt et al., 1994). A recent study 
demonstrated that application of AAV-ChM-1 in micro-fractured porcine cartilage 
lesions stimulated chondrogenic differentiation of ingrowing progenitor cells and 
inhibited excessive endochondral ossification via an unknown mechanism, 
suggesting that ChM-1 is involved in chondrocyte phenotype changes associated 
with transitions to a hypertrophic tendency (Klinger, et al., 2011). In this study, 
lentivirus vectors carrying ChM-1 complementary DNA (LV-ChM-1) was used to 
overexpress ChM-1 in chondrocytes and cartilage tissues. The rational for choosing 
lentivirus is the fact that it belongs to Retroviridae family, which can integrate the 
gene with the host genome to produce a more stable and sustained gene transfer 
(Fleming, et al., 2001).  
The hypothesis of this chapter is that the anti-angiogenic factor is essential in 
maintaining the physiological functions of chondrocytes and preventing hypertrophy 
in OA progression. Therefore, the involvement of ChM-1 in chondrogenesis and 
inflammatory cytokine-induced hypertrophy were studied by using gene transfer of 
LV-ChM-1 vector or ChM-1 siRNA in chondrocyte in vitro; the role of ChM-1 in 
OA progression in vivo was investigated with rat OA model.  
 
5.2 MATERIALS AND METHODS 
Details of materials and methods used in this chapter are described in Chapter 3. The 
following is a brief outline of the materials and methods used to generate the data in 
this chapter.  
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5.2.1 Cell culture and chondrogenic differentiation 
Articular cartilage and bone marrow were obtained from osteoarthritic patients 
undergoing knee replacement surgery. For chondrocyte isolation, cartilage slices 
from macroscopically healthy parts of the anterior compartment of femoral condyles, 
which showed smooth surface, were digested as described in section 3.10.1. The 
human bone marrow stromal cells (BMSCs) were isolated as described in section 
3.10.1. Freshly isolated articular cartilage chondrocytes (ACCs) and BMSCs were 
expanded in monolayer culture in humidified air with 5% CO2 at 37°C. ACCs at 
passage 1 and BMSCs at passage 3 were used in the subsequent experiments.  
To determine the role of ChM-1 during chondrogenesis, in vitro chondrogenic 
differentiation of ACCs and BMSCs using a pellet culture method were performed as 
described in section 3.10.2. Pellet cultures were harvested at 7, 14 and 21 days for 
histological, immunohistochemical staining as described in section 3.4. Gene 
expression of ChM-1, VEGFA and chondrogenic markers (COL2A1, SOX9 and 
ACAN) were detected by qRT-PCR as described in section 3.7. Assays of pellet 
culture were performed in triplicate, with each sample tested individually three times 
from three different OA patients. 
5.2.2 Lentivirus and siRNA transfections 
To determine the role of ChM-1 in chondrocyte hypertrophy in OA, LV-ChM-1 and 
ChM-1 siRNA were constructed to respectively overexpress and down-regulate 
ChM-1. Lentivirus vector carrying ChM-1 cDNA were constructed and produced as 
described in section 3.11. Lentivirus titration was determined by flow cytometry. 
In mono-layer-cultured model, ACCs were infected with LV-ChM-1 or LV-GFP 
(serves as empty vector control) for 48 h. Then the transfected cells were stimulated 
with TNF-α for 48 h. Non-transfected ACCs without TNF-α stimulation serves as 
empty control. Subsequently, samples were harvested for qRT-PCR and Western blot 
analysis, as described in sections 3.7 and 3.5, respectively. To knockdown ChM-1 
expression in chondrocytes, ACCs were transfected with ChM-1 siRNA and 
scrambled siRNA at 100 nM using Lipofectamine 2000, as described in section 3.12. 
Twenty-four hours after transfection, cells were subjected to TNF-α stimulation for 
48 h. Subsequently, samples were harvested for qRT-PCR and Western blot analysis, 
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as described in section 3.7 and 3.5, respectively.  
For pellet cultures, ACCs were first infected by LV-ChM-1 or LV-GFP in monolayer 
culture and then cells were digested and centrifuged to form pellets, following the 
protocols in section 3.10.2. After 21 days, pellets were harvested and subjected to 
qRT-PCR and Western blot analysis, as described in section 3.7 and 3.5, respectively. 
Data generated from this part were from three independent experiments, with each 
sample tested individually three times from three OA donors. 
5.2.3 Animal OA model 
Experimental osteoarthritis was induced in Wistar rats by surgically removal of 
mesial meniscus (menisectomy, MSX) of the right knee. Intra-articular injection of 
50 μL lentivirus (LV-ChM-1 or LV-GFP) or PBS was performed four times post OA 
surgery (on 8, 12, 16 and 20 days, respectively), and knee joints were collected at 5-
weeks and 9-weeks post-OA surgery for histology analysis and RNA extraction. LV-
GFP was used as an empty vector control. Further details are described in section 
3.13.1. Nine rats were used for each group. In each group, six rat joint samples were 
processed for histological analysis and three samples were preserved for RNA 
extraction.  
5.2.4 Histological and immunohistochemical staining 
The isolated rat right knee joints were fixed and sectioned to 5 µm thickness. 
Safranin-O staining was used to evaluate OA severity as described in section 3.13.2. 
Mankin’s histologic grading system (Mankin score, 0 to 14) were used to evaluate 
OA severity in tibial plateau. Frozen sections (8 µm) were prepared to visualize GFP 
fluorescence in LV-GFP infected knee cartilage and viewed under confocal 
microscopy. The infection efficacy of LV-ChM-1 was evaluated by 
immunohistochemical staining of ChM-1 and V5-tag in rat OA cartilage. The 
expression of chondrogenic and hypertrophic markers, including COL2A1, aggrecan, 
MMP-13, COL10A1 and VEGFA were also evaluated by immunohistochemical 
staining as described in section 3.13.2.   
5.2.5 Detection of gene expression in OA rat cartilage 
To determine gene expression of ChM-1 and hypertrophic markers (VEGFA, 
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COL10A1 and MMP-13), total RNA was extracted from experimental osteoarthritis 
rat cartilages (5-weeks group), as described in section 3.13.3. Gene expressions were 
detected by qRT-PCR as described in section 3.7. Primers for the target genes are 
listed in Table 3-1. Assays were performed in triplicate, with samples from three 
rats.  
5.2.6 Statistical analysis 
All the data, including qRT-PCR and Mankin score, were presented as means ± SEM 
and were analysed using one-way ANOVA. If significant differences were revealed 
among conditions, SNK post hoc tests were used for pairwise comparisons. Analysis 
was performed using SPSS version 21.0 software. p-value < 0.05 were considered to 
be statistically significant difference. 
 
5.3 RESULTS 
5.3.1 ChM-1 was positively correlated with chondrogenic differentiation  
ACCs and BMSCs are the major seed cells for intrinsic cartilage repair and tissue 
engineering, therefore the expression of ChM-1 and VEGFA in chondrogenesis was 
investigated by pellet culture of ACCs and BMSCs. Significantly increased ChM-1 
expression was observed during the chondrogenic differentiation of ACCs with more 
intensive staining in the 3-weeks pellets compared to that in 1-week pellets. Gene 
expression of ChM-1 and COL2A1 was also increased gradually with time of 
chondrogenic differentiation, while VEGFA expression decreased commensurately 
with time (Figure 5-1A). At the 3-weeks’ time-point, histological analysis showed 
that a significant increased matrix deposition in ACCs pellets with stronger intensity 
of Safranin-O staining compared to BMSCs pellets (Figure 5-1B). Immuno-
histochemical staining for ChM-1 and COL2A1 showed a stronger staining pattern in 
ACCs pellet than BMSCs pellet. Conversely, BMSCs pellets showed higher VEGFA 
expression than ACCs pellets. These observations were further confirmed by the 
gene expression showing a higher level of ChM-1, COL2A1, ACAN and SOX9, and 
lower level of VEGFA in ACCs pellets than BMSCs pellets. The result demonstrated 
the consistency of ChM-1 expression with chondrogenic markers and that cartilage 
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derived cells have higher constituent ChM-1 expression than that in BMSCs. 
 
Figure 5-1. Expression of chondrogenic and angiogenic-related markers in chondrogenic 
differentiation of ACCs and BMSCs. (A) Immunohistochemical staining of ChM-1 and qRT-PCR 
analysis of ChM-1, VEGFA and COL2A1 gene expression in pellet culture of ACCs for 1, 2 and 3-
weeks. Values are mean ± SEM (n = 3). *p < 0.05 versus week 1. (B) Safranin-O staining and 
immunohistochemical staining of COL2A1, ChM-1 and VEGFA in pellet culture of ACCs or BMSCs 
for 3-weeks. Gene expression of chondrogenic markers (COL2A1, ACAN, SOX9) and angiogenic-
related cytokines (ChM-1, Endostatin and VEGFA) were measured by qRT-PCR. Values are mean ± 
SEM (n = 3). *p < 0.05 versus ACCs group. Scale bars, 100 µm.  
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5.3.2 TGF-β3 could not up-regulate ChM-1 
TGF-β, known as chondrogenic stimulator, plays a key role in cartilage development, 
such as stimulating chondrogenic condensation, chondroprogenitor cell proliferation 
and differentiation (Onyekwelu et al., 2009; Quintana et al., 2009). TGF-β3 is also 
an essential component of chondrogenic differentiation medium in the standard 
protocols of in vitro experiments (Jiang et al., 2013; Xu et al., 2008). Previous results 
showed that ChM-1 is also an important marker during chondrogenesis. Therefore, 
the effect of TGF-β3 on ChM-1 expression was evaluated by qRT-PCR. Monolayer 
cultured BMSCs were subjected to TGF-β3 stimulation under normoxic (20% O2) or 
hypoxic (2% O2) conditions for three days. Results showed that TGF-β3 significantly 
up-regulated chondrogenic markers of COL2A1 and SOX9 in both normoxic and 
hypoxic conditions, but could not up-regulate (or even down-regulate) ChM-1 
expression (Figure 5-2).  
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Figure 5-2. Gene expression of ChM-1, COL2A1 and SOX9 in BMSCs in response to TGF-β3.  
Monolayer cultured BMSCs were subjected to TGF-β3 stimulation under normoxia (20% O2) or 
hypoxia (2% O2) condition for 3 days, and gene expression were detected by qRT-PCR. Data showed 
that TGF-β3 significantly up-regulated chondrogenic markers of COL2A1 and SOX9 in both 
normoxia and hypoxia conditions, but had no effect or decreased ChM-1 expression. Values are mean 
± SEM (n = 3). *p < 0.05 versus blank group in normoxia,  # p < 0.05 versus blank group in hypoxia. 
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5.3.3 Lentivirus ChM-1 production and infection efficacy 
Lentivirus vector carrying ChM-1 cDNA was constructed and produced to 
overexpress ChM-1 in target cells (that is ACCs in this experiment). Briefly, human 
chondromodulin-1 cDNA was isolated from human chondrocytes and amplified by 
PCR with the SpeΙ and XhoΙ restriction enzyme cutting site inducted (Figure 5-3). 
The amplified segment was subcloned into the plasmid pLenti6/V5 (Figure 5-4) 
under the control of the CMV promoter. The insert was confirmed by both 
restriction-enzyme digestion (Figure 5-5) and DNA sequencing. The resulting 
plasmid pLenti6/V5-ChM-1 was used for the production of lentivirus vector to 
deliver ChM-1 cDNA into the target cells. Plasmid pLentiLox 3.7 (pLL3.7) with 
GFP was used as empty control vector. Subsequently, lentivirus was packaged by 
using HEK293T cell line and then concentrated for further experiments. During 
lentivirus production, GFP fluorescence could be detected in pLL3.7 GFP transfected 
HEK293T cells (Figure 5-6).  
Lentivirus titration was performed by using serial dilution of concentrated lentivirus 
(LV-ChM-1 or LV-GFP) in HEK293T cell line. Lentivirus titres were calculated by 
the flow cytometry results, showing V5-tag positive or GFP positive cells (Figure 5-
7 and Figure 5-8). The lentivirus titre used in this experiment was 2 × 108/mL. 
Transfection efficacy was also confirmed by Western blot and qRT-PCR. Gene 
expression of ChM-1 increased above 50 fold in LV-ChM-1 infected HEK293T 
cells, and protein level of ChM-1 was also detected following infection, showing a 
clear band around 37 kDa (Figure 5-7). In LV-GFP infected HEK293T cells, GFP 
fluorescence was detectable in the majority of cells under fluorescence microscopy, 
and a solid band of GFP protein was also visible by Western blot (Figure 5-8).  
After lentivirus titration, ACCs were transfected with LV-ChM-1 or LV-GFP (serves 
as empty vector control). In LV-GFP infected ACCs, GFP fluorescence was 
detectable in the majority of cells (Figure 5-9). Infection efficacy was validated by 
Western blot and qRT-PCR. ChM-1 expression significantly increased at both 
protein and gene levels in LV-ChM-1 transfected ACCs (Figure 5-9). 
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Figure 5-3. Amplification of ChM-1 cDNA by PCR (A) and linearization of plasmid vector 
pLenti6/V5 (B).  (A) Human ChM-1 cDNA was isolated from primary chondrocytes and amplified by 
PCR. The PCR product was detected by 1% agarose gel electrophoresis and then was purified for 
further experiment. (B) Plasmid vector pLenti6/V5 was digested to generate a linear vector. Then the 
ChM-1 cDNA segment and pLenti6/V5 linear plasmid were connected to generate ChM-1 expression 
plasmid.       
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Figure 5-4. Map of pLenti6/V5 containing ChM-1 cDNA insert. The amplified ChM-1 cDNA 
segment was cloned into the SpeΙ and XhoΙ restriction enzyme cutting site, with the control of human 
CMV promoter. Adapted from Life Technology (www.invitrogen.com).      
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Figure 5-5. Gel electrophoresis of positive clones.  E.coli SURE2 was transformed with pLenti6/V5 
ChM-1 plasmid and positive clones were selected by Ampicillin. The amplified plasmids were 
collected by mini-prep plasmid purification and digested by restriction enzymes of SpeΙ and XhoΙ. 
The fragment was detected by 1% agarose gel electrophoresis. Data showed two positive clones (lane 
1 and 3). Red arrow is for the target gene ChM-1 fragment, Blue arrow for the plasmid vector.    
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Figure 5-6. GFP fluorescence in HEK293T cells during lentivirus GFP (LV-GFP) production. pLL3.7 
GFP vector along with three packaging plasmids (pRSVRev, pMDLgpRRE and pMD.G) were 
transfected into HEK293T cells to produce LV-GFP. GFP fluorescence was detected in HEK293T 
cells during lentivirus production process. Scale bars, 50 μm.  
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Figure 5-7. Validation of LV-ChM-1 transfection efficiency and titration by using HEK293T cells. 
(A) Western blot and qRT-PCR analysis of ChM-1 expression in HEK293T cells with LV-ChM-1 
transfection. Western blot showed ChM-1 protein were expressed in transfected cells, which showed a 
clear band at around 37 kDa. Gene expression of ChM-1 increased above 50 times in 10 μL LV-ChM-
1 transfected HEK293T cells. (B) Titration of LV-ChM-1 in HEK293T cells by flow cytometry. 
HEK293T cells were seeded into 6-well plate at a density of 1 × 106 cells/well. Serial dilution of 
concentrated LV-ChM-1 (10 μL, 1 μL, 0.1 μL, 0.01 μL, 0.001 μL) was added to each well to transfect 
HEK293T cells. Cells were labelled with V5 Tag antibody and Alexa Fluor® 488 secondary antibody. 
Data showed 37.36% of cells were V5-tag positive with 1 μL LV-ChM-1 transfection.       
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Figure 5-8. Validation of LV-GFP transfection efficiency and titration by using HEK293T cells. (A) 
GFP fluorescence in LV-GFP transfected HEK293T cells. Western blot showed the expression of 
GFP protein in LV-GFP transfected HEK293T cells. Scale bars, 20 μm. (B) Titration of LV-GFP in 
HEK293T cells by flow cytometry. HEK293T cells were seeded into 6-well plate at a density of 1 × 
106 cells/well. Serial dilution of concentrated LV-GFP (10 μL, 1 μL, 0.1 μL, 0.01 μL, 0.001 μL) was 
added to each well to transfect HEK293T cells. Data showed 43.16% of cells were GFP positive with 
1 μL LV-GFP transfection.  
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Figure 5-9. Transfection efficiency of LV-GFP and LV-ChM-1 in primary articular cartilage 
chondrocytes (ACCs). (A) GFP fluorescence in LV-GFP transfected ACCs. ACCs were transfected 
with LV-GFP. Scale bars, 20 μm. (B) Western blot and qRT-PCR analysis of ChM-1 expression in 
ACCs cells with LV-ChM-1 transfection. ACCs were transfected with lentivirus containing LV-ChM-
1. ChM-1 expression significantly increased in both protein and gene levels in LV-ChM-1 transfected 
ACCs.      
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5.3.4 ChM-1 exerted protective effect on catabolic response induced by TNF-α  
It is well known that pro-inflammatory factors, especially IL-1β, IL-6 and TNF-α, 
are major mediators of initiating and enhancing the catabolism in OA cartilage 
(Kapoor, et al., 2011). To investigate whether ChM-1 protects chondrocyte from 
hypertrophy in OA conditions, TNF-α was applied to mimic the inflammatory 
environment of OA. As shown in Figure 5-10A, ACCs transduction with LV-ChM-1 
effectively resulted in the up-regulation of ChM-1 gene (> 100-fold) and protein 
expression in ACCs. Hypertrophic genes of RUNX2, COL10A1, MMP-13 and 
VEGFA were stimulated by TNF-α. However, in ACCs with ChM-1 overexpression, 
TNF-α failed to induce chondrocyte hypertrophy. ChM-1 also decreased the protein 
level of hypertrophic markers RUNX2, COL10A1 and MMP-13 in the presence of 
TNF-α. Conversely, inhibition of ChM-1 by siRNA resulted in notably enhanced 
chondrocyte hypertrophy (Figure 5-10B). Following TNF-α stimulation, ChM-1 
siRNA up-regulated hypertrophic markers of RUNX2, COL10A1 and MMP-13 at 
both gene and protein levels compared to uninfected and scrambled siRNA 
transfected ACCs. These results indicate that under the influence of TNF-α 
stimulation, ChM-1 could resist up-regulation of hypertrophic markers (RUNX2, 
COL10A1, MMP-13 and VEGFA).  
Subsequently, the role of ChM-1 overexpression in maintaining the chondrocyte 
phenotype during ACCs pellet culture was studied. Accordingly, ACCs were infected 
with LV-ChM-1 and then subjected to pellet culture in chondrogenic medium for 
three-weeks. However, results showed that ChM-1 overexpression had no significant 
effect on the expression of chondrogenic and hypertrophic genes at either mRNA or 
protein levels, including COL2A1, ACAN, RUNX2, MMP-13, ALP and COL10A1 
(Figure 5-11).  
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Figure 5-10. Effects of gain and loss of function of ChM-1 on hypertrophic markers in primary 
cultured ACCs. (A) mRNA and protein expression of RUNX2, COL10A1, MMP-13, and VEGFA in 
ACCs with ChM-1 overexpression. ACCs were transfected with LV-ChM-1 or LV-GFP (serves as 
empty vector control) and exposed to TNF-α (10 ng/mL) for 48 h. (B) Analyses of the hypertrophic 
markers in ACCs transfected with ChM-1 siRNA (100 nM) or scrambled siRNA, followed by 
treatment with TNF-α (10 ng/mL) for 48 h. Non-transfected ACCs serves as empty control for both 
(A) and (B). Values are mean ± SEM (n = 3). *p < 0.05 versus LV-GFP group. 
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Figure 5-11. Effects of ChM-1 overexpression on chondrogenic differentiation of ACCs in pellet 
culture. (A) Expression of chondrogenic genes (COL2A1, ACAN and SOX9) and hypertrophic genes 
(RUNX2, COL10A1, MMP-13, ALP and VEGFA) in ACCs pellets with ChM-1 overexpression. 
ACCs were infected with LV-ChM-1 and then subjected to pellet culture in chondrogenic medium for 
3-weeks. (B) Protein expression of chondrogenic and hypertrophic markers in ACCs pellets with 
ChM-1 overexpression. Values are mean ± SEM (n = 3). *p < 0.05 versus LV-GFP group. 
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5.3.5 Overexpression of ChM-1 in articular cartilage delayed OA progression in 
vivo 
Based on the in vitro data, I therefore evaluated the therapeutic efficacy of ChM-1 
overexpression in an experimental rat model of OA induced by surgically removal of 
meniscus (MSX). Lentivirus ChM-1 and GFP were injected intra-articular into rat 
OA knee joints. Gross morphology demonstrated severe cartilage surface damage in 
LV-GFP and PBS-treated OA group having a rough appearance, osteophyte 
formation and proliferation of peripheral fibrous tissues in both tibia and femur 
cartilage. LV-ChM-1 treatment had no significant influence on the surface roughness 
of cartilage, but alleviated osteophyte and fibrous tissue formation at five-weeks 
(Figure 5-12). Safranin-O staining showed similar severity of proteoglycan depletion 
in LV-GFP and PBS-treated OA rats. Interestingly, intra-articular injection of LV-
ChM-1 reduced proteoglycan depletion compared to LV-GFP and PBS-treated OA 
groups (Figure 5-13). Cartilage degradation in the tibial plateau was further 
quantified by Mankin’s histologic grading system. LV-ChM-1 treatment significantly 
reduced the Mankin score by 65.62% ± 11.35% and 64.51% ± 13.22% at five-weeks 
compared to LV-GFP and PBS-treated OA groups, respectively (Figure 5-13). 
Ectopic expressions of these constructs were confirmed by V5-tag staining and GFP 
fluorescence, respectively (Figure 5-14). Immunohistochemical staining and qRT-
PCR showed that ChM-1 expression in articular cartilage was successfully enhanced 
by LV-ChM-1 injection at five-weeks (Figure 5-14 and Figure 5-16). Furthermore, 
overexpression of ChM-1 in articular cartilage chondrocytes markedly decreased 
gene and protein abundance of catabolic markers, including COL10A1, MMP-13 and 
VEGFA (Figure 5-15 and Figure 5-16). Additionally, immunohistochemical staining 
of COL2A1 and aggrecan were correspondingly enhanced in cartilage following LV-
ChM-1 treatments (Figure 5-15).  
At late time-points (nine-weeks), intra-articular injection of LV-ChM-1 seemed to 
have higher cartilage thickness as revealed by Safranin-O staining (Figure 5-17A). 
However, Mankin score of LV-ChM-1 treatment showed no statistically significant 
difference at nine-weeks, compared to LV-GFP treatment and PBS group (Figure 5-
17B). Immunohistochemical staining showed that ChM-1 abundance was slightly 
elevated at nine-weeks (Figure 5-17). Taken together, the in vivo experiment 
revealed that overexpression of ChM-1 by lentivirus infection delayed cartilage 
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degradation in OA rat model at the early time-point. 
 
Figure 5-12. Gross observation of femur and tibia cartilage surface in surgical osteoarthritis rat model 
at 5-weeks.  Experimental rat model of OA were induced by surgically removal of meniscus. LV-
ChM-1 or LV-GFP was injected intra-articular into rat OA knee joints. Severe cartilage surface 
damage were shown in LV-GFP and PBS groups with rough appearance, osteophyte formation and 
proliferation of peripheral fibrous tissues in both tibia and femur cartilage. LV-ChM-1 treatment 
alleviated osteophyte and fibrous tissue formation.   
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Figure 5-13. Histology analysis of tibia cartilage section in surgical osteoarthritis rat model at 5-
Weeks. (A) Safranin-O staining showed similar severity of proteoglycan depletion in LV-GFP and 
PBS-treated OA rats. LV-ChM-1 treatment reduced proteoglycan depletion compared to LV-GFP and 
PBS-treated OA groups. Scale bars, 50 µm. (B) Quantification of osteoarthritis progression by 
Mankin scoring system.  Values are mean ± SEM (n = 6). *p < 0.05 versus LV-GFP group. 
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Figure 5-14. Validation of lentivirus transfection efficacy in surgical osteoarthritis rat cartilage at 5-
weeks. Transfection efficacy was confirmed by GFP fluorescence in LV-GFP group and 
immunohistochemical staining of ChM-1 and V5-tag in LV-ChM-1 group. Scale bars, 50 µm. 
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Figure 5-15. Immunohistochemical staining of chondrogenic and hypertrophic markers in surgical 
osteoarthritis rat cartilage at 5-weeks.  Expression of chondrogenic marker (COL2A1 and aggrecan) 
were enhanced in cartilage upon LV-ChM-1 treatment, while catabolic markers (MMP-13, COL10A1 
and VEGFA) were correspondingly decreased in LV-ChM-1 group. Arrows means the immune-
positive cells with indicated antibodies. Scale bars, 100 µm. 
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Figure 5-16. Gene expression of ChM-1 and hypertrophic markers in surgical osteoarthritis rat 
cartilage at 5-weeks. Intra-articular injection of LV-ChM-1 resulted in markedly increasing gene level 
of ChM-1. Gene level of hypertrophic markers (COL10A1, MMP-13 and VEGFA) significantly 
decreased in LV-ChM-1 treatment group. Values represent mean ± SEM (n = 3). *p < 0.05 versus 
LV-GFP group. 
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Figure 5-17. Histology analysis of tibia cartilage in surgical osteoarthritis rat model at 9-weeks.   (A) 
Safranin-O staining showed severity of proteoglycan depletion in LV-ChM-1, LV-GFP and PBS-
treated OA rats. Immunohistochemical staining showed the expression of ChM-1 in OA tibia 
cartilage. (B) Quantification of osteoarthritis progression by Mankin scoring system. Values represent 
mean ± SEM (n = 6). 
  
Chapter 5: Role of ChM-1 during chondrocyte hypertrophy and its therapeutic efficacy in OA progression in vitro  
and in vivo 91 
5.4 DISCUSSION 
This study extended our knowledge on the importance of anti-angiogenic factor in 
maintaining the physiological functions of chondrocytes and preventing hypertrophy. 
My data showed the anti-angiogenic factor ChM-1 is closely correlated with 
chondrocyte maturation and stabilize chondrocyte phenotype. It was found that the 
ChM-1 can regulate catabolic genes of VEGFA, COL10A1 and MMP-13 in 
chondrocytes and thus protect chondrocytes from TNF-α-induced hypertrophy. More 
importantly, the in vivo study provided evidence that ChM-1 supplementation to 
articular chondrocytes delays OA progression, suggesting that ChM-1 could have a 
therapeutic potential in OA pathological conditions. 
The role of ChM-1 as a potent anti-angiogenic factor has been widely studied 
(Hayami, et al., 1999; Hiraki, et al., 1997a; Miura, et al., 2010; Shukunami & Hiraki, 
1998; Yoshioka, et al., 2006).  Further, ChM-1 has been reported to stimulate 
proliferation of cultured chondrocytes (Hiraki, et al., 1991). During chick wing 
development ChM-1 expression co-localizes with the cartilage matrix marker 
COL2A1 (Shukunami, et al., 2008). Pelttari et al. reported that mesenchymal stem 
cell (MSCs) pellets transplanted to ectopic sites in severe combined 
immunodeficiency (SCID) mice underwent endochondral ossification with 
hypertrophy and angiogenesis, whereas chondrocyte pellets resisted calcification and 
vascular invasion in vivo (Pelttari et al., 2006), suggesting different potential of 
chondrogenic differentiation between MSCs and chondrocytes. However, the 
importance of anti-angiogenic factor had not been taken into consideration in that 
study. My results showed that during chondrogenic differentiation of ACCs, up-
regulation of ChM-1 was consistent with the expression of cartilage marker COL2A1 
and SOX9. BMSCs produced ChM-1 at significantly lower level than chondrocytes 
and cannot undergo complete chondrogenic differentiation, with less matrix 
deposition and COL2A1 expression. These results suggested the ChM-1 may be 
correlated with chondrogenesis and ChM-1 may act as an anabolic marker in 
chondrocyte phenotype. Furthermore, TGF-β, known as a chondrogenic stimulator, 
significantly up-regulated SOX9 and COL2A1, but had no influence on ChM-1 
expression. This may indicate that ChM-1 is an independent anabolic marker or 
regulated through unknown upstream signalling in chondrocytes.  
Surprisingly, in pellet culture, overexpression of ChM-1 in chondrocytes did not 
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enhance chondrogenic differentiation of ACCs. In Pelttari’s study, chondrocytes 
pellet possess the ability to resist vascular invasion in vivo (Pelttari, et al., 2006), 
indicating chondrocytes pellet contains physiologically significant amounts of anti-
angiogenic protein, which might include ChM-1. As shown in my previous data, 
ChM-1 expression could be up-regulated with time of chondrogenic differentiation in 
pellet culture. Besides, chondrocytes possess higher constituent ChM-1 level than 
that in BMSCs. Therefore, I hypothesize that the pellet culture of chondrocytes could 
induce sufficient amount of ChM-1 protein to maintain chondrocyte phenotype; 
whereas the excessive ChM-1 has no additional function. But this result cannot rule 
out the protective function of ChM-1 in cartilage homeostasis. My results showed 
ChM-1 could protect chondrocyte in hypertrophic condition, that is monolayer 
culture with TNF-α stimulation. Compared to monolayer culture system, pellet 
culture method of chondrogenic differentiation has been proved to be a better model 
to mimic the chondrocyte micro-environment, which can preserve chondrocyte 
phenotype. However, it will be more interesting and more convincing to show the 
effect of ChM-1 overexpression/knockdown on chondrogenesis in pellet culture 
system with hypertrophic stimuli, such as inflammatory cytokine or mechanical 
loading, which will be subjected to my future study. 
Pro-inflammatory factors, especially IL-1β, IL-6 and TNF-α, are major mediators of 
initiating and enhancing the catabolism of OA cartilage (Kapoor, et al., 2011). My 
results demonstrated that TNF-α up-regulates hypertrophic genes of RUNX2, 
COL10A1, MMP-13, ALP and VEGF, and down-regulates ChM-1 in ACCs, which 
is consistent with previous reports. Interestingly, ACCs with ChM-1 overexpression 
effectively resist TNF-α induced hypertrophy, with constant higher level of 
chondrogenic marker and low expression of hypertrophic markers, thus indicating 
that ChM-1 could protect chondrocyte from catabolism induced by pro-inflammatory 
cytokine. Additionally, Klinger et al. showed that osteochondral progenitor cells with 
AAV-ChM-1 infection stimulated chondrogenic differentiation and inhibited 
endochondral ossification with decreased COL10A1 abundance in a micro-fractured 
cartilage repair model, but ChM-1 had no effect on VEGFA gene expression in vitro 
(Klinger, et al., 2011). However, as shown in my result, ChM-1 could suppress up-
regulation of VEGFA and COL10A1 in an inflammatory environment and MSX-
induced OA model. The data implies that ChM-1 may not target angiogenic and 
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hypertrophic genes directly, but target the signals of initiating these catabolic genes.  
Based on these encouraging in vitro results, I set to test the functional relevance of 
ChM-1 supplementation to OA progression in vivo. I found that ChM-1 
overexpression in articular chondrocytes significantly ameliorated OA progression at 
five-weeks, characterized by reduced COL10A1, MMP-13 and VEGFA expression 
and matrix degradation. At late stage of OA (nine-weeks post-surgery), ChM-1 
showed no tendency to reduce cartilage matrix degradation, as there is no significant 
difference in Mankin scores. As shown by immunostaining, the abundance of ChM-1 
also decreased at week nine. This observed phenomenon might be explained as 
follows: the N-terminal 14 kDa truncated form of ChM-1 has been recently identified 
in hypertrophic and calcified zone of cartilage in developing long bone (Miura et al., 
2014). The ChM-1 cleavage has little inhibitory effect on angiogenesis in contrast to 
its intact 25 kDa form, indicating other mechanisms regulating ChM-1 function at 
post-transcriptional level in vivo (Miura, et al., 2014). In my study, lentivirus 
carrying ChM-1 efficiently increased gene level of ChM-1; however, at late stage 
OA cartilage, the intact form of ChM-1 might be proteolyzed and thus its protective 
effect on cartilage is compromised. Nevertheless, considering the time-scale 
correlation between laboratory rats and human (10.5 rat days equals to one human 
year (Sengupta, 2013)), my in vivo data showed ChM-1 supplementation at least 
postponed OA progression, providing evidence for utilizing anti-angiogenic strategy 
in OA therapy. Further studies will aim to clarify the post-transcriptional regulation 
of ChM-1, as well as to develop more sustained strategy to improve ChM-1 
efficiency in OA therapy.   
In conclusion, my results indicate that ChM-1 is important to maintain the 
chondrocyte phenotype and prevent hypertrophy by inhibiting catabolic factors of 
COL10A1, MMP-13 and VEGFA. Moreover, this study provides a new therapeutic 
strategy for OA through supplementation of anti-angiogenic protein ChM-1.  
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Chapter 6: ChM-1 inhibits catabolic 
changes of OA chondrocytes 
through HIF-2α pathway 
6.1 INTRODUCTION 
As discussed in the previous chapters, ChM-1 is closely correlated with chondrocyte 
maturation and stabilizes the chondrocyte phenotype. The expression of ChM-1 is 
confined within normal avascular cartilage, whereas its expression is abolished in 
hypertrophic chondrocytes, in both growth plate and osteoarthritis. My results 
indicate that ChM-1 can regulate the catabolic genes of VEGFA, COL10A1 and 
MMP-13 in chondrocytes, and thus protect chondrocytes from TNF-α-induced 
hypertrophy in vitro and delay OA progression in an animal model. Therefore, it 
could be inferred that ChM-1 is not merely an anti-angiogenic protein in cartilage, 
but more importantly, serves as the intrinsic factors to maintain its phenotype.  
Articular cartilage is an avascular tissue by nature and oxygen supply to the 
chondrocytes is limited to the capacity of synovial fluids to carry oxygen and its flow 
rate during joint movement (Lee, et al., 2007; Lund-Olesen, 1970; Pfander & Gelse, 
2007). Therefore, being avascular, hypoxia is the physiologic environment for 
articular cartilage. Hypoxia has generally been regarded as the condition most 
favourable to induce the chondrocyte phenotype; nevertheless, it is a stress condition 
in vascular tissues. The hypoxic response is mediated by hypoxia inducible factor 
(HIF) family members (mainly HIF-1α, -2α). In vitro studies have demonstrated that 
hypoxia enhances SOX9 activity – considered the master regulator of 
chondrogenesis – and leads to an increased expression of COL2A1 (Duval, et al., 
2009; Robins, et al., 2005). HIF-1α has been reported to be essential for chondrocyte 
survival, energy generation and matrix synthesis (Pfander, et al., 2003; Yudoh, et al., 
2005). Recently, several studies have revealed a catabolic effect of HIF signalling in 
osteoarthritic cartilage, particularly HIF-2α (Saito, et al., 2010; Yang, et al., 2010). 
The hypothesis is that the shift from HIF-1α to HIF-2α initiates and promotes 
chondrocyte hypertrophy and cartilage degradation in OA (Husa, et al., 2010). In 
spite of HIF-1α and HIF-2α having approximately 50% amino acid sequence 
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identity, they have remarkably different expression patterns and functions in cartilage 
metabolism (Husa, et al., 2010). HIF-2α has been shown to potentiate Fas-mediated 
chondrocyte apoptosis, which actively promotes osteoarthritic cartilage destruction 
(Ryu, et al., 2012). Moreover, two independent studies reported that HIF-2α, as a 
central catabolic regulator of osteoarthritic cartilage destruction, directly targets 
hypertrophic genes in OA cartilage, such as VEGFA, COL10A1, RUNX2, MMP-1, 
MMP-3, MMP-9, MMP-12, MMP-13 and ADAMTS4 (Saito, et al., 2010; Yang, et 
al., 2010).  
In normal cartilage, as in other tissues, hypoxia enhances the expression of both HIF-
1α and HIF-2α. Although the literature concerning the HIF-2α abundance in OA 
cartilage seems contradictory – with reports of both increased and decreased level, in 
healthy articular cartilage HIF-2α has been detected in considerable amounts 
(Bohensky, et al., 2009; Coimbra, et al., 2004). Interestingly, the existence of HIF-2α 
in normal cartilage does not initiate the angiogenic and catabolic cascades. Hence, it 
seems that chondrocytes in normal cartilage are capable of blocking angiogenic and 
hypertrophic pathways induced by HIF-2α, whereas OA chondrocytes cannot.  
Therefore, it would appear that ChM-1, as an intrinsic and abundant protein in 
cartilage, may play a regulatory role in the function of HIFs.   
Therefore, the hypothesis of this study is that ChM-1 may influence HIF-2α 
abundance or transcriptional activity and subsequently suppress catabolic marker 
expression. To verify this hypothesis, I first examined the effect of ChM-1 
overexpression on HIF-2α expression in chondrocytes. Next, since HIF-2α is a 
transcription factor, translocation into the nucleus is essential for it to exert its 
function; therefore, the nuclear accumulation of HIF-2α under ChM-1 
overexpression condition was investigated by Western blot and immunocytochemical 
staining. Last, chromatin immunoprecipitation (ChIP) assays were performed to 
clarify whether ChM-1 could influence the recruitment of HIF-2α to the promoter 
regions of COL10A1, MMP-13 and VEGFA.  
 
6.2 MATERIALS AND METHODS 
Details of materials and methods used in this chapter are described in Chapter 3. The 
following is a brief outlines of the materials and methods used to generate the data in 
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this chapter.  
6.2.1 Immunohistochemical staining of HIF-1α and HIF-2α in rat OA cartilage 
 An experimental rat model of OA was induced by surgically removing the meniscus 
as described in section 3.13.1. After five-weeks, the rats were sacrificed and the knee 
samples were collected for histology analysis. The expression of HIF-1α and HIF-2α 
during OA pathology was explored by immunohistochemical staining of HIF-1α and 
HIF-2α, as described in section 3.13.2. Six rat joint samples from each group were 
processed for histological analysis.  
6.2.2 Expression of HIF-2α in chondrocyte under hypoxia or TNF-α stimulation 
To explore the molecular mechanisms underlying the inhibitory effect of ChM-1 on 
catabolic changes of chondrocytes, C28/I2 cells with or without ChM-1 
overexpression were used in this part of the study.  C28/I2 cells were cultured and 
expanded in DMEM/F12 medium supplemented with 10% v/v FBS and 1% v/v P/S. 
To study expression of HIF-2α under hypoxia environment, the cells were seeded in 
6-well plates and cultured in a BINDER CO2 Incubator with O2 Control, which was 
set as 1% O2, 5% CO2 and 94% N2. To determine the expression of HIF-2α under 
osteoarthritic hypertrophic environment, the cytokine TNF-α was added to the cell 
culture medium at different concentrations (1, 10, 50 ng/mL). At the nominated time-
points, whole cell lysates were extracted using RIPA lysis buffer and subjected to 
Western blot to determine the protein expression of HIF-2α, as described in section 
3.5. Assays were performed in triplicate, with each sample tested individually three 
times from three different C28/I2 cell line passages. 
6.2.3 Effect of ChM-1 overexpression on HIF-2α production and nucleus 
translocation in chondrocytes 
To investigate the effect of ChM-1 overexpression on HIF-2α production, C28/I2 
cells were infected with LV-ChM-1 or LV-GFP at 50–60% confluence (details are 
described in section 3.11.3). Infected cells were exposed to TNF-α (10 ng/mL) 
stimulation for the nominated time-points. Whole cell lysates were extracted using 
RIPA lysis buffer. Nucleus lysate and cytoplasmic protein were prepared using NE-
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PER Nuclear and Cytoplasmic extraction kit. Protein abundance of HIF-2α was 
detected by Western blot as described in section 3.5. 
To visualize HIF-2α location in chondrocytes, C28/I2 cells overexpressing ChM-1 
was seeded on coverslips and exposed to 10 ng/mL TNF-α stimulation for 1 h. The 
cell were fixed in 4% PFA for 1 h and immunocytochemical staining of HIF-2α 
performed, as described in section 3.14. The stained cells were viewed under 
confocal microscopy (Leica TCS SP5). 
6.2.4  ChIP assay 
To determine if ChM-1 interferes with the recruitment of HIF-2α to the promoter 
region of the catabolic genes of COL10A1, MMP-13 and VEGFA, ChIP assays were 
performed using Pierce Agarose ChIP kit. LV-ChM-1 and LV-GFP infected C28/I2 
cells were exposed to TNF-α for 6 h then the samples subjected to ChIP analysis. 
HIF-2α antibody and normal rabbit IgG were used for immunoprecipitation. Primers 
were designed to span the identified HRE in the promoter or intron of target genes 
(Liu, et al., 1995; Saito, et al., 2010), as follows: COL10A1 (-59 to +121 bp), MMP-
13 (–214 to –28 bp), VEGFA (–1,000 to–795 bp). Further details are described in 
section 3.15.  
6.2.5 Statistical analysis 
Assays were performed in triplicate, with each sample tested individually three times 
from three different C28/I2 cell line passages. All the data, including qRT-PCR, 
Western blot and ChIP assay results, were presented as means ± SEM and were 
analysed using one-way ANOVA. Analyses were performed using SPSS version 
21.0 software. A p-value <0.05 were considered to be statistically significant 
difference. 
 
6.3 RESULTS 
6.3.1 Expression of HIF-1α and HIF-2α in normal and OA cartilage 
The cellular expression of HIF-1α and HIF-2α in normal and OA rat cartilage was 
determined by immunohistochemical staining. As shown in Figure 6-1, HIF-1α and 
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HIF-2α protein were both moderately expressed in chondrocytes in normal rat 
cartilage, and the expression of both were sustained in OA rat cartilage with no 
significant enhancement or decrease. The expression of ChM-1 and VEGFA were 
also shown in Figure 6-1. Consistent with the results in human OA cartilage 
(Chapter 3), in rat OA cartilage there was a significantly reduced ChM-1 expression 
and enhanced VEGFA expression, compared to normal rat cartilage.  
 
 
Figure 6-1. Immunohistochemical staining of HIF-1α and HIF-2α in rat OA cartilage.  Experimental 
rat model of OA were induced by surgically removal of meniscus (n = 6).  After five-weeks, rats were 
sacrificed and knee samples were collected for histology. Immunohistochemical staining showed the 
expression of HIF-1α and HIF-2α, as well as ChM-1 and VEGFA in OA and normal cartilage. Scale 
bars, 100 µm.  
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6.3.2 ChM-1 delayed HIF-2α translocation to nucleus  
ChM-1 overexpression in C28/I2 was achieved by infection with LV-ChM-1 or LV-
GFP (serves as empty vector control). GFP fluorescence was detectable in majority 
cells infected with LV-GFP (Figure 6-2). Infection efficacy was also validated by 
Western blot and qRT-PCR. ChM-1 gene and protein expression was significantly 
increased LV-ChM-1 transfected C28/I2 (Figure 6-2). 
As is shown in Figure 6-3A, both hypoxic conditions and TNF-α stimulation 
markedly increased the total protein level of HIF-2α, whereas ChM-1 overexpression 
had no effect on either mRNA or cellular protein levels of HIF-2α compared to 
control and GFP group (Figure 6-3B). Nuclear accumulation of activated HIF-2α in 
ChM-1 overexpression condition was determined by immunofluorescence and 
Western blot. Figure 6-4A shows there was a substantial nuclear translocation of 
HIF-2α occurring at 30 min of TNF-α stimulation in “wild type” C28/I2 cells, 
whereas this was delayed up to 2 h in the ChM-1 overexpressing cells. 
Immunofluorescence staining revealed that a considerable amount of HIF-2α was 
localized to the nucleus upon TNF-α stimulation at 1 h, whereas HIF-2α remained in 
the cytoplasm in ChM-1 overexpressing cells (Figure 6-4B). These data suggest that 
ChM-1 has no effect on the gene expression and de novo protein synthesis of HIF-
2α, but rather delays HIF-2α translocation to nucleus. 
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Figure 6-2. Transfection efficiency of LV-GFP and LV-ChM-1 in chondrocyte cell line C28/I2.  (A) 
GFP fluorescence in LV-GFP transfected C28/I2. C28/I2 cells were transfected with LV-GFP. GFP 
fluorescence was detectable in majority cells. Scale bars, 50 μm. (B) Western blot and qRT-PCR 
analysis of ChM-1 expression in C28/I2 cells with LV-ChM-1 transfection. ChM-1 expression 
significantly increased in both protein and gene level in LV-ChM-1 transfected C28/I2. 
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Figure 6-3. Effect of ChM-1 overexpression on HIF-2α production in chondrocyte cell line C28/I2.  
(A) HIF-2α protein expression in chondrocyte cell line C28/I2 under the stimulation of TNF-α (1, 10 
or 50 ng/mL) or hypoxia condition (1% O2) for indicated time-points. GAPDH was included as a 
loading control. (B) Western blot and qRT-PCR analysis of HIF-2α expression in C28/I2 transfected 
with LV-ChM-1 or LV-GFP and exposed to TNF-α (10 ng/mL) for indicated time-points. Values 
represent mean ± SEM (n = 3).  
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Figure 6-4. ChM-1 delayed HIF-2α translocation to nucleus in C28/I2.  (A) Cytoplasmic and nuclear 
abundance of HIF-2α in C28/I2 with ChM-1 overexpression demonstrated by Western blot. C28/I2 
cells were transfected with LV-ChM-1 or LV-GFP and exposed to TNF-α for indicated time-points. 
Tubulin and PCNA serve as a loading control for cytoplasmic and nuclear protein, respectively. The 
intensities of the bands were normalized to loading control and then further converted to the fold 
change of the first time-point. Values are mean ± SEM (n = 3). (B) Intra-cellular localization of HIF-
2α in C28/I2 with ChM-1 overexpression demonstrated by immunofluorescence staining. C28/I2 cells 
were transfected with LV-ChM-1 and exposed to 10 ng/mL TNF-α for 1 h. DAPI was used to 
visualize nuclei. Non-transfected ACCs serves as control. Scale bars, 50 µm. Arrow head, positive 
nucleus staining of HIF-2α; Arrow, negative nucleus staining of HIF-2α. 
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6.3.3 ChM-1 inhibited transcriptional activity of HIF-2α on hypertrophic genes 
ChIP assays were performed to determine whether ChM-1 associates with HIF-2α 
when recruited to the promoter of the catabolic genes of COL10A1, MMP-13 and 
VEGFA. Primer sets (positions are indicated in Figure 6-5) were designed to 
amplify the identified HIF-2α binding regions on the promoter or intron of target 
genes (Liu, et al., 1995; Saito, et al., 2010). After exposure to TNF-α for 6 h, qRT-
PCR showed that the binding activities of HIF-2α to the promoter of COL10A1, 
MMP-13 and VEGFA were significantly decreased in ChM-1 infected C28/I2 cells, 
compared to the GFP infected group (Figure 6-5). These data therefore indicate that 
ChM-1 inhibits the transcriptional activity of HIF-2α on genes of COL10A1, MMP-
13 and VEGFA.  
 
Figure 6-5.  ChM-1 inhibited transcriptional activity of HIF-2α on hypertrophic genes.  ChIP assay 
for detection the DNA binding activity of HIF-2α to the promoter of hypertrophic genes of MMP-13, 
COL10A1 and VEGFA in C28/I2 with ChM-1 overexpression. C28/I2 cells were transfected with 
LV-ChM-1 or LV-GFP and exposed to TNF-α for 6 h. Chromatin was immunoprecipitated with HIF-
2α antibody, and ChIP DNA was amplified by primer sets that span the HRE site. TSS, transcription 
start site. Non-transfected ACCs serves as empty control. Values are mean ± SEM (n = 3). *p  < 0.05 
versus LV-GFP group. 
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6.4 DISCUSSION 
The protective effect of ChM-1 on the chondrocyte phenotype has been shown in an 
OA model in my previous studies, as well as in a cartilage regeneration model by 
other researchers (Klinger, et al., 2011). The mechanism underlying this function of 
ChM-1 is fundamentally important in cartilage biology, since ChM-1 is an intrinsic 
and abundant protein in cartilage. Here, I report that ChM-1 delays HIF-2α 
translocation to nucleus at early time-points and inhibits the transcriptional activity 
of HIF-2α on the genes COL10A1, MMP-13 and VEGFA. This is the first study to 
report such a mechanism in the regulation of the chondrocyte phenotype by ChM-1. 
The HIF family of proteins was first discovered by virtue of its expression and 
function depending mainly on the oxygen levels surrounding cells (Bruick & 
McKnight, 2001; Epstein, et al., 2001). Under normal oxygen condition, HIF-α is 
hydroxylated by PHDs and degrades rapidly through ubiquitination (Ivan, et al., 
2001; Jaakkola, et al., 2001; Yu, et al., 2001). On the other hand, under hypoxia (1-
5% oxygen), PHD activity is inhibited and HIF-α becomes stabilized, translocating 
into the nucleus and heterodimerizes with the constitutively expressed HIF-β (Huang, 
et al., 1998; Jiang, et al., 1996; Salceda & Caro, 1997; Semenza, et al., 1994; Wang 
& Semenza, 1993). The HIF-α/β heterodimer then trans-activates target genes by 
binding to hypoxia-response elements (HRE, 5’-RCGTG-3’; R is A or G). In vitro 
studies showed that HIF-2α is not solely dependent on oxygen level, but also 
sensitive to non-hypoxic stimuli, including inflammatory cytokines, growth factors 
and catabolic stress. It has been shown that IL-1β and TNF-α up-regulate HIF-2α in 
chondrocytes through the NF-κB and p38 pathways (Saito, et al., 2010; Yang, et al., 
2010). Classically, the best characterised targets of HIFs are angiogenic genes, such 
as VEGF, EPO (Firth, et al., 1994; Forsythe, et al., 1996). Recently, the chondrocyte 
hypertrophic markers VEGFA, COL10A1 and MMP-13 have been shown also to be 
targets of HIF-2α, as shown by transcription factor screening, immunoprecipitation, 
luciferase reporter assay, site-directed mutagenesis of luciferase assay and ChIP 
assay. These data provides solid evidence for the catabolic role of HIF-2α in cartilage 
(Saito, et al., 2010). Based on these results, therefore, this study aimed to explore the 
mechanistic pathway of ChM-1 with a focus of the regulation of HIF-2α activity.   
My results show that HIF-2α could be induced both by hypoxia (1% O2) and TNF-α 
stimulation in the chondrocyte cell line C28/I2, which is consistent with previous 
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studies (Saito, et al., 2010; Yang, et al., 2010). Furthermore, in the surgery-induced 
OA rat model, my results showed that there was no significant difference in HIF-2α 
protein expression in either normal or OA rat cartilage. It is not at all surprising to 
observe moderately expressed HIF-2α in normal cartilage, considering the low 
oxygen tension in cartilage. However, there are great discrepancies concerning the 
expression of HIF-2α in OA cartilage, most likely because the short half-life of HIF-
2α protein (approximately 5 min) makes its detection in tissues difficult (Thoms, et 
al., 2013). For instance, studies conducted by Yang et al. and Saito et al. showed 
increased levels of HIF-2α in human and experimentally-induced mouse OA 
cartilage (Saito, et al., 2010; Yang, et al., 2010), whereas a study by Bohensky 
reported reduced HIF-2α protein expression in human OA cartilage (Bohensky, et 
al., 2009). In my study, the isolated rat femur and tibia samples were immediately 
immersed in PFA to avoid protein degradation, and the results showed that HIF-2α 
was moderately expressed in rat OA cartilage, but not significantly different to that 
seen in normal cartilage, indicating that the decreased O2 tension and increased 
inflammation in OA environment did not increase total protein levels of HIF-2α.  
To determine any interaction between ChM-1 and the HIF-2α pathway, ChM-1 
overexpression in the chondrocyte cell line C28/I2 was achieved by lentivirus 
infection of the cells. My results showed that ChM-1 has no effect on the gene and de 
novo protein synthesis of HIF-2α. However, this result cannot rule out the influence 
of ChM-1 on HIF-2α activity, since regulation of HIF-2α depends on post-
translational hydroxylation and nuclear translocation and not the total protein level. 
Interestingly, the data indeed showed that ChM-1 overexpression delays HIF-2α 
nuclear translocation at early time-points and inhibits the DNA binding activity of 
HIF-2α to the promoter regions of COL10A1, MMP-13 and VEGFA, indicating the 
protective effect of ChM-1 on TNF-α-induced hypertrophy might be achieved, at 
least in part, through the inhibition of HIF-2α activity. This could also explain why, 
in normal cartilage in vivo, HIF-2α fails to induce angiogenesis factors and catabolic 
markers. It may be that in normal cartilage, the abundant expression of ChM-1 
blocks the angiogenic and hypertrophic activity of HIF-2α, whereas in OA cartilage, 
the catabolic function of HIF-2α is unlocked due to a lack of ChM-1.  
Although ChM-1 overexpression has no effect on gene expression of PHD2, it will 
be interesting to detect the protein level of PHD2 as it initiates the first step of HIF 
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degradation. And also it is still not clear whether ChM-1 could directly interact with 
HIF-2α or influence other co-transactivators of HIFs pathway, such as STAT3, p300 
and up-stream stimulating factor 2 (USF2). As ChM-1 has been shown to suppress 
STAT activity in human cancer cells (Mera, et al., 2009), the inhibitory effect of 
ChM-1 on the HIF pathways may be through these co-transactivators. Further studies 
are needed to address these questions. 
In conclusion, my results demonstrated that ChM-1 delays the translocation of HIF-
2α into the nucleus and inhibits transcriptional activation of HIF-2α on the genes 
COL10A1, MMP-13 and VEGFA. Based on the results it has been summarized in 
the following scheme illustration (Figure 6-6) for the possible mechanism of ChM-1 
in preventing the HIF-2α nuclear translation and binding on the promotors for 
hypertrophic markers. The data suggests a novel mechanism of ChM-1 in 
maintaining chondrocyte phenotype and preventing hypertrophy.  
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Figure 6-6. Schematic illustration of underlying molecular mechanisms of ChM-1. HIF-2α is a 
catabolic regulator of osteoarthritis cartilage, which directly targets hypertrophic genes of VEGFA, 
COL10A1 and MMP-13 (Saito, et al., 2010). This study showed that ChM-1 inhibits the translocation 
of HIF-2α into the nucleus at early time-points and inhibits transcriptional activation of HIF-2α on the 
genes COL10A1, MMP-13 and VEGFA. And thus ChM-1 protects chondrocyte phenotype and 
prevents hypertrophy. 
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Chapter 7: Conclusion and Discussion 
7.1 INTRODUCTION 
Cartilage is a highly specialized connective tissue with an avascular structure and 
limited innate regenerative ability. Osteoarthritis (OA) is the most common form of 
musculoskeletal disorder and a leading cause of disability in the elderly (Woolf & 
Pfleger, 2003). The key pathophysiological features of OA joints include articular 
cartilage degradation and abnormal subchondral bone metabolism; however the 
aetiology is largely unknown. Apart from providing relief for symptomatic pain, the 
most common treatment option for OA patients is joint (knee/hip) replacement 
surgeries, since there is no treatment available to slow down the cartilage degradation 
and OA progression. Normal cartilage maintains a stable phenotype that suppresses 
hypertrophy and angiogenesis throughout life. The molecular and cellular basis for 
the ability to maintain the chondrocyte phenotype and cartilage homeostasis is still 
poorly understood. It is important to gain a better understanding of the physiology of 
healthy cartilage in order to develop therapies with which to arrest or reverse OA 
progression. Therefore, the specific biological factors responsible for maintaining 
cartilage homeostasis must be identified and targeted to fulfil the goal of disease 
medication.  
Angiogenesis, controlled by a balance between endogenous angiogenic and anti-
angiogenic factors, has been found to contribute to pathogenesis of OA. Normal 
cartilage is known to contain considerable amounts of anti-angiogenic factors, which 
are extensively expressed in chondrocyte cytoplasm and cartilage matrix (Bonnet & 
Walsh, 2005; Patra & Sandell, 2012). Of the anti-angiogenic factors, ChM-1 is the 
one most specific and abundantly expressed in cartilage and its expression closely 
related with the chondrocyte phenotype. The regulatory effect of ChM-1 in 
chondrocyte maturation and bone remodelling has been verified in genetically 
modified mice (Nakamichi, et al., 2003; Yukata, et al., 2008). Motivated by these 
findings, the aim of this project was to address the balance between angiogenesis and 
anti-angiogenesis in OA cartilage with a focus on the function of ChM-1. As part of 
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this study I performed an expression profiling of angiogenic-related cytokines in 
human OA cartilage. The involvement of ChM-1 in chondrogenesis and OA 
progression were investigated in a rat OA model and in vitro using human articular 
cartilage chondrocytes cell culture, in an effort to determine the prevention of 
chondrocyte hypertrophy and the molecular mechanism underlying ChM-1’s 
function. The overarching goal of this study was to gain a better understanding of the 
aetiology of OA thus providing new insights into the molecular mechanisms of OA 
progression, and also potential new treatment options for OA.  
 
7.2 PROJECT DESIGN AND MAIN FINDINGS 
The first aim of this study was to build an expression profile of angiogenesis-related 
cytokines in OA cartilage, as shown in Chapter 4. In normal articular cartilage, anti-
angiogenic factors play a dominant role, since in normal physiological conditions 
cartilage is essentially devoid of a vasculature. However, this property appears to be 
lost in OA cartilage, in which blood vessels and channels invade from the 
subchondral bone into the calcified and noncalcified cartilage in OA (Suri, et al., 
2007; Suri & Walsh, 2012). The distribution of angiogenesis-related factors in OA 
cartilage is largely unknown, as previous studies on angiogenesis regulators usually 
focused on osteoarthritic synovium and synovial fluid (Bonnet & Walsh, 2005). The 
data from this study demonstrated disequilibrium between the expression of 
angiogenic and anti-angiogenic factors in cartilage tissue. It was demonstrated that a 
significant down-regulation of some anti-angiogenic factors in severe OA cartilage 
and an up-regulation of angiogenic signalling molecules, providing further evidence 
that a shift from anti-angiogenesis to angiogenesis precipitates osteoarthritis in 
cartilage. The altered angiogenic profile in OA cartilage not only explains the 
observed invasion of blood vessels, but also indicates that the loss of the anti-
angiogenic phenotype may be one of the most important characteristic of OA 
cartilage and that its role in cartilage destruction has been underestimated. 
Specifically, my results confirmed a down-regulation of ChM-1 and up-regulation of 
VEGFA in OA cartilage samples. The mRNA levels of several anti-angiogenic 
factors (ChM-1, TIMP-1, TIMP-2, TSP-1 and TSP-2) were decreased in OA 
cartilage. Furthermore, I also identified an up-regulation of VEGFR2, PECAM-1, 
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VE-Cadherin, ANGPT2, TIE2, AKT, CXCL5, CXCL6, PF4 and ANGPTL4, whose 
relationship with osteoarthritis has never previously been reported. Among these, the 
angiopoietin-Tie system might be of great interests in future OA research, since 
angiopoietin-Tie system has been shown to have a deteriorating effect on rheumatoid 
arthritis (RA) (Hashiramoto, et al., 2007).  
In part two of this study (Chapter 5), I focused the on the function of the anti-
angiogenic factor ChM-1. The involvement of ChM-1 in chondrogenesis and OA 
progression in vivo and in vitro was systematically studied. First, ChM-1 expression 
during chondrocyte maturation was investigated in chondrogenic culture conditions 
using cells derived from cartilage and bone marrow. The rationale for this is the fact 
that ACCs and BMSCs are the major seed cells for intrinsic cartilage repair and 
tissue engineering. My results showed that during chondrogenic differentiation of 
ACCs, ChM-1 up-regulation coincided with the expression of the canonical cartilage 
markers SOX9 and COL2A1. BMSCs expressed lower levels of ChM-1 than 
chondrocytes and were unable to undergo complete chondrogenic differentiation 
with less matrix deposition and COL2A1 expression. These results suggest that the 
correlation of ChM-1 and chondrogenesis and ChM-1 may act as an anabolic marker 
in chondrocyte phenotype.  
Since TGF-β3 is commonly used in chondrogenic differentiation protocols, its effect 
on ChM-1 expression was evaluated in monolayer-cultured BMSCs. These 
experiments showed that TGF-β3 down-regulated ChM-1 gene expression. These 
data are in agreement with an earlier report which showed that ChM-1 was down-
regulated when treated with FGF-2, TGF-β2 and PTH-rP (Shukunami & Hiraki, 
1998). Currently, the upstream signalling cascades that regulate the intrinsic 
expression of ChM-1 in chondrocytes are largely unknown; as such my data all but 
rule out TGF-β3 as an upstream regulator of ChM-1. Cartilage regeneration research 
has tended to focus on enhancing the expression of anabolic cartilage makers (such 
as COL2A1, ACAN and SOX9), however, my results suggest that in addition to 
these traditional anabolic markers, the anti-angiogenic nature of cartilage (especially 
the expression of ChM-1) deserve greater attention if the goal is to regenerate 
cartilage with proper physiological properties.  
Subsequently, the effect of ChM-1 on chondrocyte hypertrophy was investigated in 
vitro using the pro-inflammatory factor TNF-α to induce hypertrophy. Given the 
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short half-life of recombinant ChM-1 protein (Klinger, et al., 2011), I engineered a 
lentivirus construct carrying ChM-1 cDNA and also purchased a ChM-1 siRNA from 
a commercial vendor in order to manipulate in vitro ChM-1 gene expression. I 
demonstrated in ACCs that TNF-α up-regulates the hypertrophic genes RUNX2, 
COL10A1, MMP-13 and VEGFA, and down-regulates ChM-1, which are consistent 
with previous reports. Interestingly, ACCs overexpressing ChM-1 were able to resist 
TNF-α induced hypertrophy as was seen by their low expression of hypertrophic 
markers. This was a strong indication that ChM-1 could protect chondrocytes from 
catabolism induced by pro-inflammatory cytokines. In a similar study, Klinger et al 
showed that VEGF gene expression was not down-regulated in chondrocytes and 
osteochondral progenitor cells infected with AAV-ChM-1 (Klinger, et al., 2011). A 
caveat must be made in regards to the different methodologies between mine and 
Klinger’s studies. Klinger et al. used ordinary culture medium, whereas in my 
experiment TNF-α was used to stimulate the cells to undergo hypertrophy. However, 
these observations indicate that ChM-1 may exert its protective effect only in 
response to adverse or challenged environment of cartilage. Further evidence from 
my pellet culture study is that chondrocytes overexpressing ChM-1 had no 
significant effect on the expression of chondrogenic and hypertrophic markers, 
including COL2A1, ACAN, RUNX2, MMP-13 and COL10A1. It is well 
documented that pellet cultures grown in chondrogenic differentiation medium better 
maintains the cartilaginous properties, such as the expression and deposition of 
COL2A1 and aggrecan (Mauck et al., 2006). It will be of interest to determine 
whether ChM-1 has a protective effect on pellet culture in challenged situation, such 
as cytokine stimulation or mechanical loading, which will be the subject to future 
studies. 
Encouraged by the in vitro results, I decided to test the functional relevance of ChM-
1 supplementation to OA progression in an in vivo model. I found that ChM-1 
overexpression in articular chondrocytes significantly ameliorated OA progression at 
5-weeks, characterized by reduced COL10A1, MMP-13 and VEGFA expression and 
matrix degradation. Klinger et al showed that osteochondral progenitor cells infected 
with AAV-ChM-1 stimulated chondrogenic differentiation and inhibited 
endochondral ossification as was evidenced by decreased COL10A1 abundance in a 
micro-fractured cartilage repair model, whereas ChM-1 had no effect on VEGFA 
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gene expression in vitro (Klinger, et al., 2011). By contrast, my study demonstrated 
that ChM-1 could suppress up-regulation of VEGFA and COL10A1 both when 
challenged by TNF-α induced inflammation, as well as in an MSX-induced OA rat 
model. The data implies that ChM-1 may not target angiogenic and hypertrophic 
genes directly, but target the signals of initiating these catabolic genes. However, at 
the late stage of OA (9-weeks post-surgery) there was no statistically significant 
difference in Mankin scores between treated and non-ChM-1 treated animals, 
suggesting that ChM-1 did not have any effect in reducing cartilage matrix 
degradation in this model. Furthermore, immunostaining revealed a decrease in 
ChM-1 expression at 9-weeks, an observation that may be due to degradation of 
ChM-1 itself, since it has been shown that the N-terminal 14 kDa truncated form of 
ChM-1 is present in the hypertrophic and calcified zone of cartilage in developing 
long bone (Miura, et al., 2014) and has little inhibitory effect on angiogenesis in 
contrast to the intact 25 kDa form. These results also indicate other mechanisms 
regulate ChM-1 in vivo function at the post-transcriptional level (Miura, et al., 2014). 
In my study, lentivirus carrying ChM-1 efficiently increased gene level of ChM-1; 
however, at late stage OA cartilage, the intact form of ChM-1 may be proteolyzed, 
thus compromising its protective effect in cartilage. Nevertheless, my in vivo data 
showed that ChM-1 supplementation could at least delay the effects of OA 
progression, providing evidence of the utility of anti-angiogenesis as a therapeutic 
strategy of OA.   
In third part of this study, I set out to explore the molecular mechanism by which 
ChM-1 maintains the chondrocyte phenotype and exerts its anti-hypertrophic 
function (Chapter 6). To recap, hypoxia is the normal physiologic environment for 
articular cartilage and is the optimal condition required to induce the chondrocyte 
phenotype. However, it is well documented that hypoxia initiates an angiogenic 
signals by stabilizing HIF-1α and/or HIF-2α. It has been found that hypoxia induced 
VEGF expression is HIF-1α-dependent in chondrocyte, indicating that the hypoxia 
response pathway is intact in cartilage (Lin, et al., 2004). Coincidently, two recent 
studies from independent groups reported that HIF-2α, as a transcriptional factor, 
could directly target hypertrophic genes of VEGFA, COL10A1, MMP-13 and 
RUNX2 in OA cartilage (Saito, et al., 2010; Yang, et al., 2010). The scientific 
literature concerning the HIF-2α abundance in OA cartilage is contradictory, with 
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reports of both increased and decreased level; however, there is no doubt that 
considerable amounts of HIF-2α is found in healthy articular cartilage (Bohensky, et 
al., 2009; Coimbra, et al., 2004). HIFs have been regarded as master regulator of 
VEGFA (Lin, et al., 2004; Liu, et al., 1995), however, my results show that HIF-1α 
and HIF-2α protein was detectable in both normal and OA rat cartilage with no 
significant difference, whereas VEGFA is significantly up-regulated in OA 
conditions. This suggests that in normal cartilage tissue the HIF-VEGF axis is 
otherwise kept in check by certain mechanisms. It seems that chondrocytes in normal 
cartilage could block angiogenic and hypertrophic pathways induced by HIFs, 
whereas OA derived chondrocytes were unable to do so. This mechanism is 
fundamentally important in cartilage biology. Here, I speculated that ChM-1, as an 
intrinsic and abundant protein in cartilage, may play a regulatory role in HIFs’ 
function. As my result shows, HIF-2α is not only sensitive to oxygen levels, but can 
also be induced by non-hypoxic mechanisms including stimulation by the 
inflammatory cytokine TNF-α. This latter finding is consistent with Yang’s study in 
which murine chondrocytes were used (Yang, et al., 2010). My data, for the first 
time, showed that ChM-1 overexpression delays HIF-2α nucleus translocation at 
early time-points. However, at the 2 h time-point, there is no discernible difference in 
cells overexpressing ChM-1 compared with controls. As cartilage need long-term 
maintenance and OA is a disease with a long lead time, the short timeframe involved 
would have negligible effect on the function of HIF-2α. Next, I tested if ChM-1 
could influence the intra-nuclear function of HIF-2α and the data showed that ChM-1 
inhibits the DNA binding activity of HIF-2α to the promoter regions of COL10A1, 
MMP-13 and VEGFA. This indicates a protective effect of ChM-1 on TNF-α 
induced hypertrophy might be achieved, at least in part, through the inhibition of 
HIF-2α activity. This may also explain why HIF-2α in normal in vivo cartilage fails 
to induce angiogenic factors and catabolic markers. It could be speculated that in 
normal cartilage, the abundant expression of ChM-1 blocks the angiogenic and 
hypertrophic activity of HIF-2α, whereas in OA cartilage, the catabolic function of 
HIF-2α is unlocked due to lack of ChM-1. 
Taken together, this is the first study to look at the potential of ChM-1 as an 
osteoarthritis treatments strategy and the underlying mechanisms governing this 
particular property. The data show that ChM-1 is closely correlated with chondrocyte 
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maturation and stabilizes the chondrocyte phenotype. It was found that the ChM-1 
can regulate the catabolic genes of VEGFA, COL10A1 and MMP-13 in 
chondrocytes and thus protect chondrocytes from TNF-α-induced hypertrophy. More 
importantly, the in vivo study provided evidence that ChM-1 supplementation in 
articular chondrocytes delays OA progression. The underlying mechanism could be 
the inhibitory effect of ChM-1 on HIF-2α translocation into the nucleus, as well as its 
DNA binding activity. My study also suggests ChM-1 supplementation as a potential 
therapeutic modality in the treatment of OA. The major findings in this thesis have 
been summarised in the following schematic (Figure 7-1).  
 
 
Figure 7-1. Schematic illustration showing the protective effect of ChM-1 on cartilage homeostasis 
and the underlying mechanisms. In normal cartilage, the abundant expression of ChM-1 blocks the 
angiogenic and hypertrophic activity of HIF-2α; whereas in OA cartilage, lack of ChM-1 leads to the 
activation of HIF-2α signalling pathway, resulting in chondrocyte hypertrophy and cartilage 
degradation through the enhancement expression of catabolic genes of COL10A1, MMP-13 and 
VEGFA. 
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7.3 CLINICAL IMPLICATIONS 
In this study, lentivirus vector was used to carry ChM-1 gene into the cartilage. In 
recent years, research has focused on the lentivirus vector as a useful gene therapy 
tool. Lentivirus vector have the advantages of not producing viral proteins and are 
not capable of replication; they are also specifically designed to transduce non-
dividing cells, which make this method particularly suitable to treat post-mitotic and 
highly differentiated cell types (Escors & Breckpot, 2010; Fleming, et al., 2001). The 
first approved human clinical trial using lentivirus vector were for the treatment of 
acquired immune deficiency syndrome (AIDS), and for which no proof of 
oncogenesis has been reported (Escors & Breckpot, 2010). There are over one 
hundred approved clinical trials using lentivirus-based gene therapy, which occupy 
4.6% of total clinical trials using viral vectors (Escors & Breckpot, 2010; Manilla et 
al., 2005). Lentivirus have been widely used in gene therapy for metabolic diseases, 
including β–thalassemia (Zhao et al., 2009) and severe combined immunodeficiency 
(SCID) (Mortellaro et al., 2006).  
In gene therapy of osteoarthritis, there are two potential sites for gene transfer: (1) 
the synovium and (2) the articular cartilage (Evans et al., 2004). The cartilage matrix 
may serve as a barrier to in vivo gene transductions. Lentivirus has been seen as 
providing long-term transgene expression and low immunogenicity (Evans, 2004; 
Evans, et al., 2004). Besides my study, there are other preliminary reports concerning 
gene transfer in cartilage that utilized liposomal formulation (Tomita et al., 1997), 
AAV (Arai et al., 2000) and lentivirus technologies (Chu et al., 2013; Zhu et al., 
2015). Although the transduction efficiency in my study was satisfactory, the 
immunogenicity of lentivirus in synovium waits to be clarified and will be the 
subject of future studies. It is hoped that lentiviral vectors will have the necessary 
safety and therapeutic value in a clinical setting.    
Besides gene therapy, other treatment option could be used to combine the ChM-1 
protein or its functional peptides with appropriate slowly-releasing drug carriers, 
such as hydrogels, which can be delivered locally into joint space. The consistency of 
results and the safety concerns might be the most important issues when utilizing 
ChM-1 products in the clinic, and various animal models, ranging from small size to 
large size, are needed to verify the results before proceeding with clinic trials.  
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7.4 LIMITATION  
The limitations of the particular research approach have been discussed throughout 
the individual chapters of this thesis. In particular, this study focused the function of 
ChM-1 itself, but did not explore how ChM-1 itself is regulated. This study showed a 
correlation of ChM-1 and chondrogenesis and that ChM-1 may act as an anabolic 
marker in the chondrocyte phenotype; however, ChM-1 protein can be induced in 
chondrogenic differentiation of ACCs in pellet culture system, and ChM-1 
overexpression by itself did not enhance chondrogenesis, indicating that 
chondrocytes may possess an intrinsic mechanism to regulate ChM-1. The upstream 
signals that regulate ChM-1 are largely unknown. 
Furthermore, there is lack of full understanding concerning the metabolism of ChM-
1 protein, especially at the post-transcriptional level. Recently, the truncated 14 kDa 
N-terminal form of ChM-1 has been identified in hypertrophic and calcified zone of 
cartilage in developing long bones (Miura, et al., 2014). This ChM-1 cleavage 
product has limited inhibitory effects on angiogenesis, in contrast to the full-length 
25 kDa form, indicating mechanisms regulating ChM-1 function at the post-
transcriptional level (Miura, et al., 2014). My data showed that lentivirus carrying 
ChM-1 efficiently increased gene and protein expression of ChM-1 at early time-
point (5-weeks), whereas the abundance of ChM-1 seems to be decreased at later 
time-point (9-weeks). This result is probably due to the efficiency of gene delivery 
vector as well as other deteriorating factors at late stage of OA (such as mechanical 
loading, inflammation), or, alternatively, degradation of the ChM-1 protein. In late 
stage OA cartilage, the intact form of ChM-1 may be proteolyzed, thus 
compromising its protective effects in cartilage. Further studies will aim to clarify the 
post-transcriptional regulation of ChM-1, as well as to develop more sustained 
strategy to improve ChM-1 efficiency as an OA therapy.   
In addition to this, my data showed an inhibitory effect of ChM-1 on HIF-2α nuclear 
translocation and DNA binding activity. However, it is still not clear whether ChM-1 
interacts directly with HIF-2α or influences other co-transactivators of HIFs 
pathway, such as STAT3, p300 and USF2. As ChM-1 has been shown to suppress 
STAT activity in human cancer cells (Mera, et al., 2009), the inhibitory effect of 
ChM-1 in HIFs pathway may be via these co-transactivators. Also, it is still unclear 
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whether ChM-1 influences HIF-1α function. Further studies, such as 
immnunoprecipitation and luciferase assay, are needed to address all these questions. 
 
7.5 FUTURE DIRECTION 
This study has demonstrated the protective effect of ChM-1 in chondrocyte 
hypertrophy and OA progression in vitro, as well as in surgery-induced OA animal 
model in vivo. As discussed previously (refer to 7.3 Limitation), it is of great 
importance to discover the upstream and post-transcriptional regulation of ChM-1. 
Earlier studies have reported that ChM-1 is a hypoxia-inducible and SOX9-regulated 
gene in human articular chondrocytes (Lafont, et al., 2008). However, there is no 
detailed molecular evidence yet to support this notion. My results showed that the 
chondrogenic stimulator TGF-β3 significantly up-regulated SOX9 and COL2A1, but 
had no positive influence on ChM-1 expression, which may indicate that SOX9 is 
not an upstream regulator of ChM-1. Further studies are required to identify the 
master regulator of ChM-1, as well as chondrocyte phenotype.  
It has been a controversial issue for long time concerning whether hypoxia is 
beneficial for chondrocyte differentiation and cartilage homeostasis. The scientific 
literature concerning functions of HIF-1α and HIF-2α in cartilage is contradictory, 
with claims of both anabolic and catabolic effects; although the majority of studies 
considered HIF-1α to have an anabolic role and HIF-2α a catabolic role in 
chondrocytes. My result showed that ChM-1 could inhibit HIF-2α activity in 
chondrocytes, which goes some way in explaining why hypoxia in normal in vivo 
cartilage does not induce angiogenic factors or catabolic markers. An exploration of 
this mechanism in vivo would be of great interest.  
Furthermore, my results also indicate the homeostasis of cartilage, as an avascular 
and hypoxic tissue, is maintained by a complicated molecular network. Factors other 
than HIF-1α and HIF-2α, needs to be identified, to clarify the unique feature that is 
hypoxia in cartilage. It is also of great interest to further clarify the molecular 
mechanism of ChM-1, such as to identify its receptor or binding protein by 
immnunoprecipitation, to screen signalling pathway related to ChM-1 using signal 
transduction reporter array, and to discover potential target genes of ChM-1 using 
luciferase assay.  
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7.6 CONCLUDING REMARKS 
This study highlights the importance of anti-angiogenic factors in cartilage 
homeostasis and osteoarthritis progression. In particular, the findings of this study 
indicate that the anti-angiogenic protein ChM-1 is important to maintain the 
chondrocyte phenotype and prevent hypertrophy, by inhibiting the catabolic factors 
of COL10A1, MMP-13 and VEGFA. The underlying mechanism for this may be the 
inhibitory effect of ChM-1 on catabolic activities of transcriptional factor HIF-2α. 
More importantly, the in vivo study showed evidence that ChM-1 supplementation in 
articular chondrocytes delays OA progression. The findings from this work provide a 
new perspective on the molecular mechanisms of cartilage maintenance and OA 
progression, and also points to potential treatment options for OA. 
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Appendices 
 
 
Appendix 1. Schematic outline of lentivirus-mediated gene manipulation of target cells. pLenti6/V5 
ChM-1 vector or pLentiLox 3.7 GFP vector along with three packaging plasmids (pRSVRev, 
pMDLgpRRE and pMD.G (contains VSV.G gene)) are transfected into HEK293T cells. The 
lentivirus particles are packaged by HEK293T cells and secreted into the medium. Then the medium 
will be collected and concentrated to purify lentivirus particle. Gene of ChM-1 or GFP will be 
expressed by the target cells (such as ACCs and C28/I2) by infection of these lentivirus particles.   
